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Patients with Progressive Idiopathic Fibrotic Interstitial Lung Diseases (PIF-ILD) have a median 
survival of 3 years. Research into the palliative care needs of these patients is limited. The 
Hospital2Home (H2H) case conference (CC) is a new multi-professional, patient centred 
intervention at the end-of-life. Individualised care plans provide a comprehensive Palliative Care 
assessment with follow up. Research into use of H2H in the UK or the non-malignant setting 
has not been carried out.  
This thesis describes a study which aimed to develop and evaluate H2H in PIF-ILD. The study 
followed the Medical Research Council’s (MRC) guidance on developing and evaluating 
complex interventions, focussing on the Development and Feasibility/Piloting stages and using 
a sequential mixed methods study design. The Development stage included a systematic 
review which showed a paucity of interventions to improve symptoms and quality of life (Qol).  
Qualitative in-depth interviews of 18 patients, informal caregivers and HPs showed that patients 
had uncontrolled symptoms which profoundly impacted on every part of patients’ and informal 
caregivers’ lives. There was good understanding of the terminal nature of PIF-ILD but a poor 
understanding of prognosis. All participants were positive about H2H.  
The adapted H2H model was trialled in a fast-track Randomised Controlled Trial (RCT) forming 
the Feasibility/Piloting stage. 122 patients were screened of which 53 were randomised. The 
primary outcome was mean change in Palliative Care Outcome Score (POS) at 4 weeks- Fast-
Track -5.7 (7.5) vs Waiting List -0.4 (8.0) p=0.02. There were also improvements in patient Qol, 
anxiety and depression scores and informal caregiver anxiety and depression scores. The 
intervention and study design were largely both feasible and acceptable. 
Findings from this PhD suggest that H2H may improve palliative care needs, Qol and anxiety 
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Interstitial lung disease (ILD) results in progressive inability to maintain normal blood oxygen 
levels due to impaired transfer of gas across the alveolar-capillary membrane.(1) ILD includes a 
variety of conditions all of which share the common characteristics of lung scarring and 
progressive loss of the normal gas transfer ability.(2) Where the cause is unknown and disease 
is progressive, this is will be referred to as Progressive Idiopathic Fibrotic Interstitial Lung 
Disease (PIF-ILD).  
There are over 5,000 new cases of PIF-ILD each year in England and Wales, with a similar 
number of deaths.(3) The most common disease in this group is idiopathic pulmonary fibrosis 
(IPF) with an overall incidence rate during  2000-2008 in UK primary care of 7.44 per 100,000 
person years.(3) 
Patients with PIF-ILD have irreversible disease with no effective curative options. Patients 
experience a progressive loss of functional ability and, ultimately die from acute respiratory 
failure. However, survival varies widely;(4) Some patients die within one year of diagnosis, 
whereas others live longer than six years.(5, 6) Median survival from diagnosis in the UK is 
approximately 3 years.(7, 8)  IPF is predominately a disease of later life, with two-thirds of 
patients being over 60 years old at presentation(9) with survival being poorest in those 
diagnosed later in life.  This demographic profile is important as the incidence is set to double 
by 2030 as populations age.(10)  
The UK End of Life Care Strategy has highlighted the importance of developing effective 
palliative care interventions for non-malignant diseases.(11) In addition, the British Thoracic 
Society guidelines for the management of patients with ILD include recommendations on the 
management of IPF patients which include “liaison with palliative care specialists”.(12) 
Despite awareness that patients with IPF have poor Qol, no primary research has been 
conducted to guide palliative care delivery. Before palliative care can be delivered to this 
disease group it is essential that the needs of these patients and informal caregivers must be 
fully described and understood. It is important to then build on this work to develop and evaluate 
appropriate palliative care interventions.  
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This study therefore aims to explore the palliative care needs of patients and informal 
caregivers with PIF-ILD, to then adapt a case conference (CC) model of care (Hospital2Home, 
H2H) for PIF-ILD patients and their informal caregivers and then evaluate it in terms of feasibility 
and acceptability whilst gathering preliminary data on possible effects on patients and informal 
caregivers. The Medical Research Council’s (MRC)  guidance on the development and 
evaluation of complex interventions (13) has been used as the methodological approach 










Overview of thesis 
As each phase of the study (the PhD as a whole) has influenced the next, I have presented the 
chapters with methods and results for each phase. An overview of the chapters is presented 
here: 
 
Chapter 1 is the background chapter for the study and comprises the following components: i) I 
will firstly present details of the pathophysiology and epidemiology of PIF-ILD ii) I will then 
explain what palliative care is and its potential role in the care of those living with PIF-ILD iii) I 
will explain both the MRC guidance on developing and evaluating complex interventions and the 
subsequent MOREcare guidance on developing interventions for End of Life Research iv) I will 
describe the Hospital2Home model of care and discuss how it may be adapted for the PIF-ILD 
group. As part of the identifying the evidence base phase of the MRC guidance, the published 
paper of the systematic review examining the evidence base for current interventions to improve 
symptoms and quality of life (Qol) in PIF-ILD will be presented v) I will discuss the current 
evidence of the palliative care needs of patients and informal caregivers with PIF-ILD (forming 
part of the identifying the evidence base phase of the MRC guidance) vi) I will then present the 
published retrospective review of medical notes to gain some preliminary understanding of the 
palliative care needs of these patients which will form the background for the identifying or 
developing theory phase of the MRC guidance vii) I will present a theoretical model of how an 
adapted H2H intervention may work in this group. 
 
Chapter 2 outlines the aims and objectives of this study.  
 
Chapter 3 presents an overview of the methods for the study. This includes discussion of how 
the MRC guidance (supported by the MOREcare guidance) will be used in developing and 
evaluating the H2H intervention, the rationale and the use of mixed methods and finally how 




Chapter 4 i) presents the aims and methods of the qualitative work ii) presents the results of the 
qualitative work used to build on the evidence base for the palliative care needs of patients with 
PIF-ILD. This builds on the evidence base of the palliative care needs of these patients and 
informal caregivers presented in Chapter 1 forming part of the identifying theory/developing 
theory stage of the Development Phase of the MRC guidance iii) the results of the qualitative 
work forming the modelling theory/processes phase are presented iv) a summary of all the 
findings for the modelling theory/processes phase will be presented and integration of the 
results from the systematic review, retrospective review of case notes and qualitative work will 
follow to produce the adapted H2H model of care.  
 
Chapter 5 will form the Feasibility and Piloting stage of the MRC guidance. I will initially present 
aims of the RCT and then the submitted paper followed by more detailed methods, results and 
discussion.  
 







Chapter 1 Background 
1.1 Introduction 
In this chapter I will present details of the pathophysiology and epidemiology of PIF-ILD. 
Secondly, I will discuss what palliative care is and its potential role in the care of those living 
with PIF-ILD.  Thirdly, I will describe the MRC guidance on developing and evaluating complex 
interventions and the subsequent MOREcare guidance on developing interventions for End of 
Life Research. Fourthly, I will describe the Hospital2Home case conference model of care 
(H2H) which is used in the cancer setting and how it may be adapted for the PIF-ILD group. I 
will then present research conducted identifying the evidence base for current interventions to 
improve symptoms and quality of life (Qol) in PIF-ILD and the limited research available on the 
supportive care and Qol needs of these patients. Fifthly, I will discuss the current evidence of 
the palliative care needs of patients and informal caregivers with PIF-ILD (forming part of the 
identifying the evidence base part of the MRC guidance). I will then present the published 
retrospective review of medical notes conducted as background work to gain some preliminary 
understanding of the palliative care needs of these patients which will form the background for 
the identifying or developing theory part of the MRC guidance. Finally, I will present a theoretical 
model of how the adapted H2H intervention may work in this patient and informal caregiver 
group. 
 
1.2 Interstitial Lung Disease 
ILD refers to a group of conditions affecting the interstitium of the lung, all of which share the 
common characteristics of lung scarring and progressive loss of the normal gas transfer 
ability.(2) There are almost 300 distinct injurious or inflammatory causes of ILD that can result in 
diffuse lung scarring and many others arise for no obvious reason and are termed 
idiopathic.(15) Typically, lung scarring serves as a valuable healing role following injury.(16) 
However, the lung may become progressively scarred following more chronic and/or repeated 
injuries, resulting in abnormal function.(16) If a significant proportion of the lung becomes 
scarred, respiratory failure can occur.(16)  
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The main ILD diseases that are fibrotic (resulting in scarring) and progressive in nature are 
Idiopathic Pulmonary Fibrosis (IPF) and Non-Specific Interstitial Pneumonia (NSIP). For the 
purposes of this study, these diseases will be collectively referred to as Progressive Idiopathic 
Fibrotic Interstitial Lung Disease (PIF-ILD). Hamman and Rich are generally considered to have 
been the first to describe IPF as a new clinical and pathological entity.(17) Classification of 
these diseases within the wider ILD scheme is shown in Figure 1-1 Page 19 . 
 
Figure 1-1 Classification of interstitial lung diseases including IPF and NSIP (16) 
 
There are at least 5,000 new cases of PIF-ILD each year in England and Wales, with a similar 
number of deaths.(3) This means that in the UK, more people will die each year from PIF-ILD 
than from ovarian cancer, lymphoma, leukaemia, mesothelioma or renal cancer.(3) The most 
common disease in this group is IPF with an overall incidence rate during 2000-2008 in UK 
primary care of 7.44 per 100,000 person years.(3) Death registration in the UK analysed 
between 1968 and 2008 showed a six fold increase across the study period from 0.92 per 




period.(3) This was supported by primary care data from the same study. In both data sets, the 
size of the increase was 5% per year and this was not explained by ageing of the population.(3)  
At present there are approximately 15,000 people in the UK with a PIF-ILD diagnosis.(3) 
Patients with IPF have irreversible disease with no effective curative treatment options. Patients 
experience a progressive loss of functional ability and ultimately, die from acute respiratory 
failure. However, survival varies widely.(4) Some patients die within one year of diagnosis, 
whereas others live longer than six years.(5, 6) Median survival from diagnosis in the UK is 
approximately 3 years.(7, 8)  IPF is predominately a disease of later life, with two-thirds of 
patients being over 60 years old at presentation(9) with survival being poorest in those 
diagnosed later in life (Figure1-2 Page 20).  This demographic profile is important as the 






Figure 1-2 Kaplan Meir survival estimates stratified by age at time of diagnosis for IPF using the THIN (The 
Health Improvement Network) data set of n=2074 as found by Navaratnam et al.(3) 
Age group (years) HRs (95% CI) 
<54 0.38 (0.25 to 0.6) 
55-59 0.58 (0.38 to 0.88) 
60-64 0.93 (0.70 to 1.23) 
65-69 1.0 
70-74 1.23 (0.98 to 1.55) 
75-79 1.37 (1.09 to 1.70) 
80-84 1.74 (1.38 to 2.19) 
>85 2.42 (1.91 to 3.05) 









The clinical manifestation of fibrotic NSIP is similar to IPF.(18) It is important to differentiate 
NSIP from IPF in the early stages when the disease is potentially responsive to therapy.(18) 
However, when the disease is advanced and irreversible, this becomes less important as the 
disease is no longer responsive to treatment. Fibrotic NSIP follows a similar survival pattern to 
IPF. Figure 1-3 Page 21 shows comparison of survival of fibrotic NSIP and IPF. As the clinical 
manifestations of advanced fibrotic NSIP and IPF and survival patterns are similar, the two 
diseases will be considered together and be referred to as PIF-ILD.    
 
Figure 1-3 Survival of IPF compared to fibrotic and cellular NSIP in biopsy diagnosed ILD patients (n=78) 
as found by Nicholson et al. (19) 
 
1.3 Palliative Care and PIF-ILD 
Palliative Care is defined by the World Health Organisation as being:  
“…..an approach that improves the Qol of patients and their families facing the problem 
associated with life-threatening illness, through the prevention and relief of suffering by means 
of early identification and impeccable assessment and treatment of pain and other problems, 
physical, psychosocial and spiritual….using a support system to help patients live as actively 
as possible until death, a support system to help the family cope during the patients illness and 
in their own bereavement and using a team approach to address the needs of patients and 
their families, including bereavement counselling, if indicated”.(20) 
 
Survival is as poor for PIF-ILD as it is for many cancers(3) who traditionally receive palliative 
care. The UK End of Life Care strategy has highlighted the importance of developing effective 





Society guidelines for the management of patients with ILD include recommendations on the 
management of IPF patients. These state: 
“Best supportive care should be considered a specific and important treatment strategy in all 
patients with IPF. It is a proactive approach to symptomatic treatment and may include oxygen 
therapy, pulmonary rehabilitation, opiates, antireflux therapy, withdrawal of steroids and other 




Importantly, this is supported by the 2013 NICE clinical guidelines on the diagnosis and 
management of IPF(21) which recommend considering referral to palliative care where 
appropriate. Historically, ILD patients have been largely managed by general respiratory 
services. However, there is now a drive for these patients to be managed in specialist centres 
which are adhering to NICE guidance. Consideration of the role of palliative care in the 
management of these patients and informal caregivers is therefore needed.  
 
Palliative care has predominantly focussed on management of cancer at the end of life. 
However, non-malignant lung disease has a high mortality and symptom burden and 
encompasses various pathologies including chronic obstructive pulmonary disease (COPD), 
cystic fibrosis (CF), pulmonary hypertension, neuromuscular disorders and infections.(22) The 
physical and psychosocial needs of patients with these chronic lung diseases at EOL are 
comparable to those with lung cancer.(23) Despite survival and prognosis rates as poor as 
many cancers and an awareness that these patients have specific palliative care needs (24-27), 
primary research to quantify the needs of PIF-ILD patients or guide delivery is limited.  
 
It is important to understand the needs of other non-malignant diseases. However, PIF-ILD is an 
individual group of diseases which has some similarity to diseases such as COPD in that they 
share the commonality of both being non-malignant progressive respiratory diseases that 
experience breathlessness. However, are the palliative care needs in PIF-ILD different? The 
palliative care needs in PIF-ILD are likely to relate in part to symptoms but also to the lack of 
recognition to the palliative care needs of PIF-ILD by HPs. Does this may make PIF-ILD unique 
in its disease journey for both patients and informal caregivers and influence the experiences of 
those living with the disease? Before palliative care can be delivered to PIF-ILD patients and 
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informal caregivers, it is essential that the needs and experiences of these patients and informal 
caregivers must be further described and understood. 
 
1.4 Use of the Medical Research Council Guidance supported by the 
MORECare Statement 
The MRC framework for developing and evaluating complex interventions was first developed in 
2000.(28) This framework was then updated in 2008 and is now referred to as the MRC 
guidance.(13) Complex interventions have traditionally been defined as “interventions with 
several interacting components” where the active ingredient(s) may be difficult to identify.(13)  
This guidance aimed to help researchers to adapt appropriate methods whilst recognising that 
the extra problems of developing and evaluating complex interventions related to the difficulty of 
standardising the design and delivery of the interventions,(29, 30) their sensitivity to features of 
the local context (31, 32) and the complexity of the relationship between interventions and 
outcome.(33)  The MRC guidance addresses how there are several dimensions of complexity. 
Palliative care interventions are likely to be a complex interventions. For example, a palliative 
care intervention usually involves a prescribing component and a number of interactions 
between multi-disciplinary team members, the patient and informal caregiver. In addition, 
delivery of the intervention itself occurs in variable settings (hospital, hospice or home) and is 
dependent of local service provision. Similarly, if you were to have a palliative care intervention 
in ILD, it is likely to be a complex intervention. The development and evaluation of a palliative 
care intervention poses challenges in identifying the individual and interdependent effects of 
components and choosing reliable outcome measures.  
The MRC guidance counsels how the researcher deals with the complexity is reliant on the 
aims of the evaluation.(13) The two are inextricably linked. However, once effectiveness has 
been established, the intervention may be modified in an iterative manner as required. 
Fundamental questions are how does the intervention work, what are the vital constituents and 
how do the constituents fit together to exert their effect? (13, 34)  
The MRC guidance advises: 
‘Best practice is to develop interventions systematically, using the best available evidence and 
appropriate theory, then to test them using a carefully phased approach, starting with a series 
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of pilot studies targeted at each key uncertainties in the design, and moving on to an 
exploratory and then a definitive evaluation.’(13) 
 
 
The MRC framework consists of four stages: Feasibility and Piloting, Development, 
Evaluation and Implementation. The previous linear framework has been replaced with a 











Figure 1-4 Key elements of the development and evaluation process of the MRC guidance (13) 
 
The MRC guidance (13) stresses the importance of the Development phase and advises 
where possible to conduct a systematic review to identify the existing evidence base. In 
addition, it advises the importance of developing a theoretical understanding of “what changes 
are expected, and how change is to be achieved”. This should be done through identifying and 
appreciating existing evidence. However, if this evidence is not available, conducting new 
research on stakeholders ought to be conducted. Through amalgamation of existing and new 
evidence, a deeper understanding of the theoretical model of how the complex intervention may 
work is then achieved in the identifying/developing theory phase.(13)  
In the modelling theory or processes phase, understandings and perceptions from the theory 
stage are used to develop the intervention and gain a comprehension into how the intervention 
DEVELOPMENT 
 Identifying the evidence base 
 Identifying or developing theory 




 Surveillance and monitoring 
 Long term follow-up 
 
EVALUATION 
 Assessing effectiveness 
 Understanding change process 
 Assessing cost-effectiveness 
FEASIBILITY AND PILOTING 
 Testing procedure 
 Estimating recruitment and 
retention 




may affect the relationship between intervention and outcome.(13) In addition, the researcher 
must identify who needs to know about the outcome of the evaluation and what kind of 
information they will require in order to implement the changes that may be indicated and what 
kind of obstacles/difficulties may be encountered.(13) 
The Feasibility and Piloting stage includes amongst other things, testing procedure (including 
testing methods for their acceptability and feasibility), estimating the likely rates of recruitment 
and retention of participants and the determination of appropriate sample sizes for the 
evaluation study(ies).(13) The Feasibility and Piloting stage should aim to address all the 
uncertainties identified in the Development stage. The MRC guidance stresses the importance 
of this stage. This stage may be repeated multiple times (interspersed with repeated visits to the 
Development stage as needed) before moving on to the formal evaluation of the complex 
intervention in the Evaluation stage. (13) 
The Methods of Researching End of Life Care (MORECare) project provides guidance on the 
development and evaluation of complex end of life care (EoLC) research.(14) This project took 
the MRC guidance for developing and evaluating complex interventions as its basis and then 
conducted a phased study of systematic literature reviews, transparent expert consultations and 
stakeholder workshops to identify challenges and best practice in EoLC research. A guidance 
statement was then produced on the best methods to research EoLC research. Please see 






Table 1-1 MORECare Statement- Checklist of components that require consideration when designing 
EoLC interventions (14) 
 Recommendations 
Introduction 1. Present theoretical framework for the intervention and levels of need established 
2. Present objectives appropriate to the level of intervention development 
Study design 3. Indicate and justify stage in MRC guidance for development and evaluation of complex interventions, for 
example, feasibility, preliminary evaluation, efficacy/cost effectiveness and wider effectiveness 
4. Feasibility stages should test both feasibility of the intervention and of methods of evaluation, including 
outcome measurement 
5. Justify methods, considering appropriate use of existing data sets and secondary analysis as these may 
produce rapid information 
6. Justify methods of empirical studies considering mixed methods, observational studies and randomised 
trials 
Study team 7. Ensure involvement from: (i) consumers, patients and caregivers; (ii) relevant clinicians; (iii) relevant 
methodologists to develop study questions, questionnaires and procedures; and (iv) researchers familiar with 
the challenges in EoLC studies 
8. Ideally, involvement should be well established and continuing, beyond a specific study, with joint 
meetings or rotations between clinical and research staff 
Ethics 9. Note in ethics committee application MORECare recommendations that it is ethically desirable for 
patients and families in EoLC to be offered involvement in research and MORECare evidence of patient 
willingness to be approached 
10. Work within legal frameworks on mental capacity, consent and so on, to ensure that those who may 
benefit from interventions are offered an opportunity to participate if they wish 
11. Collaborate with patients and caregivers in the design of the study, vocabulary used in explaining the 
study, consent procedures and any ethical aspects 
12. Attend the ethics committee meeting with a caregiver or patient, as a means to help the committee better 
understand the patient perspective 
13. Ensure proportionality in patient and caregiver information sheets, appropriate to the study design and 
level of risk, as excessive information in itself can be tiring/distressing for very ill individuals 
Participants 14. Adjust eligibility criteria to recruit those patients who may benefit most from intervention, ensuring 
equipoise 
Procedures 15. Minimise burden for existing clinical staff for participation in the study 
16. Clearly distinguish between service received and research activity interviews in study arms when 
multiple interviews with patients are undertaken in trials, for example, using a graphical system 
Outcome 
measures 
17. Choose outcome measures that meet the following criteria: 
 • established validity and reliability in relevant population 
 • responsive to change over time 
 • capture clinically important data 
 • easy to administer and interpret (for example, short and with low level of complexity) 
 • applicable across care settings to capture change in outcomes by location (for example, patients’ home, 
      hospital, hospice) 
 • able to be integrated into clinical care 
 • minimise problems of response shift (see below) 
18. Consider including patients’ experience of care, as this is central to many interventions 
19. Select time points of outcome measurement to balance the value of early recording, to reduce attrition, 
but to allow enough time for the intervention to have had an effect 
20. Consider the potential effect of response shift (that is, a change in a person’s internal conceptualisation or 
calibration of the aspects measured). Questionnaires that include anchor points or descriptions of each 
response category may be less problematic in this regard 
Missing data & 
attrition 
21. Estimate in advance levels of, and reasons for, attrition and missing data, integrating these into sample 
size estimates and planned collection of data from proxies 
22. Monitor during the study and report all levels of, and reasons for, attrition and other missing data 
23. Assume missing quantitative data NOT to be at random unless proven otherwise 
24. Test results from different methods of imputation – noting that ‘using only complete cases’ is a form of 
imputation 
25. Use the MORECARE classification of attrition to describe causes of attrition: that is, 
 • ADD – attrition due to death; 
 • ADI - attrition due to illness; 
 • AAR - attrition at random. 
26. Consider reasons for missing data which are not due to attrition, for example missed questionnaire, or 
missed data item in questionnaire. Consider these in analysis and the potential imputations 
Mixed methods 
studies 
27. Mixed methods can be appropriate in all phases of development and evaluation 
28. Ensure appropriate multi-disciplinary skills mix or training of team 
29. Define the theoretical paradigm and method of integrating results and safeguards to ensure rigour at the 
outset 
30. Plan investigation to avoid undue burden of qualitative and quantitative questionnaires – perhaps 
dividing data collection or selecting questions and/or sampling appropriately 
31. Take into account any potential therapeutic effect of qualitative interviews where participants can 
express their feelings, if these are similar to components of the intervention 
32. Ensure that those collecting data are appropriately trained in qualitative data collection 
Implementation 33. Consider implementation implications, including workforce and training needs, in all phases of the study 
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1.5 The Hospital2Home case conference: an example of a complex 
intervention  
In the UK, a case conference (CC) model of care (Hospital2Home, H2H) has been used in 
cancer patients at the Royal Marsden Hospital for the last 3 years. The H2H CC is a multi-
professional, patient centred meeting for people nearing the end-of-life. The patient, the informal 
caregiver, H2H clinical nurse specialist (CNS), GP, district nurse, social worker and community 
palliative care CNS attend a CC in the patient’s home. Current and anticipated care needs are 
discussed, and an action plan is agreed which allocates a responsible health care professional 
for each item. Individualised care plans provide a quality comprehensive palliative care 
assessment.  This is then communicated with local services aiming to result in streamlining of 
transfer of data and codifying responsibility for the patient, informal caregiver and HPs. The aim 
is for follow up care to be provided by the community HPs. The patient and informal caregiver 
may contact the H2H CNS if there are difficulties in implementation of the care plan or 
breakdown in care and the H2H CNS will aim to resolve any issues by liaising with the relevant 
community HPs. 
 
The H2H CC model of care is unique as it has the advantages of a CC (multi-professional, 
holistic, coordinated and integrated services across providers improving co-ordination of care 
and communication) and a care plan (care individualised to each patient and informal 
caregiver), but in addition there is a designated HP (the H2H CNS) who will follow up the CC 
with the patient/informal caregiver (at a 2 week, 1 month and 2 month interval) and is available 
as a point of contact to intervene for the patient and informal caregiver if the care plan were to 
breakdown.  
 
The H2H model represents a complex intervention for the following reasons: 
1. The H2H CC in its present form involves targeting multiple HPs as well as the patient 
and informal caregiver across both hospital and community settings.  
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2. There are several outcomes which may be changed by the intervention (including 
symptom control, Qol and health service use). This is also complex as these outcomes 
inter-relate.  
3. There is flexibility in the intervention which may be tailored to individual patients, across 
settings and to this disease group. 
 
An audit of 308 cancer patients at the Royal Marsden Hospital in which H2H was used, has 
shown that 47% patients died at home and 36% in hospice.(35) This equated to 83% 
congruence between actual and preferred place of death. However, the sample is likely to have 
been biased to those who wanted to die at home. Formal assessment in a trial of how H2H may 
affect place of death has not been conducted. A longitudinal trial looking at other outcomes 
such as symptom control, Qol and resource utilisation is currently underway at the Royal 
Marsden Hospital. The CC model of care or H2H has not been used in non-malignant terminal 
disease. It is possible that H2H may be effective as a complex palliative care intervention for the 
PIF-ILD group.  
 
In developing and evaluating H2H for the PIF-ILD group, the MRC guidance for developing and 
evaluating complex interventions will be used.(13) The Development and Feasibility and 
Piloting stages have been conducted for this thesis. In addition, the MOREcare guidance (14) 




1.6 Current interventions to improve symptom control and Qol 
needs 
The MRC guidance advises that the first step in developing and evaluating a complex 
intervention is to first assess the existing evidence base through a systematic review.(13)  
I have therefore conducted a systematic review identifying and appraising interventions to 
improve symptoms and Qol in PIF-ILD. This research forms part of the Development stage of 
the MRC guidance in identifying the evidence base for palliative interventions in this group. The 
published paper will be presented followed by a summary of the findings.  
 
 Bajwah S, Ross JR, Peacock JL, Higginson IJ, Wells AU, Patel A, 1.6.1
Koffman J, Riley J.  Interventions to improve symptoms and Qol of 
patients with fibrotic ILD: a systematic review of the literature. 


















































































































 Summary of systematic review 1.6.2
 Main points from systematic review 1.6.2.1
 Paucity of evidence for any intervention to improve symptom control; 
 Evidence for pulmonary rehabilitation and sildenafil in improving Qol; 
 Only 4 RCTs with the primary outcome of symptom improvement or Qol; 
 Primary focus of research in this area has been for radical interventions. 
 
 Implications from the review related to the study  1.6.2.2
There has been a focus on developing radical interventions (focussed on improving survival) in 
this group. In developing a palliative intervention (focussed on improving symptoms and Qol), I 
would need to focus on using appropriate primary outcomes related to symptom control and 
Qol.  
In addition, the methodological quality of studies focusing on developing palliative interventions 
has been low. Where possible, robust study designs (such as RCT) should be used in 




1.7 The palliative care needs of patients and informal caregivers with 
PIF-ILD 
In this section, I will present the evidence for the palliative care needs of patients and informal 
caregivers. Alongside the previous section, this will form the identifying the evidence base part 
of the Development stage of the MRC guidance.  I will show that there is limited research 
related to palliative care needs of this group and that there are unmet patient and informal 
caregiver concerns and information needs. I will then present a retrospective review of medical 
notes/audit conducted as background work to gain some preliminary understanding of the 
palliative care needs of these patients which will form the background for the identifying or 
developing theory part of the Development stage.  
 
 Current evidence base 1.7.1
No primary research has been conducted to assess the palliative care needs of patients and 
informal caregivers with PIF-ILD. However, there have been studies which have focused on 
supportive and general care needs which are relevant to this research. Schoenheit et al (36) 
undertook single in-depth interviews with 45 IPF patients from five European countries. The 
authors asked participants to select images that expressed their feelings and asked them to 
recall what was said in a particular situation. IPF was found to have a substantial impact on 
daily life in terms of reduced independence, difficulty in continuing relationships and struggling 
financially through being unable to work. The study also collated details of symptoms and 
revealed that dyspnoea was experienced by 68% of participants, 59% reported a cough and 
28% reported fatigue. In addition, there have been two qualitative studies (37, 38) which have 
focussed on identifying factors which may affect Qol in the development of/evaluation of Qol 
tools. A Dutch study conducted focus groups of 10 IPF patients to identify the aspects of Qol or 
health status relevant to the patients in comparing two Qol measures.(37) No formal qualitative 
analysis was performed but the investigators reported findings from the focus groups. Swigris et 
al conducted a study of 20 IPF patients using focus groups and individual in-depth interviews to 
assess patients’ perspectives on how IPF affected the quality of their lives.(38) The aim of this 
study was to identify domains which could then be used to aid development of a Qol instrument. 
Both of these studies suggested IPF patients experience an adverse effect on physical health, 
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general health, energy levels, respiratory symptoms and level of independence. Swigris et al 
(38) analysed patients’ perspectives and organised them into a conceptual framework 
consisting of 12 domains. A diagrammatic representation of the Swigris paper is found in Figure 




Figure 1-5 Diagrammatic representation of domains identified by Swigris et al for IPF patient (38)
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 Addressing concerns and information needs 1.7.2
Quantitative analysis of the perceptions of illness in IPF patients and their family members in 
one study is limited as numbers were small (N=32). However it observed that most patients 
understood their disease to be a ‘serious condition’ and that family members understood the 
patient might not survive (N=16).(39) In addition, a survey of 52 defined choice and open-ended 
questions of 1448 IPF patients and caregivers conducted in the United States reported that two 
thirds of respondents felt there was a clear lack of information at the time of diagnosis.(40) 
Schoenheit et al (36) found in their study of 45 European IPF patients interviewed, that the 
majority of participants had experienced delayed diagnoses and criticised the care they 
received, while a minority of participants who were diagnosed promptly reported their care more 
positively. Both groups reported rushed and insensitive diagnosis of IPF and that there was a 
lack of information provided to them about their disease. Qualitative methods have been shown 
to provide a richness of data and allow the researcher to delve deeply into issues which 
quantitative analysis may not allow.(41) In spite of this, there have been no qualitative studies to 
explore informal caregivers’ information needs.  
Research conducted in other non-malignant disease groups has identified that there is limited 
discussion between patients, informal caregivers and HPs directly addressing patients’ and 
informal caregivers’ concerns.(42, 43) This in turn has been shown to affect psychological 
morbidity.(44) A 2004 study in COPD patients observed that although most patients knew the 
name of their condition, over half wanted more information.(45) Research into satisfaction with 
communication and care in PIF-ILD has not been conducted.  
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1.8 Retrospective review of medical notes 
To gain some preliminary understanding of the palliative care needs of PIF-ILD patients, I 
conducted a retrospective review of medical notes of deceased PIF-ILD patients for patients 
dying in a one year period. Approval for this piece of work was obtained from both the Royal 
Brompton and King’s College NHS Foundation Trusts audit committees and protection of 
patient information was in line with each trusts’ policy. 
The two very different study settings were chosen to allow assessment of palliative care needs 
and end of life preferences of PIF-ILD patients from different cultural, socio-economic groups 
and two distinct ILD centres. This piece of work forms background work for the 
identifying/developing theory stage of the MRC guidance.  The published paper is presented 
followed by a summary of the findings.  
 
 Bajwah S, Higginson IJ, Ross JR, Wells AU, Birring SS, Patel A, 1.8.1
Riley J. Specialist palliative care is more than drugs: a 


















 Summary points from retrospective review 1.8.2
This review showed that these patients experience: 
 A high symptom and psychological burden in the last year of life: 
Nearly all patients (42/45) experienced breathlessness in their last year of life. 
Additional symptoms included cough, fatigue, depression/anxiety and chest pain.  
 Non-pharmacological treatments were rarely used. 
All patients given opioids (22/45) or benzodiazepines (8/45) had documented benefit 
but non-pharmacological treatments were rarely used.  
 Limited palliative care involvement 
Despite having a large amount of uncontrolled symptoms, only 17/45 had palliative care 
team involvement in the last year of life.  
 Limited documentation of end of life preferences 
Few patients had preferred place of care (8/45) or preferred place of death (6/45) 
documented.  
In developing a palliative care intervention at the end of life for PIF-ILD patients, an intervention 
would need to address the symptom control needs of patients, involve palliative care services 
and document end of life preferences. However, as this is a retrospective review of clinical 
notes any findings from this piece of work must be treated cautiously.  
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1.9 Theoretical model of H2H for PIF-ILD 
This section will form the identifying/developing theory phase of the development stage of the 
MRC framework.(13) In considering a theoretical model of H2H which may be appropriate for 
PIF-ILD patients and which may meet their palliative care needs, I will first appraise what the 
most appropriate definition of need is, its context in health care and its relevance to PIF-ILD 
palliative care. I will then use this definition and integrate it with previous work examining factors 
affecting the Qol of these patients and the new identifying/developing theory work I have 
conducted in this chapter to develop a theoretical model of H2H for advanced PIF-ILD patients 
and their informal caregivers.  
 
 Definitions of need 1.9.1
Need is a multi-faceted concept with no one universal definition. Sociologists such as Bradshaw 
(46) have proposed a taxonomy of need. Here he defines “normative need” as an expert’s 
definition of need in a given situation. “Felt need” is equated with “want”, expressed as a lay 
person’s own assessment of his or her requirement for health. “Expressed need” or demand is 
felt need converted into action, by seeking assistance, either by use of services or request for 
information. “Comparative need” is assessed by comparing the services received by different 
people with similar characteristics. If some and not others have received care, then there is a 
comparative need in those not receiving it. 
Philosophers such as Baldwin(47) have proposed a 'tension need' which implies a desire to 
compensate for some dis-equilibrium such as thirst due to fluid loss. He also proposed a 
'teleological need' reflecting the gap between actual and desired status. In addition Maslow 
proposed a hierarchical definition of need in which basic needs (food and water) progress 
upwards through safety needs, belonging needs, and esteem needs and culminate in self-
actualisation.(48) Maslow argues that as the basic needs are met, the higher needs become 
more important.(49, 50). However, this may be too simplistic as higher needs may be important 
even when basic needs are not met. For example existential suffering may be considered a 
higher need which warrants attention from palliative care professionals as it may be inextricably 
linked to basic needs such as pain control. This higher need does not necessarily become more 
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important as basic needs are met. In fact the basic need of effective pain control may never be 
met unless the higher existential needs are.  
 
 Health and healthcare needs 1.9.2
Pragmatically, Carr and Wolfe (51) describe an aspect of health needs which they term as 
“unmet need”. This is the difference, if any, between the health care judged to be needed and 
the healthcare actually provided. According to Sheiham et al (52), true treatment need may lie 
somewhere between the objective (assessed by a doctor) and subjective (assessed by the 
patient). Donabedian (53) describes need as a state of being that creates a requirement for care 
and therefore represents a potential for use of health services.  
However, the need for healthcare should be distinguished from the need for health. The need 
for health is broader (incorporating the wider social and environmental determinants of health 
such as deprivation, housing etc (54)) and can include problems for which there is no known 
treatment.  
Within the NHS, healthcare needs are defined as those that can benefit from health care ie that 
a need for healthcare exists when an individual has an illness or disability for which there is 
effective and acceptable treatment or care.(55) The benefit may not just be a change in clinical 
status or cure but can include reassurance, supportive care and the relief of informal 
caregivers.(56)  However, this definition implies that the need for healthcare only exists if there 
is capacity to benefit from a particular healthcare service. The onus here is on the outcome 
“capacity to benefit”.(55)   
This definition has some problems when applied to this PIF-ILD group of patients. Firstly, the 
benefit of healthcare may be affected inversely by the severity of the disease. For example, a 
patient with advanced PIF-ILD may “benefit less” from receiving cardiac surgery compared to a 
patient without PIF-ILD who may have many years to live post-surgery. How “capacity to 
benefit” is defined becomes very important. Secondly, if there isn’t an effective intervention for a 
healthcare need, this definition would imply that there is no longer a healthcare need. In 
essence, if there is no solution or appropriate supportive care available, the problem is ignored. 
This definition of healthcare need could be used to justify refusing patients treatment or care 
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rather than focussing on the very real health needs of populations. The “capacity to benefit” as 
an outcome measure differs from health care needs and is discussed in detail by Culyer.(57) 
These two concepts are measurable in different ways which do not necessarily match.(55) PIF-
ILD palliative care is an under-researched area for which there are few interventions available to 
improve symptoms and Qol. In addition there is little knowledge on how supportive care ought 
to be delivered to these patients and informal caregivers.  Applying the NHS definition of need 
could imply that as there are few effective/acceptable interventions available, PIF-ILD patients 
do not have symptom control/Qol health care needs.  
In a similar vein, Buchan et al defined health service needs as 'those for whom an intervention 
produces a benefit at reasonable risk and acceptable cost'.(58) This definition incorporates 
effectiveness and cost-effectiveness and is the one favoured by health economists. However, 
by this definition, if an intervention does not result in benefit or does result in a benefit but at 
unreasonable cost, there is no health service need. Again, this would not be appropriate for PIF-
ILD palliative care.   
 
 The concept of need in palliative care 1.9.3
Another way of defining need is: 
 
'the requirement of individuals to enable them to achieve, maintain or restore an acceptable 
level of social independence or Qol, as defined by particular care agency or authority' .(59) 
 
This definition does not negate healthcare needs (including specialist palliative care needs) if 
there isn’t an effective or reasonably priced intervention available or if the interventions 
available are unable to improve the need. However, there are a number of problems with this 
definition. Social independence does not necessarily equate to need. A patient may have 
acceptable social independence and have a number of needs. Conversely, terminal patients 
may have very little social independence but not necessarily have a large number of needs. In 
addition, an acceptable level of Qol ought to be defined by the patient, not a “particular 
agency/authority”. However, improving Qol through holistic assessment and treatment of the 
patient and informal caregiver is integral to the WHO definition of palliative care(20) (which I 
believe is fundamental to the practice of palliative care).  Therefore, Qol as defined by the 
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patient (and measured through appropriate methods), ought to be an integral part of any 
definition of need. It may be argued that Qol may be functionally driven. However, in this group 
of patients, work done by Swigris et al (38) has shown that patient’s perspectives of how their 
disease affects the Qol is multi-factorial with physical, psychosocial and spiritual components.  
Therefore the definition of need which I have built and will be using for this group of patients and 
informal caregivers will be: 
‘The requirement of individuals to enable them to achieve, maintain or restore an acceptable 
level of Qol as defined by the individual. ’ 
 
In using this definition, I am not proposing that we ignore the effectiveness/possible cost 
implications of interventions used in PIF-ILD palliative care (as this is important for translation of 
the work clinically). However, I do not believe that these factors should have any importance in 
defining a need (and more specifically a specialist palliative care need) in PIF-ILD. This 
definition also links to the WHO definition of palliative care which focusses on improving the Qol 
of patients and their families through holistic means but importantly leaves the onus of defining 
Qol with the patient. The different definitions of need and their application to palliative care are 






Table 1-2 Table summarising different definitions of need and their application to palliative care 
 Type of 
need 
Definition Examples in palliative care Pros Cons 
Sociological (46) Normative  Need that is defined by experts Decision that a patient requires a syringe driver to 
control symptoms 
Explicit standard applied 
consistently and fairly  
May be paternalistic and arbitrary and thresholds 
manipulated to manage “unmet need” 
Felt  
 
Need perceived by individual  Completion of patient palliative care outcome 
scales such as POS 
Affirms the patient’s definition of 
need 
Felt needs are limited by individual perceptions and 
knowledge of services 
Expressed  Felt needs taken into action. Help 
seeking.  
Patients and informal caregivers requesting input 
and support from community palliative care 
services 
More testing of the commitment of 
the individual to do something 
about meeting their needs 
Smaller proportion in need than might be. Excludes all 
those unaware that a service exists.  
Comparative  Individuals with similar 
characteristics to those receiving 
help 
Compiling a list of palliative care patients in need of 
specialist palliative care support based on 
characteristics which have been associated with 
high palliative care needs in the past.  
An easy case for parity of provision 
can be established 
Based on experience.  
Philosophical Tension(47) Desire to compensate for some dis-
equilibrium 
Breathlessness due to large volumes of ascites  Recognises the symptoms 
experienced by the patient  
Limited by HP’ knowledge and ability to recognise.  
Teleological 
(47) 
The gap between actual and 
desired status 
The desire for palliative brain radiotherapy for brain 
metastases to improve symptom control and 
longevity of life 
Recognises what the patient deems 
important for their symptom 
control and Qol 
Smaller proportion in need than might be. Excludes all 
those unaware that a service exists. 
Hierarchy 
(48) 
Need in which basic need (eg food 
and water) progress upwards 
through safety needs, belonging 
needs, and esteem needs and 
culminate in self-actualisation 
(1) distressing symptoms, such as pain or 
dyspnea;(2) fears for physical safety, of dying or 
abandonment; (3) affection, love and acceptance in 
the face of devastating illness; (4) esteem, respect, 
and appreciation for the person; (5) self 
actualisation and transcendence.(60) 
Allows comprehensive assessment 
of physical, psychosocial and 
spiritual need 
May be overly simplistic linear model (not necessary that 
lower order needs be met before higher level needs can 
be addressed) 
Pragmatic Unmet (51) Healthcare judged to be needed 
and healthcare actually provided  
Patients judged to require community palliative 
care support but this is not possible due to poor 
staffing levels 
An easy case for parity of provision 
can be established directing 
allocation of resources for the 
future 
Does not prioritise the patient’s concerns. Likely to be 
smaller proportion in need than might be.  
NHS(61) Healthcare 
need 
Need for healthcare exists when 
there is capacity to benefit from an 
intervention  
Breathlessness which is opioid responsive  Outcomes of health interventions 
become more important and there 
is greater focus on developing 
effective interventions. “Benefit” 
may be comfort or reassurance. 
Capacity to benefit is not fixed and is subject to current 
knowledge, current research agenda and the 
effectiveness of interventions. Need is ignored if there is 
not an effective intervention  
Health 
economic(58) 
 Health care needs are those for 
which an intervention produces a 
benefit at a reasonable cost 
Expensive palliative chemotherapies which have 
few side effects and are effective in terms of 
symptom control and Qol but are only successful in 
the very few 
Ethically we must consider justice 
in allocation of finite resources 
within the NHS 
Ignores health service needs for which there are only 






 The requirement of individuals to 
enable them to achieve, maintain 
or restore an acceptable level of 
Qol as defined by the patient 
Developing complex palliative care interventions at 
the end of life aimed at improving the palliative 
care needs (as defined by WHO) of patients and 
informal caregivers with PIF-ILD.  
This definition does not negate 
healthcare needs (including 
specialist palliative care needs) if 
there isn’t an effective or 
reasonably priced intervention 
available or if the interventions 
available are unable to improve the 
need. Onus is on patient to define 
Qol.  
Ignores practical and ethical implications of having to 





 Care for patients with PIF-ILD 1.9.4
 Integrating care 1.9.4.1
Integration has been described as the ‘‘glue’’ that bonds organisations together, thus enabling 
them to achieve common goals.(62) Integrated care “seeks to improve the quality of care for 
individual patients, service users and informal caregivers by ensuring that services are well co-
ordinated around their needs”.(63) Integrated care has been described as necessary for any 
individual for whom a lack of co-ordination of care leads to an adverse impact on care 
experience and outcomes.(63)  
In its June 2011 summary report, the NHS Future Forum called for the commissioning of 
integrated care for patients with long-term conditions, complex needs, and at the end of life.(64) 
In addition, the NICE quality standard for IPF states: 
“…..services should be commissioned from and coordinated across all relevant agencies 
encompassing the whole idiopathic pulmonary fibrosis care pathway. A person-centred, 
integrated approach to providing services is fundamental to delivering high-quality care to 
adults with idiopathic pulmonary fibrosis.”(65) 
 
 
In considering whether to use integrated care for patients at the end of life and specifically for 
patients with PIF-ILD, examples of integrated care across different healthcare settings with 












Table 1-3 A table to show the positive effects of integrated care and their possible relevance to PIF-ILD 
Examples of Integrating care Methods Positive effects Relevance for PIF-ILD 
Care for older people in Torbay(66) Care delivered through integrated 
teams of health and social care 
staff. Budgets were pooled and 
used flexibly by teams who were 
able to arrange and fund services 
to meet the specific needs of 
older people. 
Increased spending on intermediate 
care services enabled older people to 
be supported at home and helped 
avoid inappropriate hospital 
admissions. Results included a 
reduction in the daily average 
number of occupied beds and a 
reduction in emergency bed day use. 
Many PIF-ILD patients are elderly 
with unnecessary hospital 
admissions. Integrating and 
individualising care delivered may 
help prevent hospital admissions.  
Diabetes care in Bolton (67) A team of community-based 
diabetes specialists worked with 
the local hospital for inpatient care 
and with general practices to 
provide support and undertake 
shared consultations. 
High satisfaction levels and the 
lowest number of hospital bed days 
per person with diabetes in the 
Greater Manchester area were 
reported. 
Many ILD services are specialist 
services. Education and easy 
access to advice from ILD 
services may reduce hospital bed 
days.  
Chronic care management in 
Wales (68) 
Three Health Boards pioneered 
strategies to co-ordinate care for 
people with multiple chronic 
illness. By employing a ‘shared 
care’ model of working between 
primary, secondary and social 
care – and investing in 
multidisciplinary teams 
There was a reduction in the total 
number of bed days for emergency 
admissions for chronic illness by an 
average of 19.5 per cent between 
2007 and 2009. This represented an 
overall cost reduction of £2,224,201 
PIF-ILD patients often have 
multiple co-morbidities. A ‘shared 
care’ model across primary, 
secondary and social care may 
reduce bed days for emergency 





Many factors in the health care setting have been described which inhibit integration of 
healthcare. These include inter sector boundaries between different healthcare settings, 
divisions between different members of the multi-disciplinary team and initial costs for staff, 
support systems and services. (62) On an international level, problems of co-ordination and 
continuity of care are experienced when patients transition between acute curative care and 
long term/end of life care. This is more likely to be the case if curative and long term care/end of 
life care are financed and regulated by different organisations. (69) 
 
 Care planning  1.9.4.2
The National Service Framework for patients with long term conditions (70) focuses on people 
with long term neurological conditions but much of the guidance it offers can apply to anyone 
living with a long-term condition eg PIF-ILD. It offers people as part of a quality requirement a 
full assessment of their health and social care needs. In addition they are offered information 
and education about their condition; the chance to make decisions about their treatment; and to 
be involved in writing a plan about how their care needs will be met (a care plan). There is a 
requirement to deliver a patient-centred service which focuses on a holistic, integrated, 
interdisciplinary approach to care planning, review and service delivery involving a range of 
agencies. The onus is on local NHS and social services to ensure they meet this requirement. It 
is also identified in the NSF that some people with more complex needs requiring skilled multi-
disciplinary input from a number of different agencies will need an identified person who co-
ordinates care.  
 
Care planning may provide a framework to support the policy imperative of ‘no decision about 
me without me’ prioritised in the ‘Equity and Excellence: Liberating the NHS (2010)'(71) , and 
the delivery of shared decision making. It aims to provide a gateway for the delivery of choice 




 Integrated care planning and palliative care 1.9.4.3
In 2008 the NHS developed the End of Life Care Strategy (11) which recognised that the quality 
of care at the end of life was generally variable and the strategy was to bring about a stepped 
change. Key recommendations included: 
 development of care plans that reflect people’s needs, wishes and preferences that are 
reviewed as circumstances change and are available across different healthcare 
settings. 
 co-ordination of care in accordance with the care plan and the delivery of high-quality 
services across all sectors and at all times. 
In the examples shown previously (Table 1-3 Page 96), integrated care may improve patient 
care, resulting in improved patient satisfaction, making services more efficient, reduce hospital 
admissions and save the NHS money.  In addition, care planning may provide a tool to meet 
patients’ and informal caregiver’s needs and wishes at the end of life. It has been proposed that 
to achieve integrated care planning, those involved with planning and providing services must 
impose the user's perspective as the organising principle of service delivery (72, 73) and that 
this is a negative and time consuming concept. However, the opposing and stronger argument 
is that integrated care approach with the individualised care planning encourages more holistic 
and personalised approaches to multi-dimensional health needs.(74) This is certainly important 
at the end of life and should be encouraged for palliative care patients including PIF-ILD 
patients and informal caregivers who may have considerable unmet needs and who may 
experience an adverse impact on care experience and outcomes as a result of lack of co-
ordination of care.  
 
 Co-ordination of care 1.9.4.4
PIF-ILD patients are often seen in specialised centres. During the early stages of the disease, 
patients and informal caregivers may become reliant on specialist care. In addition, there may 
be poor communication with primary healthcare professionals and a deskilling of community 
HPs on how to manage these diseases. Conventional care systems were proposed and 
intended to treat people with acute illnesses and therefore required little co-ordination of 
care.(75) These systems are adequate for early PIF-ILD (where the focus of care is in the 
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specialist centre).  Conversely, the management of patients with complex conditions (such as 
PIF-ILD) at the end of life requires cooperation between disciplines across multiple healthcare 
settings. However, when patient care is shared between primary, secondary or tertiary settings, 
evidence has identified significant problems in team coordination and communication.(76) 
Targeted organisation of care with improvement in co-ordination and communication is required 
to enable appropriate delivery of palliative care (77) for these patients and informal caregivers.  
 
 A model of integrated care planning for PIF-ILD 1.9.4.5
 
The term “specialised palliative care” refers to a service model that incorporates coordination 
and support for clinicians (GPs, ILD physicians etc) and for other services (district nursing) and 
management of patient and family concerns. Holistic care underpins a palliative approach; 
encompassing the physical, social, psychological and spiritual dimensions as defined by 
WHO.(20) 
The End of Life Care Strategy (11) also identified other key areas which may be important to 
PIF-ILD patients and their informal caregivers. These include: 
 Identifying people approaching the end of life with emphasis on HPs’ skills development 
in this area 
 Rapid access to care that responds to a rapid change in a person’s condition and that is 
available in the community 24/7, avoiding unnecessary emergency admissions and 
facilitating people to die in their place of choice. 
 Involving and supporting informal caregivers, including the provision of information 
about the likely progress of a person’s condition and services that are available.  
 
Swigris et al (38) when developing a Qol tool, used focus groups and individual in-depth 
interviews with 20 idiopathic pulmonary fibrosis (IPF) patients to collect their perspectives on 
how IPF affects their lives (with a focus on Qol). Swigris et al(38) analysed these perspectives 
and organised them into a conceptual framework consisting of 12 domains. A diagrammatic 
representation of the Swigris paper is found in Figure 1-5 Page 80 
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These domains have been used alongside the WHO model of palliative care with the underlying 
directions of the NSF framework for long term conditions and End of Life Care Strategy to 
develop the theoretical model underpinning the H2H intervention.  
 
 The CC model of care and Hospital2Home (H2H) 1.9.4.6
The management of patients with chronic and complex conditions relies heavily on cooperation 
between disciplines. Specialist services frequently use multidisciplinary team meetings to 
determine management. When patient care is shared between secondary or tertiary informal 
caregivers and community informal caregivers, evidence has identified significant problems in 
team coordination and communication.(76) Case conferencing involves a formal meeting 
between multi-disciplinary HP involved in care. The goal of case conferencing is to provide 
holistic, coordinated, and integrated services across providers improving co-ordination of care 
and communication.  
There have been 2 randomised trials conducted looking at the use of the CC in the palliative 
care setting. Both of these have been conducted in Australia. The first of which was conducted 
by Mitchell et al.(78) This was a multi-centre RCT to assess whether telephone CCs between 
GPs and specialist palliative care teams (without the patient or informal caregiver present) 
improved patients’ Qol and reduced the strain of caring for the informal caregivers compared to 
usual care. This trial randomised 159 cancer patients and found that the primary outcome- 
global Qol was not influenced by the intervention but the CC group showed better maintenance 
of physical and mental health measures of Qol in the 35 days before death. It was suggested 
that CCs may improve clinical relationships and care plans at referral but that these were not 
usually implemented until severe symptoms developed. There was a positive impact on 
caregiver burden with significantly lower carer burden in two of the five domains (impact on 
schedule and lack of family support) on the Caregiver Reaction Assessment (79) as well as the 
total score. Subsequently, GPs who had participated in the CCs were interviewed by telephone 
and specialist palliative care teams were interviewed in focus groups. GPs reported that the CC 
allowed them to be better informed, made discharge planning easier and allowed clear 
delineation of role between the GP and the palliative care service.(76) Palliative care teams felt 
that the CC provided particular insight as to the GPs’ willingness to provide after-hours care and 
house calls and knowledge of palliative care treatments. Both GPs and palliative care teams felt 
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that routine CCs were less useful than those held at critical points in the patient’s illness (before 
discharge home or when there were complex issues). (76) 
A second RCT also conducted in Australia, evaluated 3 interventions 1) a single CC between 
GP and the specialist palliative care team vs control 2) educational outreaching on palliative 
pain relief delivered to specific patients’ GPs vs control and 3) education interventions on pain 
and other symptom management provided to the patient and primary carer, delivered by 
palliative care nurses vs control. A single CC was found to reduce hospitalisations rates by 0.5 
per patient. CCs maintained a 10% improved performance status compared with normal care 
from 60 days after the CC until death. The greatest benefit in terms of performance status 
occurred when the patient could not manage without help. (80) 
A fundamental difference between these studies and the H2H model is that the CCs in these 2 
studies are built directly and explicitly around the GP, not around the patient and informal 
caregivers. In the Mitchell et all trial (78), patients and informal caregivers were not in 
attendance.  
 
Figure 1-6 Page 102  shows the theoretical model of the H2H that I have developed and its 
possible mechanisms of effect in improving PIF-ILD patients’ and their informal caregivers’ 









  102 
 
Figure 1-6 The proposed H2H PIF-ILD model and possible mechanisms of effect on the PIF-ILD patient and informal caregivers’ disease journey 
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1.10 Conclusion 
PIF-ILD is an irreversible disease with no effective treatment options. Patients experience a 
progressive loss of functional ability and ultimately die from acute respiratory failure. Despite 
awareness that PIF-ILD patients have specific palliative care needs, little primary research has 
been conducted to guide delivery.  
The MRC guidance has been developed to guide researchers in developing and evaluating 
complex interventions. In addition the MOREcare statement is used when developing complex 
interventions at the end of life. The H2H CC model of care is a complex intervention which 
brings together the components of a CC with individualisation from a care plan. This model of 
care has not yet been used in the non-malignant setting. In developing and evaluating the H2H 
intervention for PIF-ILD patients and informal caregivers, the MRC complex intervention 
guidance supported by the MOREcare guidance has been used as the methodological 
approach.  
This chapter forms part of the identifying the evidence base and identifying/developing theory 
phase of the MRC guidance. In this chapter, I found that there is a paucity of interventions 
focussing on symptom control and Qol. In addition, there is limited research into the palliative 
care needs of these patients. However, background work conducted as the retrospective review 
of medical notes/audit, shows that these patients have a high symptom burden in last year of 
life with limited palliative care involvement.  
In addition, in this chapter I have appraised the most appropriate definition of need and more 
specifically healthcare need deciding that the most appropriate definition links to the WHO 
definition of palliative care and focusses on improving the Qol of patients and their families 
through holistic means but leaves the onus of defining Qol with the patient.  I have discussed 
the advantages of integrated care- improvement in the quality of care for individual patients, 
service users and informal caregivers by ensuring that services are well co-ordinated around 
their needs. I have also discussed the possible advantages of the H2H CC for PIF-ILD which 
may include providing holistic, coordinated, and integrated services across providers improving 
co-ordination of care and communication. Finally, I have presented a theoretical model to 
describe the way in which H2H may work in the PIF-ILD setting. I will now go on to present the 
overall aims and objectives of this study followed by the methods.  
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Chapter 2 Aims and Objectives 
2.1 Aims 
The aim of this thesis is to develop and evaluate a complex intervention to improve the palliative 
care needs for those affected with PIF-ILD, by adopting the MRC complex intervention guidance 
as the methodological approach.  
 
2.2 Objectives 
1. To identify and describe specialist palliative care needs within this population. 
2. To identify patients’, informal caregivers’ and HPs’ perceptions on co-ordination of 
care, communication and information needs.   
3. To identify patients’, informal caregivers’ and HPs’ views on the H2H model of care 
and ways in which it may be improved/adapted for the PIF-ILD population.  
4. To integrate the above findings from 1-3 to adapt an acceptable and accessible 
model of the H2H intervention.  
5. To define appropriate outcomes and measures for the adapted H2H intervention. 
6. To begin to evaluate H2H in a phase II study.  
7. To evaluate the intervention in terms of feasibility and acceptability in a phase II 
study.  
8. To use the above work to inform a future larger randomised controlled trial (RCT 
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Chapter 3 Overall methods 
3.1 Introduction 
This chapter presents a rationale for the use of mixed methods in this study. The detailed 
methods used for each component will be presented in their respective publications and 
chapters. This chapter focuses on how the MRC guidance will be used in developing and 
evaluating the H2H intervention, whilst supported by the MOREcare guidance, the rationale and 
the use of mixed methods and finally how integration of the mixed methods will be used within 
the MRC guidance.  
3.2 Paradigm debates as applied to this study 
Epistemology is “the study of the nature of knowledge and justification”.(81) Research 
methodology is located in the philosophy of how we come to know things, that is 
epistemology.(82) In turn, methodology provides justification for the methods of a research 
project which produces data and analyses.(83) Qualitative and quantitative methods have been 
used with differing frequencies throughout the relatively short history of palliative care 
research.(84-86) During the 2000s, qualitative methodologies gained increased momentum(87), 
perhaps raising the question of whether today these methodologies are moving towards the 
position formally occupied by quantitative methodologies. This concerns not only the 
precedence of one methodology over the other in terms of how often they are used, but also the 
relationship between the two approaches. Traditionally, qualitative and quantitative methods 
belong to different paradigms or worldviews that guide research (88), and the relationships 
between the two have even been referred to as ‘battlefields of wars’. (89) Purists argue that 
quantitative and qualitative methods stem from different ontologic, epistemologic and axiologic 
assumptions about the nature of research. (89) Moreover, for purists, the assumptions 
associated with both paradigms are incompatible regarding how the world is viewed and what it 
is important to know. Purists, that include Smith (90) and Smith and Heshusius (91), suggest 
that quantitative and qualitative approaches cannot and should not be mixed. This is referred to 
as the compatibility thesis. (92) ‘Situationalists’ maintain the mono-method (paradigmatic) 
stance held by purists, but also contend that both methods have some intrinsic value. However, 
they believe that certain research questions lend themselves more to quantitative approaches, 
whereas other research questions are more suitable for qualitative methods. Therefore, 
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although representing very different orientations, the two approaches are treated as being 
‘complementary’.(93) Finally, at the other end of the continuum, ‘pragmatists’, unlike purists and 
situationalists, contend that a false dichotomy exists between quantitative and qualitative 
approaches.(94) These proponents believe that quantitative methods are not necessarily 
positivist, nor are qualitative techniques necessarily hermeneutic.(95)  As such, pragmatists 
advocate integrating methods within a single study.(96) Moreover, Sieber (97) stated that 
because both approaches have inherent strengths and weaknesses, researchers should utilise 
the strengths of both techniques in order to understand better social phenomena. Indeed, 
pragmatists ascribe to the philosophy that it is the research question that should drive the 
method(s) used, believing that ‘epistemological purity does not get research done’.(98) Bryman 
discusses how “this position with regard to the debate about quantitative and qualitative 
research prioritises the research question and relegates epistemological and oncological 
debates to the sidelines”.(99) This stance is supported by Teddle and Tashakkori (100)and 
Erzberger and Kelle. (101) In considering methods for this study, I have adopted a pragmatic 
philosophy and have allowed the research question to guide my choice of methods.  A summary 
of the general characteristics and weaknesses of pragmatism are summarised in Table 3-1Page 
106.  
Table 3-1 Table summarising general characteristics and weaknesses of pragmatism
(102)
 
General characteristics of Pragmatism Considerations 
Finds a middle ground between philosophical 
dogmatisms and scepticism and to find a 
workable solution 
Basic research may receive less attention than 
applied research because applied research 
may appear to produce more immediate and 
practical results 
Rejects traditional dualisms and generally 
prefers more moderate and common sense 
versions of philosophical dualisms based on 
how well they work in solving problems 
Pragmatism may promote incremental 
change rather than more fundamental, 
structural, or revolutionary change in society 
Knowledge is viewed as being both 
constructed and based on the reality of the 
world we experience and live in 
Many come to pragmatism looking for a way 
to get around many traditional philosophical 
and ethical disputes. Many current 
philosophers have rejected pragmatism 
because of its logical failing as a solution to 
many philosophical disputes 
Theories are viewed instrumentally (they 
become true and they are true to different 
degrees based on how well they currently 
work; workability is judged especially on the 
criteria of predictability and applicability 
Prefers action to philosophising and offers the 
“pragmatic method” for solving traditional 
philosophical dualisms as well as for making 
methodological choices 
 
  107 
3.3 Use of the MRC guidance for this project 
The original MRC framework published in 2000 (28) characterised the process of development 
through to implementation of a complex intervention in terms of the phases of drug development 
 
Figure 3-1 Sequential phases of developing randomised controlled trial of complex interventions as shown 
in the MRC framework 2000 (103) 
 
However, in practice these may not follow a linear or even a cyclical sequence.(104) Craig et al 
(105) discuss how several authors have identified limitations in the 2000 framework and 
recommending, for example, greater attention to early phase piloting and development work 
(106), a less linear model of evaluation process (104), integration of process and outcome 
evaluation (107), recognition that complex interventions may work best if they are tailored to 
local contexts rather than completely standardised (108) and greater use of the insights 
provided by the theory of complex adaptive systems.(109) Subsequently, the MRC framework 
was subsequently updated from that shown in Figure 3-1 Page 107 to that shown in Figure 1-4 
Page 24.  
In developing and evaluating the H2H CC for the PIF-ILD population, the Development and 
Feasibility and Piloting stages of the MRC guidance have been undertaken. The MRC 
guidance advises researchers to select a study design most suited to the intervention with 
particular consideration given to the choice of outcomes. In addition, the guidance recommends 
the use of a wide range of study designs. I have therefore used a systematic review, qualitative 
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methods and quantitative methods within a randomised controlled trial. How each individual 











This body of work will consist of an initial Development stage followed by the Feasibility and 
Piloting stage. Findings from the Feasibility and Piloting work will be used to inform future 
Development and Evaluation work as appropriate. However, this will not form part of this 
thesis.  
Three shortcomings for the MRC 2008 guidance were identified by the MOREcare group(14): 
a)moving from Feasibility and Piloting to implementation without robust evaluation; b) failing to 
develop the feasibility of the evaluation methods alongside the feasibility of 
treatment/intervention; and c) lack of theoretical framework underpinning treatment/intervention. 
A key point in the MOREcare recommendations (14) was that considerations about 
implementation be integrated into all phases of evaluation rather than only at the end. This is 
represented in the diagram in Figure 3-3 Page 109. 
 
DEVELOPMENT 
 Identifying the evidence base 
Systematic review 
 Identifying or developing theory 
Retrospective review of medical notes* 
Qualitative interviews 




FEASIBILITY AND PILOTING 
 Testing procedure 
RCT quantitative and qualitative data 
 Estimating recruitment and retention 
RCT quantitative and qualitative data 
 Determining sample size 
RCT quantitative data 
 
Figure 3-2 Use of the MRC guidance in developing and evaluating H2H for PIF-ILD  
*Background work 
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Figure 3-3 Key steps in developing and evaluating EoLC interventions in MOREcare guidance (14) 
 
 
 I will aim to address each of these issues during this study whilst ensuring that I am closely 
following the MOREcare recommendations (Table 1-1 Page 26) within the MRC guidance. 
 
3.4 The use of mixed methods  
The methods for this study are determined by the aims. In developing a complex intervention, 
mixed methods are needed. The MRC guidance (13) and MOREcare statement (14) both 
recommend the use of mixed methods. Mixed methods studies have become increasingly 
common in health services research.(110)  It is recognised that mixed methods are more time 
consuming and expensive with the researcher having to learn new skills to be able to conduct 
mixed methods research to a high standard.(102) However, the advantages are felt to outweigh 
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Table 3-2 Table to show possible reasons for mixing methods.(111, 112) 
Offset refers to the suggestion that the research 
methods associated with both quantitative and 
qualitative research have their own strengths 
and weaknesses so that combining them 
allows the researcher to offset their 
weaknesses to draw on the strengths of both. 
Completeness refers to the notion that the researcher can 
bring together a more comprehensive account 
of the area of inquiry in which he or she is 
interested if both quantitative and qualitative 
research are employed 
Unexpected results refers to the suggestion that quantitative and 
qualitative research can be fruitfully combined 
when one generates surprising results that 
can be understood by employing the other. 
Credibility refers to the suggestion that employing both 
approaches enhances the integrity of findings.  
Triangulation seeks convergence, corroboration, and 
correspondence of results from the different 
methods. 
Complementarity seeks elaboration, enhancement, illustration, 
and clarification of the results from one 
method with the results from the other method 
Development seeks to use the results from one method to 
help develop or inform the other method 
Initiation seeks the discovery of paradox and 
contradiction, new perspectives of 
frameworks, the recasting of questions or 
results from one method with questions or 
results from the other method. 
Expansion seeks to extend the breadth and range of 
inquiry by using different methods for different 
inquiry components. 
 
The MRC guidance and MOREcare statement state that mixed methods can be appropriate in 
all phases of development and evaluation. The MOREcare statement gives specific checklists 
for ensuring that mixed methods are used appropriately when designing and evaluating 
complex interventions in EoLC research (please see Table 1-1 page 26). This will be followed 
and referenced where appropriate.  
I believe there is a place for the use of mixed methods in palliative care and more specifically 
PIF-ILD research where the complex end of life experience may not necessarily be fully 
captured in the quantitative nor the qualitative methods alone. Lindell et al(113) conducted a 
mixed methods RCT of 21 patients looking at a disease management program delivered using a 
format of support group for both IPF patients and informal caregivers with a control group of 
best usual care. They found that on quantitative analysis, there was increased anxiety and 
decreased Qol in the intervention group. However, the qualitative work showed that patients did 
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not feel isolated and felt the intervention had enabled them to put the disease into perspective, 
gave comfort and provided an improved mental picture. In this instance, the use of mixed 
methods allowed the authors to identify important discrepancies and identify inconsistencies 
between results found from the two different methods.  
 
3.5 Rationale for mixed methods as applied to this study 
The MRC guidance and MOREcare statement state that mixed methods can be appropriate in 
all phases of development and evaluation of a complex intervention. The MOREcare statement 
gives specific checklists for ensuring that mixed methods are used appropriately when 
designing and evaluating complex interventions in EoLC research (please see Table 1-1 page 
26). This will be followed and referenced where appropriate.  
The MOREcare guidance(14) recommends that the theoretical paradigm and method of 
integrating results should be defined at the outset:  
In deciding on the model of the mixed methods design in this study, two main questions needed 
to be addressed(102): 
1. Which research paradigm was to take prominence or was dominant? 
2. In what order should the qualitative and quantitative components come?  
For this study the initial Development phase of the study was represented by a smaller 
qualitative component which informed the larger quantitative component in the Feasibility and 
Piloting stage. A smaller component of qualitative interviews in the Feasibility and Piloting 
stage was also conducted to complement the larger quantitative data.  
 
 Qualitative component 3.5.1
In order to develop a complex palliative care intervention for patients with PIF-ILD it was first 
important to explore in detail the patients’ and informal caregivers’ needs and experiences of 
the disease. In doing so, a qualitative approach was used. Qualitative methods have been 
shown to provide a richness of data, with emergent theories and allow the researcher to delve 
deeply into issues.(41) In using qualitative methods, I aimed to explore in detail the specialist 
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palliative care needs of these patients and informal caregivers. This then allowed me to assess 
the full impact of the disease and allowed me to optimise the intervention in line with the 
perceived needs of patients and informal caregivers triangulated with HPs’ views. Through 
conducting these interviews, I also aimed to maximise the cultural and local appropriateness of 
the adapted H2H intervention as recommended by the MRC guidance (13) and the MOREcare 
guidance (14). Interviewing HPs at this stage ensured that the intervention was understood by 
some key HPs and it may have helped to gear up potential stakeholders for this model of care, 
helping with recruitment for the Feasibility and Piloting phase. These interviews also informed 
appropriate outcomes for evaluating the intervention as part of the modelling process and 
outcomes stage of the MRC guidance (13).   
Qualitative interviews were used in the Feasibility and Piloting stage to firstly assess the 
effects of implementation which may not have been measured by the quantitative outcome 
measures improving both internal and external validity. This ensured that the quantitative data 
collected through the outcome measures was placed in the context of the experiences and 
views of the patients, informal caregivers and HPs. The qualitative interviews reinforced what 
was found during the quantitative data analysis but also explained any unexpected findings. 
Secondly, to assess acceptability. Qualitative interviews were conducted of patients, informal 
caregivers and HPs to assess views of the H2H intervention and whether the needs of patients 
and informal caregivers were met during the intervention. The MOREcare guidance (14) 
recommends including patients’ experience of care as an outcome and I aimed to examine this 
through the qualitative interviews. Finally to inform a future Evaluation trial. The interviews were 
used to examine any barriers to recruitment and retention. Questionnaire burden was also 
assessed.  
 
 Quantitative component 3.5.2
Quantitative outcome scales were used in the Feasibility and Piloting trial. The quantitative 
measures used in the Feasibility and Piloting trial were important to provide measureable 
information on acceptability, feasibility and possible effects of the adapted H2H intervention 
which may be used alongside the qualitative work to begin to further develop the intervention in 
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the modelling process and outcomes stage or to provide information for a future Evaluation or 
phase III trial.    
The systematic review I conducted looking at interventions to improve symptoms and Qol in 
PIF-ILD included 35 studies. Only one study, authored by Lindell et al (113), used qualitative 
methods. Study results from the Feasibility and Piloting stage should be interpreted cautiously 
as effects may be smaller or more variable and response rates lower when the intervention is 
rolled out across a wider setting.(105) However, a preliminary positive result on quantitative 
outcome measures in the Feasibility and Piloting stage may be promising and warrant further 
examination in a full Evaluation trial when the intervention may then be compared to the other 
interventions from the review.  
 
3.6 Integration and the added value of the various components in 
the larger mixed methods project.  
For this study the initial Development phase of the study is represented by a smaller qualitative 
component which informed the larger quantitative component in the Feasibility and Piloting 
stage. A smaller component of qualitative interviews in the Feasibility and Piloting stage was 
also conducted to complement the larger quantitative data. Diagrammatic representations of 
methods, showing the sequential nature of the qualitative and quantitative methods, how the 
various components of the research will fit together and their application to the MRC guidance 
are depicted in Figure 3-4 Page 114. 
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Figure 3-4 Diagrammatic representations of methods showing the sequential nature of the qualitative and quantitative methods, how the various components of the research will fit together and their 
application to the MRC guidance: size of qualitative and quantitative boxes reflective of prominence of research paradigm in MRC guidance 
* same interviews analysed using different aims 
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3.7 Ethical approvals and considerations 
 Ethical approvals 3.7.1
The qualitative phase of the project received initial approval from the Research Ethics 
Committee through addition as an amendment to a project already being conducted at King’s 
College Hospital and Royal Brompton Hospital on the same group of patients (South West 
London REC 4, reference number 09/H0806/74 AM02).  Approval for the RCT and qualitative 
interviews for Phase II was granted by the NRES Committee London – Chelsea (reference 
number 11/LO/0999). Site-specific approval was received from the Research and Development 
departments of King’s College Hospital, Royal Brompton Hospital and St. Christopher’s 
Hospice. An amendment for change in Qol outcome measure was approved (ref number 
AM1205/48).  A second amendment for change in wording on information sheets and inclusion 
criteria was also approved (ref number 2 21.08.12). Ethics application, amendments and 
approvals are included in APPENDIX A.  
 
 Ethical considerations 3.7.2
The ethical issues raised by palliative care research are, for the most part, not unique to this 
field.(114) However, they are often magnified in this group. These include the vulnerability of the 
population, high rates of mental capacity and emotional distress at the end of life creating 
challenges to informed consent, addressing conflicts of interest within the dual roles of the 
clinician-researcher, the invasiveness and increased frequency of testing relative to standard 
clinical practice, and questions of scientific value that must balance the benefits and burdens of 
the intervention.(115) I will discuss each of these issues and their relevance to PIF-ILD and this 
study: 
 
 Informed consent  
People at the end of life, as at every other stage of life, deserve the best possible care. It has 
been the central focus of the palliative care movement, through research, education and 
practice, to reach this standard. The involvement of people near to death in this research 
ensures that their problems are illuminated and the most effective solutions are developed. PIF-
  116 
ILD patients are a group in which very little palliative care research has been conducted and as 
a result there is very little recognition of their palliative care needs. Subsequently, they are 
receiving sub-optimal care. PIF-ILD patients as part of wider group of vulnerable palliative care 
patients warrant additional scrutiny to ensure informed consent is obtained. However, informed 
consent deserves close scrutiny in all clinical research.(114).  
Therapeutic misconception is a further threat to decision-making capacity in participants in end 
of life care research. This refers to the situation that occurs when a research subject fails to 
appreciate the distinction between clinical research and ordinary treatment, and may 
inaccurately attribute therapeutic intent to research procedures.(116) This may be a realistic 
outcome, if a new intervention is under study, but may represent a form of therapeutic 
misconception, where there is ambiguity about the goals of research. There is a clear need to 
be explicit about the goals of research and realistic about the benefits of participation during the 
consent process, especially when personal benefit may be a significant motivation for 
participation. In this study it was made clear when obtaining consent that the H2H intervention 
was in the preliminary stages of being tested and that it may improve symptom control and 
quality of life but that there was no evidence currently that it did.  
Undue influence refers to a situation in which the influence of a caregiver or institution, 
knowingly or otherwise, leads to an individual to change his/her decision to participate in 
research affecting his voluntariness. There is evidence that doctors have a significant influence 
on their patients’ decisions to participate in research at the end of life. In a survey of 101 
patients in an Australian oncology centre, 84% of patients were very likely to participate in 
research if their doctor was keen.(117) Debt of gratitude to care providers or institutions may 
also be an additional motivator of patients’ willingness to participate in research.(118) These 
concerns about professionals compromising a participant’s voluntariness are not unique to end 
of life care research, operating wherever individuals are dependent on care providers, invest 
great trust and/or or have a debt of gratitude towards them. The ultimate safeguard against 
coercion and undue influence in theory involves maintaining independence of care providers 
and research wherever possible. For one year of recruitment of the RCT, I was working clinically 
at the Royal Brompton Hospital. If an inpatient was suitable for enrollment into the trial, I would 
ask the H2H CNS to approach the patient. If this was not possible, another member of the 
clinical team (who was not a member of the research team) would approach the patient to 
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initially discuss the study. When obtaining consent for the study, it was made clear to the patient 
and informal caregiver (both verbally and in the consent form) that if they did not wish to take 
part in the study, this would not affect their clinical care.  
The need for continuing consent also raises ethical concerns in longitudinal studies.(119) In this 
study, the RCT raised concerns as the participants’ consent was not retaken after entry into the 
study. However, participants could choose not to return the questionnaires if they no longer 
wished to take part and they could withdraw from the study at any time if they so wished. In 
addition, if the patient lost capacity, they were no longer asked to continue taking part in the 
study. As recommended by the MOREcare guidance, I have worked within legal frameworks on 
mental capacity.   
 
 Recruitment and retention 
Interventional studies, including RCTs, are generally considered higher risk in their potential 
burden than descriptive research. Where there is equipoise to justify a RCT,  it is accepted that 
the risk of harm to the subject in being randomised to receive the inferior treatment is justified 
by the chance of benefit in receiving the superior treatment. However, this becomes difficult to 
justify in palliative care patients. To try to balance this, I adopted the fast-track design for the 
RCT to allow all participants to receive the intervention. This was also thought to have the 
advantage of being able to improve recruitment rates. To further improve recruitment, I followed 
the guidance as recommended by Jordhoy et al (120) which included firstly using several 
recruitment techniques (giving thorough and repeated personal information to the referral units, 
monitoring all inpatient and outpatient units, co-operating and developing good relationships 
with HPs in ILD services), I monitored the recruitment rates and changed or improved 
techniques as needed, I used simple phone call/email referral routes that imposed minimal 
workload on busy ILD colleagues and I allowed for attrition in the sample size calculation for the 
RCT. 
 
Retention of patients in palliative care studies is difficult (121) as the majority of attrition is due 
to advancing disease or death. As directed by the MOREcare research method guidance on 
statistical issues (121), to improve attrition, meaningful timing of end points for the RCT were 
calculated which would allow minimal attrition whilst providing primary outcome data. In 
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addition, for the RCT, informal caregivers were still able to take part in the study and complete 
outcome measures if the patient became too unwell to do so.  
 
 
 Concerns about risks, potential benefits and burdens  
A recent systematic review of palliative care oncology literature identified that 66% of studies 
were non-therapeutic in nature.(122) However, it is possible that interviews and surveys may 
still incur risk at the end of life where there is emotional or physical distress.(123) It is 
recommended that interviews of patients near the end of life should employ mechanisms to 
assess and manage distress if it occurs. (114) Therefore, the interview length in this study was 
a maximum of 45 minutes. The interviews were organised at a time and location convenient to 
the patient and could be stopped at any time if they were not keen to proceed. Any interview 
could be split into two parts over two consecutive days if the participants preferred. After any 
interview, adequate time was allowed to check the impact and effect of the interview on the 
interviewee. Interviewees were also directed to the appropriate source of health/social care 
professional as necessary and were provided with relevant information about local counselling 
services, and with the interviewee’s consent inform their GP/community medical teams of any 
concerns. If there was a high level of concern about the participant after the interview, this was 
urgently discussed with the principle investigator and the clinical team, to decide the most 
appropriate course of action. 
It has been noted that it is not necessary that researchers need to inform participants that they 
are “near the end of life”, either in the consent process or throughout data collection as this may 
cause distress in itself.(114) The information sheets provided to the patients in the RCT 
described their disease as “advanced fibrotic interstitial lung disease” but did not describe them 
as end of life. It was also noted that patients may not wish to discuss end of life planning issues 
and that this may cause distress if this was pursued. Therefore, at the baseline interview, the 
patients’ and informal caregivers’ information needs were assessed and if the patient or informal 
caregiver did not wish to discuss prognosis or end of life/advance planning at the H2H CC, this 
was done separately between the HP (with the patient’s consent). All concerns of this nature 
were documented in the clinical record file for the patient or informal caregiver. It is apparent 
that participants in research at the end of life may derive great benefit from the experience of 
  119 
participation, even in non-therapeutic research. Nonetheless risks must be minimised and 
justified and involvement of service users and experienced researchers in the design and 
implementation phases of research may be useful in this achieving this aim.(123) As directed by 
the MOREcare guidance(14), I collaborated with a patient and informal caregiver in the design 
of the study, vocabulary used in explaining the study and consent procedures. A patient and 
informal caregiver were part of the project advisory group available to give advice as needed.  
It is recognised that in end of life care, research staff can experience similar ‘burn out’ to clinical 
staff, and the stress of interviewing terminally ill patients, observing their decline and eventual 
death builds up over time. Therefore, monthly team meetings were scheduled so staff could 
reflect and share concerns. There was also additional support if needed. 
Evidence-based medicine, founded on research, has led to improvements in quality of patient 
care.(124) Importantly, there is a paucity of evidence to direct the delivery of palliative care to 
PIF-ILD patients. PIF-ILD patients should not be denied the opportunity to participate in 
research if they so wish and the research is ethically sound especially if this will mean that there 
is an improvement in the delivery of care for future patients. The MOREcare guidance (14) 
recognises that it is ethically desirable for patients and families in EoLC to be offered 
involvement in research. Throughout this study I have had an awareness of the ethical issues 
which may relate to patients, informal caregivers and staff and I have attempted to address 
these issues to the best of my ability.  
 
3.8 Conclusion 
In this chapter I have presented the overall methods for this study. I have shown in detail how I 
will use the MRC guidance alongside the MOREcare guidance to develop and evaluate the H2H 
model of care. Within this, I will use mixed methods. I have shown how I will integrate both 
research paradigms and I have defined the method of integration that will be used within each 
part of the study. Finally, I have considered the ethical considerations which are pertinent to this 
study.  
I will now go onto present the qualitative work which will form part of the identifying/developing 
theory and subsequently the modelling processes and outcomes part of the MRC guidance.  
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Chapter 4 Qualitative work to assess the palliative care needs 
of patients and informal caregivers living with PIF-
ILD 
4.1 Introduction 
In this chapter, the aims and methods of the qualitative work will be presented. Following this, 
firstly the results of the qualitative work used to build on the evidence base for the palliative care 
needs of patients with PIF-ILD will be presented.  This will build on the evidence base of the 
palliative care needs of these patients and informal caregivers presented in Chapter 1 forming 
part of the identifying theory/developing theory stage of the Development Phase of the MRC 
guidance. Secondly, the results of the qualitative work forming the modelling theory/processes 
phase will be presented. Thirdly, the discussion of all the qualitative work will be presented. 
Finally a summary of the findings for the modelling theory/processes phase will be presented 
and integration of the results from the systematic review, retrospective review of case notes and 
qualitative work will occur to present the adapted H2H model of care.  
 
Figure 4-1 Figure showing qualitative work to be presented in overall plan of study 
 
  
  121 
4.2 Aims of qualitative interviews  
 Identifying/developing theory phase 4.2.1
 
 To identify and describe specialist palliative care needs within this population. 
 
 Modelling processes and outcomes phase 4.2.2
 
 To identify patients’, informal caregivers’ and HPs’ perceptions on co-ordination of care, 
communication and information needs.   
 
 To explore patients’, informal caregivers’ and HP’ views on the H2H model of care and 
ways in which it may be improved/adapted for the PIF-ILD population.  
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4.3 Methods of qualitative in-depth interviews for Development 
Phase 
 Settings and Participants 4.3.1
Interviews took place between December 2010 and March 2011. Patients and informal 
caregivers were recruited from the Royal Brompton and Kings College Hospital NHS 
Foundation Trusts. The Royal Brompton Hospital (RBH) is a specialist ILD centre in central 
London. The unit has one of the largest diffuse lung disease patient populations in the world 
with over 500 new referrals a year for patients with ILD from across London and the surrounding 
counties. Patients come from areas with varying palliative care services and community support 
teams. King’s College Hospital (KCH) is a tertiary hospital with a specialist ILD clinic in the 
south-east of London. KCH serves a geographical area characterised by material and social 
deprivation in addition to a large population of black and minority ethnic communities. The area 
has a network of palliative care services including inpatient hospices, community services and 
hospital support teams, co-ordinated through the South London Palliative Care Network and 
other regionally based networks.  
Patients with PIF-ILD and TLCO (percentage predicted transfer factor) <40%, informal 
caregivers of patients with PIF-ILD and TLCO <40% and HPs involved in the care of these 
patients were invited to participate in the study. HPs were recruited from RBH, St Christopher’s 
Hospice and primary care. St Christopher’s Hospice is part of the St Christopher’s palliative care 
services which deliver palliative care in a range of settings including patients’ homes, in-patient 
wards and a day centre. It serves a diverse population of 1.5 million people in the London 
boroughs of Bromley, Croydon, Lambeth, Lewisham and Southwark, reaching some of 
England’s most deprived areas.(125)  
Other study inclusion criteria included an ability to understand and speak English fluently. Those 
under 18 years of age, with cognitive impairment or those unable to provide informed consent 
were excluded.  
Participants for the whole study were selected purposively. This is a process whereby particular 
participant characteristics are purposively sought out and sampled.  Gysels and Higginson(126) 
describe this form of sampling which allows a: 
  123 
‘case orientated approach in qualitative research as opposed to variable orientated in 
quantitative research……[allowing] balancing of the richness of the data with the relative 
representativeness of the sample’.  
 
 
Qualitative sampling strategies are not designed to achieve statistical generalisation or test 
hypotheses. Instead qualitative research takes an inductive approach and involves the in-depth 
study of the range and complexity of meanings and phenomena relevant to the research 
question with the aim of providing explanations and conceptual generalisation. (127) A 
purposive sampling frame was therefore devised to include potential patient participants of 
different age ranges (< or > 70 years), from different ethnic backgrounds, with or without 
respiratory or cardiovascular co-morbidities, with or without community palliative care input, and 
with or without informal caregiver support. The rationale for this was to ensure fair 
representation of different groups of patients required to address the study aims. For informal 
caregivers, inclusion criteria included that they were caring for someone who met the patient 
inclusion criteria and they had an ability to understand and speak English fluently. Those under 
18 years of age, with cognitive impairment or those unable to provide informed consent were 
excluded. For HPs, a wide range of multi-disciplinary HPs managing the care of ILD patients 
meeting this criteria were sought from both the primary and secondary care setting.  
I attended ILD clinics at both RBH and KCH and discussed potential participants with members 
of staff involved in their care to identify whether participants met inclusion criteria. Potential 
participants were then invited by the clinical teams to participate in the research, and if they 
agreed, were then approached by myself for further discussions about the study and to address 
any questions or concerns they had.  Informal caregivers were identified by patients and HPs. 
Potential HP participants were identified by patients, informal caregivers already participating in 
the study and other HPs.   
It was made clear that I was part of the research team rather than the clinical team. Where 
possible, I did not reveal that I was a doctor nor that I was from a palliative care background. 
Despite clear explanations about the ‘research’ role being distinct from the ‘doctor’ role, I felt 
that this was bound to have some impact on the interview and type of information offered by the 
interviewees.(128) For instance, if the patient or informal caregiver had experienced poor 
service provision from a member of the medical staff, I did not want information to be withheld 
because the participant was concerned that they may offend me.  I wished to reflect a naïve 
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curiosity to the participant which would not influence their response and allow me to obtain the 
richest unbiased data as possible.  
 Consent 4.3.2
I approached the participants to give the information sheets and discuss the study. Where 
possible, a quiet environment was sought to do this. However, this was not always possible and 
at times these conversations were held in a busy clinic waiting room. There did not appear to be 
any difference in the questions that were asked or refusal to participate when this occurred.  I 
answered any questions that participants had before obtaining informed consent. Two 
interviews were conducted at a later date at the participants’ request. Where possible, 
participants were interviewed on their own to ensure that there was minimal bias. This was 
possible for all but one interview (Mary, whose daughter was present).  
HPs were identified by the clinical teams and I contacted them via email when I also sent the 
information sheet. HPs were interviewed in their normal place of work at a time convenient to 
them. All participants underwent interview in the setting of their choice. Informed consent was 
obtained prior to starting the interview.  Whilst obtaining informed consent and prior to starting 
the interview, participants were assured that they could request for the interview to be stopped 
at any stage and for any reason.  
The interview process began by introducing the research and who I was. It was made clear that 
all data would be anonymised and kept completely confidential to anyone outside the research 
team. It was explained that the interview would be audio recorded and that if there were any 
questions that the participant did not wish to answer, then they could choose to omit or 
terminate the interview. In addition, it was explained that if the participant required a break or 
had any questions which they did not wish to be part of the interview, then the tape could be 
stopped.  
Recordings were made using a small unobtrusive digital recorder which was placed between 
myself and the participant. No one objected to the interview being recorded nor did anyone ask 
for the recording to be stopped during the interview.  A few of the participants did appear 
nervous and whether this was due to the interview being recorded was unclear. However, all 
participants appeared to relax once the interview was underway.  
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 Topic guide 4.3.3
The interview broadly followed the topic guide shown in Table 4-1 Page 125. This was 
developed based on the literature and discussion with experts on the Project Advisory Group. 
The interviews were semi-structured so even though the topic guide provided direction and 
highlighted areas that needed to be addressed, I was initially led by the participant in the path 
that the interview took. 
Table 4-1 Topic guide for qualitative interviews 
Patient Carer HP Prompts 
How does your disease 
affect you? 
How does the disease 
affect your loved one?  
How does the disease 
affect patients and 
carers? 
Physically (symptoms and 
what helps relieve), 
psychologically, socially 
(Activities of Daily Living -
ADLs,personal/relationship 
issues) 
What things are most 
important for you about 
your disease? 
What things are most 
important for your loved 
one about the disease? 
What things are most 
important for patients 
and carers about the 
disease? 
 
What do you feel are the 
most important things 
that affect your Qol? 
What do you feel are the 
most important things 
that affect your loved 
ones Qol? 
What do you feel are the 
most important things 
that affect patients and 
carers Qol? 
 
What is your 
understanding of your 
disease and how do you 
see your illness 
progressing in the 
future? Have you made 
any decisions about your 
treatment and care when 
you are less well? 
What is your loved ones 
understanding of their 
disease and how do they 
see their illness 
progressing in the 
future? Have they made 
any decisions about 
treatment and care when 
they are less well? 
What do you think 
patients understand 
about their disease and 
the future? Have they 
usually made decisions 
about treatment and 
care when they are less 
well? 
 
Who is currently involved 
in helping with care? 
Who is currently involved 
in helping with care? 
Who is usually involved 
in delivering care to the 
patient? 
Who helps with ADLs, 
physiotherapist, respiratory 
nurse, community palliative 
care team, district nurse, GP 
Would you like more help 
with anything in 
particular? What? 
Would you like more 
help with anything in 
particular? What? 
  
What do you think about 
current services available 
to you? 
What do you think about 
current services available 
to your loved one? 
What do you think about 
current services available 
to ILD patients? 
Prompts: What do you think 
about current symptom 
management, hospital care, 
community care, CC model of 
care, communication 
between the two, 
information provided to you 
about the disease, planning 
for when less well/ end of 
life? 
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The interview began with a general exploration of how the disease affected the participant. 
Probing and possibly difficult questions about end of life planning were left till the middle of the 
interview to allow participants to relax and become accustomed to the interview surroundings 
and the interviewer. All issues were explored in detail with both verbal and non-verbal cues 
followed up. I made field notes during and after the interview where appropriate. This allowed 
me to note reflections.  Participants were warned that the interview was coming to an end to  
allow them to discuss any issues they felt necessary. I concluded the interview with less probing 
and upsetting questions about service provision. 
At the end of the interview, participants were asked if they felt there was anything that had been 
missed or anything they would like to add further information to and were again assured of 
confidentiality.  
I had not previously conducted qualitative interviews. In preparation, I did extensive reading and 
practice interviews with colleagues (Tom Osbourne and Fliss Murtagh) within the department 
and my family members who provided constructive feedback. I also sat in as an observer on 
interviews conducted by an experienced qualitative researcher within the department. During 
this time, I learnt the importance of the spoken and non-spoken word. I refined my skills on 
picking up verbal and non-verbal cues and following them up appropriately with the use of 
silences or gentle probing.  I discussed and made a plan of how I may handle upset participants 
with supervisor IJH. This allowed me to gain confidence in an area that I had no previous 
experience. Practice interviews conducted by myself were transcribed and reviewed by 
supervisor IJH to provide feedback on transcribing technique, interview skills and content. 
 
 Conduct  4.3.4
I realised that the success of the research was dependent on my being able to form 
relationships with the participants, especially patients and informal caregivers as these were the 
participants that I hoped to elicit sensitive information from. This involved me gaining their 
confidence and trust which necessitated some emotional input on my part in the relationships 
(129)  and awareness on my part of the emotional, practical and physical needs of the 
participants. However, I was also aware of the feelings and responses which I had in the 
interview and what I portrayed to the interviewee.(129) I felt it important to strike the right 
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balance between empathy and influencing the direction in which the interview would continue.  I 
conducted interviews away from the outpatient department where possible to facilitate this. This 
was balanced with the fact that patients became symptomatic when moved to another location. 
If this happened, the patient would be given as much time as needed to recover and become 
comfortable before the interview was commenced. Care was taken to ensure that participants 
were comfortable during the interview process.  In addition, I was aware of the clothes that I 
wore. Smart (130) in conducting her research ‘definitely experienced dress as a subtle but 
important aspect of doing the research’ . Taking this into account, I aimed to dress in suitable 
attire to reflect respect for the interviewees but not so smart that I may be imposing and 
unapproachable. 
I often had to wait for long periods in the outpatient department awaiting referral of appropriate 
patients. At times I felt uncomfortable as I was worried that I may be a nuisance. Where 
possible, I tried to develop relationships with the clinical staff to facilitate referral. However, I did 
sometimes feel that the medical staff were resentful that I was not helping in the busy clinics or 
giving palliative care advice where needed.   
There were a wide range of emotions expressed during the interviews and at times both the 
patients and informal caregivers became upset. In certain instances, it was difficult to continue 
to probe when participants were upset. I found silences very helpful and productive in allowing 
participants to collect themselves and then continue without interruption.  I used my experiences 
as a palliative care doctor and courses attended in communication skills to handle sensitive 
issues. I used gentle prompts where silences were not helpful. Where possible I refrained from 
counselling participants during the interview if they became upset. However when the interview 
was over, I would always readdress any issues that had caused the participant to become 
upset, and offer advice or counselling if appropriate. I felt it ethically inappropriate to not do this. 
As I was doing this after the interview had been completed, I felt that it did not affect the 
information that I gathered. I believed it important to ensure there was overall non-maleficience 
from taking part in the interview process but I also recognised the importance of not biasing the 
data during the interview. I have completed a Masters degree in the Ethics of Cancer and 
Palliative Care and used skills that I learnt during this degree and during my clinical work to 
recognise and achieve this balance.  
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Some informal caregivers and patients did demonstrate a tendency to exhibit social desirability. 
For instance, informal caregivers would initially say that marital relationships were unaffected by 
the disease but on gentle and deeper probing, it became clear that this was not the case. All 
participants were older than I was with the majority of patients and informal caregivers 30-40 
years older. It is possible that this was a factor in them wanting to exhibit social desirability. 
Nevertheless, I felt that interviewees opened up during the interview and overall these factors 
did not hamper the quality and depth of information obtained.  
Participants appeared motivated to help take part in the interviews largely because they wanted 
to help research in an area they felt was under researched. In fact, certain participants 
demonstrated their interest and commitment by suggesting other participants that they believed 
would want to take part.  A number of participants (including those who had become upset 
during the interview) expressed that they were glad that they had participated and they had 
found it to be a valuable experience.  
Even though at times it was hard work and emotionally draining, I experienced a great deal of 
personal enjoyment from the sustained contact over time with these participants.  I felt a 
genuine pleasure in learning of their disease experiences as well as feeling very privileged that 
participants felt able to ‘open up to me’ about intensely personal issues.  
 
 Data analysis 4.3.5
All interviews were digitally recorded and then transferred verbatim onto a secure transcription 
database at the Royal Marsden NHS Foundation Trust. Two palliative care secretaries (one with 
previous experience of qualitative interviews), who received appropriate training transcribed the 
18 interviews verbatim. All interviews were anonymised during this process.  
Multiple approaches exist for analysing qualitative data. For example, the use of qualitative 
analysis approaches such as thematic analysis and Framework analysis are suitable for 
researchers who wish to pragmatically employ a relatively low level of interpretation. In contrast, 
grounded theory and interpretative phenomenological analysis (IPA) attempt to achieve a higher 
levels of complexity demanded by the research question. (131) Appraising the different 
qualitative methods is a field in evolution. The inherent strengths and limitations of using 
different analysis methods considered are presented in Table 4-2 Page 130.  
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I adopted a constant comparison approach (132) facilitated by Framework analysis, as 
described by Ritchie and Spencer. (133) This provided me with clear steps to follow and finally 
produced highly structured outputs of summarised data. (134) The nature of Framework 
approach had intuitive appeal; it provided a clear, pragmatic and transparent structure for me, a 
first-time qualitative researcher.   
Although the framework approach can appear to be mechanistic, it elegantly condensed 
participants’ accounts that facilitated inspection of data across themes and cases. At the same 
time the analysis aimed to maintain as much closeness to the original data as possible, by 
adopting the participants’ narrative as far as possible.  Moreover, I also chose the framework 
approach as it allowed me to conduct both a deductive and inductive approach to analysis. In 
the deductive approach to the analysis, themes and codes were preselected based on previous 
literature, theories or the research question. The inductive approach permitted me to identify 
new emerging themes from the data, independent of the coding framework.(134)
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Table 4-2 Table to compare different qualitative analysis methods 
(134-137)
 
Method Approach  Analysis Pros Cons 
Thematic analysis  
To describe the content of text or 
communication objectively, 
systematically and quantitatively. 
Process of data reduction. Uses 
categories, often derived from 
theoretical models. Manifest 
content analysis is the analysis of 
visible or apparent content e.g 
frequency of words 
Identifies themes i.e. patterns 
found in the information that at 
the least describes and organises 
or at the most interprets aspects 
of the phenomenon. Descriptions 
of the data are derived, classified 
and coded into categories for 
analysis. A coding framework can 
serve to divide the data into 
quantifiable units.  
Systematic and replicable 
technique for compressing many 
words of text into fewer content 
categories based on explicit rules 
of coding. It has the attractive 
features of being unobtrusive, and 
being useful in dealing with large 
volumes of data 
Synonyms may be used therefore 
may lead to underestimation of 
importance of a concept. Different 
words may not represent a 
category equally well 
Framework analysis 
Difference between framework 
analysis and thematic analysis is the 
final stage of looking at relationship 
between codes i.e mapping and 
interpretation for associations 
between codes 
Geared towards generating policy 
and practice-orientated findings- 
developing practical strategies on 













Like grounded theory- integrity of 
individual respondent accounts is 
preserved throughout the analysis. 
Not aligned to any particular 
epistemological, philosophical, or 
theoretical approach- flexible for 
use in both inductive and 
deductive analysis 
Easy to attempt to quantify 
qualitative data (eg 13 out of 20 
participants said X) 
Narrative analysis  
To reconstruct the interrelation of 
life events within the life world. 
Generates data in the form of 
biographical processes or stories 
The narrative is seen as a true 
representation of the events 
recounted. The researcher as 
narrator provides an outline of 
individuals’ stories, which the 
reader has to make sense of.  
 
All non-narrative passages are 
eliminated first. The researcher 
then segments the text and refines 
the historical sequence of 
meaningful life experiences.  
Accounts of participants which are 
“undistorted” 
Imposing structure on a story  
Grounded theory 
(also known as constant comparative 
approach) 
To develop a theory of the 
phenomenon in question which is 
more than a descriptive account. The 
aim is not to reduce complexity by 
breaking it down but to elaborate it 
by including context 
Moves from descriptive 
classification of events and facts to 
an abstract theory that accounts 
for relationships and processes. 
The theory “emerges” from the 
data. The researcher must be alert 
to the influence of the field and 
not allow this to contaminate 
developing theory but rather to 
substantiate it.  
Theory is developed from data 
which is then tested through 
further data collection and 
analysis. Constant comparative 
approach  
Inductive and emergence theory 
without preconceptions  
Explains people’s actions 
regardless of time and place. 
Not a descriptive method  
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A number of stages were undertaken in the analysis process and these were familiarisation, 
identifying a thematic framework, indexing, charting and finally mapping and interpretation. 
These are described below: 
 
 Familiarisation 4.3.5.1
First, I listened to the tapes and re-read the interviews (with field notes) multiple times to 
immerse myself in the data and participants’ stories about the disease. Even though I had 
conducted all the interviews and had gained an overall impression of the information that had 
been gathered, I felt this was important to set ideas and hunches into context and to ensure that 
recollections were not partial.(133)  Moreover this process of immersing myself in the content of 
the interviews helped me to take stock and gain a feel for the material as a whole. In addition, 
this allowed the process of abstraction and conceptualisation to begin. Key ideas, recurrent 
themes, general atmosphere and difficulty of exploring particular subjects were noted.  
 
 Identifying a thematic framework and Indexing 4.3.5.2
I then set up a framework within which the data gathered could be sorted and sifted. This was 
done through development of a formal coding scheme which consisted of reading and re-
reading interviews and making notes about themes that were emerging. The coding index or 
scheme helped me to make sense of and helped me organise all the data derived from the 
participant interviews. To some extent this process was also helped by drawing on a priori 
issues- those drawn from the original research objectives and the interview schedule. Themes 
were then sorted and grouped into sub-themes that captured participants’ views. A thematic 
framework with coding system resulted which is shown in Figure 4-2 Page 133.  
NVivo 9 was used to manage data and index the data according to the coding scheme. I 
attended a course at King’s College London to help further develop and refine my skills in using 
this qualitative package. All the data was read and annotated according to the thematic 
framework. A non-exclusive approach was used as some of the data could be coded into more 
than one category therefore single passages often contained multiple themes and codes and 
were coded as such. This helped to highlight and identify relationships/associations within the 
data. In addition, this allowed each code to be accessed and for me to review patterns and 
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contexts in which they arose. This was then reviewed by an iterative process with reflection 
back to the transcripts. Sometimes data was recoded after review. Themes and sub-themes 
were critically discussed throughout the process with supervisors IJH and JK. In addition JK 
independently reviewed and coded two transcripts of data. These were then compared and 
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1. Physical  
1.1 Shortness of Breath 
1.2 Fatigue 
1.3 Cough 
1.4 Anorexia/weight loss 
1.5 Decreased mobility 
 
2. Emotional  
2.1 Increased episodes of anger 
2.2 Frustration 
2.3 Depression 




3.1 Difficulty with ADLs 
3.2 Loss of independence 
3.3 Change in personal relationships 
3.4 Family relationships  
 
4. Spiritual 
4.1  Unmet spiritual needs 
4.2  Spiritual distress 
 
5. Information and planning 
5.1 Understanding of disease 
5.2 Information needs 
5.3 How disease will progress in future 
5.4 End of life planning 
 
6. Care and Support 
6.1 Support strategies 
6.2 HPs involved in current care 
6.3 Satisfaction with current care 
6.4 How current care could be improved 
 
7. Communication and CC model 
7.1 Views of current communication 
7.2 Views of CC model  
 
 
Figure 4-2 Thematic framework and coding system used in qualitative interviews in Development phase 
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 Charting 4.3.5.3
This process involved abstraction and synthesis of the themes that emerged from the interview 
transcripts. Each passage of text which had been coded with a particular code was studied and 
a condensed summarised version was abstracted and entered into a relevant blank cell in a 
chart in Microsoft Word. Participant terms were used as much as possible. The aim was to fill 
each cell with a summary of the relevant data, keeping as closely as possible to the original 
data by condensing its meaning and using participant terminology where possible. This allowed 
for the ordering of data by grouping similar content together. The chart had headings based on 
themes and sub-themes developed during analysis. This allowed me to build up a bigger overall 
picture of the data by considering the range of experiences, meanings, attitudes and views for 
each issue or theme. 
 
 Mapping and Interpretation 4.3.5.4
Mapping and interpretation of the data involved reviewing the charts and research notes. This 
allowed me to compare and contrast the perceptions, accounts/experiences and then search for 
patterns/connections and seek explanations for these internally within the data. In addition I 
aimed to understand and explain potential findings and discordant results where found. I 
discussed findings with my research supervisor (JK) reaching consensus on many issues. This 
iterative process enhanced the rigour of analysis and interpretation of the data and also allowed 
me to remain reflexive, to question findings and open to different viewpoints.  
 
 Rigour and validity 4.3.5.5
There has been debate that the inflexibility and confines of rigour and validity can threaten the 
very essence of qualitative research.(139) However, testing of rigour and validity are imperative 
to try to prevent researchers inventing results which may vaguely resemble but not authentically 
represent the entity being studied.(140) Criteria in the concept of validity in qualitative research 
include reflexivity, criticality, authenticity and integrity.(141) I will now discuss these in detail:  
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4.3.5.5.1 Reflexivity 
As all data was collected and analysed by myself, my own personal perspectives should be 
considered (142) and have been taken into account when analysing the data as it may 
introduce bias. This is essential as I considered what the interviewees said, interpreted this and 
then asked further questions as well as conducting analysis. My previous experiences of 
patients was largely in the cancer setting and I had had very limited contact with PIF-ILD 
patients prior to commencing this research. I was aware that PIF-ILD was a life-limiting group of 
diseases and I had awareness that there could possibly be some burdensome symptoms. 
However, I did not come to the research with any preconceived ideas of how extensive this was. 
In addition I have had first-hand experience of patients with non-malignant shortness of breath. 
My father died in 2009 with end-stage heart failure. During his disease he had periods of 
uncontrolled shortness of breath. I am aware from a pathophysiological and clinical point of view 
that heart failure is very different to ILD and I would hope that my own personal experiences did 
not influence the interviews in a negative way. I feel at times that it made me a more empathetic 
and understanding interviewer able to connect more with the participants and added to my 
research. 
Other contextual elements, such as social desirability and age differences may have introduced 
bias by affecting how the interviewee’s responded to my questions.(143) However, where 
possible I tried to move beyond accepting what appeared to be superficial answers and pick up 
on non-verbal cues to facilitate more probing discussion.  
 
4.3.5.5.2 Criticality 
Where possible I have tried to give a detailed account how I intend to appraise my research 
findings. In addition I have looked at more unusual views when they have been expressed 
(searching for negative cases) and why this data may have emerged and what it means.(142) 
 
4.3.5.5.3 Integrity 
Dodd and Davies (144) comment in their paper on rigour in qualitative research that ethics in 
qualitative research needs to be looked at contextually and flexibly. Ways in which I have 
attempted to do this are that I have ensured that consent forms are clear that participants can 
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refuse to answer any question they feel uncomfortable about, I have had access to independent 
ethical advice from experienced qualitative researchers during data collection and analysis 
should any unexpected incidents occur, participants have had access to independent 
counselling support if needed and the study was reviewed by an independent ethics committee. 
In addition I have used my own ethical skills to continuously appraise my conduct during the 
research process.  
All data has been kept in a manner that complies with the data protection act and the 
methodological detail has been optimised to enable another researcher to repeat the study. In 
addition, the rationale behind the sampling strategy has been made clear.  
All names of patients, informal caregivers and HPs have been anonymised to ensure 
confidentiality. Participant names have been changed to names which are culturally and age-
appropriate to try to make accounts come alive and illustrate each participant as an individual. 




Member checking and respondent validation enhances the authenticity of qualitative research 
as well as the credibility and criticality.(142) However, due to time constraints this was not 
possible. Sample interviews and generalised findings were however presented to members of 
the Project Advisory Group which contained HPs and a patient. This is known as ‘proxy 
respondent validation’ where community representatives, stakeholders and experts are 
consulted to help ensure that data is interpreted in a representative and balanced way.(145) 
In addition, authenticity has been demonstrated by quoting sections of relevant narrative from 
the transcripts to provide a lucid and life-like representation of the participant’s experience 
which would allow the reader to appreciate the depth of the experience and provide supporting 
data for the points I have made in the analysis.(142)  In addition, the interview was conducted 
as semi-structured and participants were allowed to discuss issues that were important to them 
and not just the issues that I was interested in which has also been shown to improve 
authenticity.(142) 
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4.4 Results of qualitative interviews  
 Participant details 4.4.1
Eight patients (four from RBH and four from KCH), four informal caregivers (from RBH) and six 
HPs agreed to be interviewed. The HPs comprised a respiratory physiotherapist, ILD specialist 
nurse, ILD Consultant, Community Palliative Care CNS, Community Palliative Care Consultant 
and General Practitioner. Five patient participants were male, four were older than 70 years and 
four were white British (other ethnicities were one Asian, one Afro-Caribbean, one Cypriate and 
one South American). No patient participants had community palliative care involvement. Five 
patient participants had informal caregivers. No patient and informal caregiver dyads were 
interviewed. Four informal caregivers interviewed were all from RBH and all white British.  
Twelve patients were approached and four declined to be interviewed. Two did not feel that they 
had the energy to be interviewed and two did not have the time and also did not feel they could 
return at a later date. This represents a response rate of 67% from the patient group. Five 
informal caregivers were approached and only one declined (he did not wish to leave his wife) 
representing a response rate of 80%. All HPs approached agreed to take part.   
The informal caregiver sample mainly comprised caregivers in spousal relationships but also 
included one daughter. All interviews except for that of Mary (name has been changed to 
ensure confidentiality), whose daughter was present, were conducted alone. The informal 
caregivers and patients interviewed had no relationship to each other.  
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Table 4-3 Description of participant characteristics (all names have been changed to ensure confidentiality) 
Name of participant Gender Age Ethnicity Diagnosis TLCO 
% 




Patients         
RBH1 Terry Male 81 White British IPF 38 No  No No 
RBH2 John Male 63 Asian IPF 35 No No No 
RBH3 Jim Male 77 White British IPF 33 Yes- COPD  No Yes 
RBH4 Peter Male 65 White British IPF 39 No No Yes 
KCH1 Mary Female 75 White British IPF 36 Yes-osteoporosis No Yes 
KCH2 Ruth Female 56 Black Carribean IPF 35 No No Yes 
KCH3 George Male 74 Cypriate IPF 31 No No No 
KCH4 Lea Female 57 South American NSIP 30 Yes- Rheumatological disease No Yes 
Informal Caregivers    Relationship to patient   
RBHC1 Penny Female 63 White Wife of James (advanced IPF)   
RBHC2 Jane Female 41 White Daughter of Anne (advanced IPF)   
RBHC3 Joan Female 55 White Wife of Paul (advanced IPF)   
RBHC4 Anthony Male 63 White Husband to Betty  (advanced IPF)   
HP       
HP1 Female   ILD Physiotherapist    
HP2 Male   ILD CNS    
HP3  Male   ILD  Consultant    
HP4 Female   Palliative Care Community CNS   
HP5 Male   Palliative Care Consultant (community)   




  139 
 Symptoms  4.4.2
The three main physical symptoms reported by patients during the qualitative interviews were 
shortness of breath, cough and difficulty sleeping. In addition, patients reported depression and 
anxiety as significant problems. This is illustrated in Table 4-4 Page 139.  
Table 4-4 Symptoms reported in qualitative interviews in Development phase 
Number of reported symptoms (patients 
reported more than one symptom) 
Patients (n=8) 
Shortness of breath 8 
Cough 5 






Whilst one patient reported one symptom, the majority of patients interviewed reported four or 
more uncontrolled symptoms. This is illustrated in Table 4-5.  
Table 4-5 Number of reported symptoms in qualitative interviews in Development phase 








  140 
 Presentation of the qualitative findings related to the 4.4.3
identifying/developing theory phase.  
 
In this section I will present details of the experiences and needs of patients and informal 
caregivers with PIF-ILD. This will be supplemented with the HPs’ perspectives.  I will first 
present the published paper, followed by more detailed results from further analyses. 
Participants’ views have been presented alongside each other regardless of whether they are 
patients, informal caregiver or HPs. This is to provide different perspectives on emerging 
themes. Finally, I will discuss what the findings from the qualitative results presented indicate 
would be needed from the adapted H2H intervention.  
Findings from the qualitative interviews and same data set related to end of life information 
needs and planning, which includes satisfaction with current care and views of the CC model of 
care, will be presented later in the chapter in a separate published paper.  
 
 Bajwah S, Koffman J, Higginson IJ, Ross JR, Wells AU, Birring SS, Riley J.  The 4.4.3.1
palliative care needs for fibrotic interstitial lung disease: A qualitative study of 
patients, informal caregivers and health professionals. Palliative Medicine 
2013;27(9):869-876 
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 Further results of qualitative findings related to identifying/developing theory 4.4.3.2
phase.  
Four main themes emerge from the qualitative analysis: 1) The extent of physical and 
psychosocial needs 2) Healthcare professionals’ experience of symptom control 3) Impact of 
disease on social activities and  4) Reliance on others and the change in relationships.  
 
4.4.3.2.1 Theme 1 The extent of physical and psychosocial needs. 
This theme relates to the presence and magnitude of the physical and psychosocial needs of 
these patients.  
The physical impact of living with PIF-ILD was commented on by all participants. The concern 
they shared was that breathlessness was the overwhelming symptom. Many participants stated 
how their breathlessness had taken on a life of its own and was consuming them. This is 
illustrated by Ruth: 
‘I’m breathless, always breathless’ (Ruth, in her 50s, black Caribbean IPF 
patient) 
 
However, some patient participants expressed that even though it was the worst aspect about 
their illness, they paradoxically felt quite healthy. An example of this includes Jim, an older man 
in his 70s with advanced IPF, who believed he was otherwise well despite his continuous 
struggle to breathe freely every day. Courageously, he quietly accepted the breathlessness and 
tried to continue with his everyday life.  
Both patients and informal caregivers recognised that breathlessness was not an isolated 
symptom. That is that it was multi-factorial and could be precipitated by anxiety. Penny, in 
caring for her husband James, had noticed that when there was even a slight question in his 
mind or any anxiety or frustration, such as not being able to get his computer to work or not 
being able to find his pen, resulted in episodes of incapacitating breathlessness.  Panic was 
often reported as being an unwelcome companion of breathlessness:  
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‘she’ll panic because although she tries not to but em she would panic 
because it’s not nice not being able to breathe you know…’ (Anthony, 
husband to Betty) 
Patients and informal caregivers recognised that the disease appeared to have control over 
them both physically and socially and no matter what they did things did not improve and this 
was difficult to come to terms with. Importantly, some HPs also recognised the seriousness of 
the symptom and it’s far reaching impact: 
‘the symptom of breathlessness is the most significant symptom that I've 
come across (...)...it could mean that they are anxious as well about the 
breathlessness and about whether this is what it is going to feel like when 
they die.’ (ILD Physiotherapist) 
Desperation resulting from symptom related distress was a common theme associated with the 
illness and its progression. Cough was also a significant problem with paroxysms or coughing 
fits leading to headaches and difficulty sleeping at night noted by many patients including 
George, Jim and Peter. The considerable effort in trying to bring up phlegm was totally 
consuming. This left them drained and utterly depleted:  
‘when it's really really bad, I'd make a trade with the devil (..) because I'm 
so (..) flat and exhausted and [I} think well I'd rather not go on.’ (Peter, in 
his 60s with advanced IPF) 
Patients such as Lea, who was in her 50s with end stage NSIP, found it difficult to sleep at night 
due to her symptoms. This then impacted on her day to day life. She felt exhausted and unable 
to engage in life in any meaningful way. Lea commented that it ‘would be a miracle’ to have a 
restful night’s sleep and clearly felt desperate that this was something that was highly unlikely to 
ever happen.  
As well as the physical impact, the disease had considerable impact on patients’ psychological 
well-being. Informal caregivers, for example Joan, felt that their loved ones often struggled 
unsuccessfully to come to terms with the disease. This led to corrosive intimations about their 
future.  Joan felt desperate to limit the psychological impact that the disease was having:  
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‘He wouldn't have it that there was anything wrong with him. But that's just 
a thing, but between us we're we're alright, it just a strain, a constant strain 
of trying to keep him (...) not happy, but trying to keep him thinking 
positively and just trying to get through each day and some days it's not 
too bad and other days it's a real struggle… he's becoming more and more 
depressed…’ (Joan, in her 50s and wife of Paul) 
 
4.4.3.2.2 Theme 2 Healthcare professionals’ experience of symptom control 
Participants from all three groups interviewed reported the challenges in adequately controlling 
patients’ symptoms. However, patient and informal caregiver participants reported few symptom 
control interventions with little or no use of pharmacological and non-pharmacological 
interventions. This left patient, informal caregivers and HP participants all struggling to find 
solutions. Non ILD HP participants admitted they did not possess sufficient understanding or 
experience of the disease. This consequently left them feeling poorly equipped to manage or 
provide guidance to support their patients. Both the GP and Palliative Care CNS were 
concerned that immediate release morphine would bring about respiratory depression with more 
distress and were reluctant to prescribe.  
HP participants who had previously experienced patients with poorly controlled symptoms 
stated this had influenced their perception of the disease, the frustration of not being able to 
adequately manage symptoms and the depressing legacy of their failure: 
‘Um I mean I have never seen quite so much phlegm (laughs nervously) 
and he was literally choking on it, he was deeply blue and there was a 
sense of sort of hopelessness that nobody could actually do anything 
about it and I thought there probably were few few worse ways to die than 
that when I saw it in that instant, sort of haunts me a bit today.’ (Palliative 
Care Consultant) 
However, despite the often bleak fate that patients had to endure some HP still recognised their 
contribution in improving symptoms. For example.....   
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‘…definitely breathlessness management, I think we are really good at it… 
if again you take breathlessness…and having all those sort of offshoots, of 
anxiety, function and oxygen we definitely definitely have a benefit, where 
even if that's to the family as well, the practicalities of managing with a 
patient with breathlessness we definitely have a role um and one's that 
been positive.’ (ILD physiotherapist) 
There was clear recognition from all participating HPs that wherever possible it was important to 
attempt to improve the symptoms of these patients and some recognised that this could be 
achieved through relatively simple measures. 
‘I still think we can make a major difference to their quality of life through 
various interventions aimed at symptoms (1) um (...) so certainly the 
feedback that one gets from patients is that they certainly feel they've gone 
from being hopeless that that what they were suffering was what they had 
to suffer and and just through the implementation of some very simple 
symptom based remedies one can make a big difference to how they feel.’ 
(ILD Consultant) 
However, other HP did not have much understanding or experience of the disease which left 
them unconfident and needing guidance in addressing treatment in these patients.  
 
4.4.3.2.3 Theme 3 Impact of the disease on social activities 
This theme refers to the day to day impact of the disease and its associated symptoms in 
preventing patients getting out and engaging in their interests or hobbies.  All participants 
commented on how their illness had progressively prevented patients from going about their 
everyday lives. In the early stages, this appeared to be because they were very self-conscious 
of the symptomatic manifestations of their illness. Ruth described how she had stopped going 
out because of her embarrassment about her cough and fear that people would feel that she 
had a disease that was ‘catching’: 
‘Yeah, um, because I’m always coughing when I’m out (…) yeah.  You get 
funny looks thinking okay (slight cough) you know people probably thinking 
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I’ve got something (...) something you’re going to pass on to them cuz I’d 
probably would think the same. (clears throat)’ (Ruth, in her 50s, black 
Caribbean IPF patient) 
However, in the later stages the limitation on social activities progressed to being more about 
physical limitations in engaging with previously taken for granted activities. Joan described how 
it had become impossible for her husband Paul to travel on the bus or train because he couldn’t 
walk very far and would have coughing fits. All three groups commented on the social isolation 
this led to and again the dependence on loved ones to function on a day to day basis. Anthony, 
husband of Betty, expressed how Betty was cut off in her own home and needed either Anthony 
or their sons to take her out or she would not be able to go anywhere. For others such as Mary, 
who did not have anyone to take them out on a regular basis, this had led to her becoming 
separated and lonely with a loss of previous relationships which had in turn impacted on her 
mood: 
‘ I can't go anywhere (…) because I I just get breathless,……. I don't don't 
[really] have a life I'm sitting indoors everyday...I used to be meet friends 
and have coffee and it [would] give you a bit of life back...’(Mary, in her 70s 
with IPF)  
Declining physical function and its consequent impact on social activities and hobbies was 
closely associated with loss. Many like Peter who was in his 60s and had been recently 
diagnosed with advanced IPF, had been looking forward to retiring and being able to enjoy 
these hobbies. He eloquently described how he felt cheated: 
‘I was gardening after 36 years of er er of working in management, and 
then starting to chop down trees and digging um holes in the ground in the 
open country side, the sun beating down and all the plants, and 
everything, I was loving every moment of it and now I can hardly get into 
my own garden, I bend down to do pull a weed out, I have to take 10 
minutes to get up off my knees again...’ (Peter, in his 60s with IPF) 
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4.4.3.2.4 Theme 4 Reliance on others and change in relationships 
This last theme refers to the increasing losses of independence patients were required to adapt 
to, the resultant changes in their relationships with close others, and how HPs attempted to 
understand their new circumstances.  
In addition to the symptom issues, there was an overwhelming effect on mobility which also led 
to a loss of independence and a reliance on others for basic activities of daily living such as 
washing and dressing.  Mary, who was in her 70s with advanced IPF but also had co-existing 
osteoporosis, described how she was no longer able to do any housework nor to wash and 
dress herself and was totally reliant on her daughter. Patients like Jim, in his 70s with advanced 
IPF, was now heavily dependent on his wife to perform tasks of a very intimate nature; washing 
and tending to parts of his body that were now inaccessible to him.  Both this greater reliance 
on loved ones, and the nature of the tasks they were called upon to perform, led to dramatic 
and interesting changes in dynamics between patients and informal caregivers that now needed 
to be accommodated. Many patients felt isolated, lonely and lacking purpose and their identities 
were consumed by their illness. Peter, a man in his 60s with advanced IPF, who had always 
been fiercely independent and the one to look after his family illustrates this:  
‘……you never think that you are going to get in a position where you um 
you can't look after um everybody else (upset).’  (Peter, in his 60s with 
advanced IPF) 
SB – (9) that's obviously quite upsetting for you? 
‘mmm. (6) (blows nose, upset). (19) It only when I talk to you like this um 
makes you realise that um how dependent really I I am on the family.  
Although um I try not to be um when you talk sit down and think about it I I 
am very dependent on them.’ (Peter, in his 60s with advanced IPF) 
Informal caregivers such as Anthony, who was husband and sole carer to Betty, recognised that 
it was paramount for the ill patient to still feel they had a legitimate role in everyday family life 
and their status be it as wife, husband etc had not been taken away.  By deliberately remaining 
close-at-hand Anthony enabled his wife Betty, a woman with advanced IPF, to continue to cook 
most of their meals.  This touching act was an open acknowledgement of that was intended to 
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reaffirm her continued importance in their relationship. However, other informal caregivers like 
Joan who was in her 50s and wife of Paul who had advanced IPF, found it more challenging to 
find the right balance:  
‘….where I find it difficult is I want to do everything for him. You tend to 
want to say no you stay there you sit there, don't move, I'll do it, and then 
that makes him cross as well and he keeps saying “I'm not dead yet”…’ 
(Joan in her 50s, wife of Paul)  
Many informal caregivers described how the experience of illness had led to a corrosive strain 
on their relationships with others, especially their spouse. Informal caregivers like Penny, wife of 
James, struggled to adapt to the increasingly reliance of her husband on her time and emotional 
well-being. She felt that he would not let her do anything on her own, even for half an hour, as 
he was scared for himself. Other informal caregivers such as Joan often took the brunt of the 
bad moods and sometimes struggled to cope. Joan recognised the impact of the disease and 
the strain on their marital relationship when Paul would often react in different ways emotionally 
which was unpredictable and left her drained: 
‘he gets um I told you, very touchy, very (...) angry and obviously I'm the 
only one around, um so from that point of view we do argue more um, (3) 
so I suppose yes it did, it's made it very difficult from the point of view of 
that, um where he um (...) he can't cope with it, and I'm there, so he'll tend 
to vent whatever he's feeling at me, um verbally or (...) you know (...) I just 
won't talk um so it is a strain, it it puts a strain on the whole relationship 
really (SIGH)... sometimes he gets quite emotional about it all, and other 
times he gets quite nasty.’ (Joan in her 50s, wife of Paul)  
Marital relationships were affected in other ways too. This included moments of sexual intimacy. 
Ruth eloquently described how the illness had affected the deepest and most sensitive depths 
of their relationship, which neither of them acknowledged, but it was always there unspoken, not 
dealt with and highly distressing. She said:   
 ‘we’re not intimate at the moment (higher pitch voice)because I find it (...) 
we don’t even talk about it, we just sort of blank it out because I just don’t 
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have the (1) the will or the energy to do (slight laugh) anything……Having 
intercourse, you know and you know, making love with each other and that 
sort of thing, yeah……..I just don’t have the energy but (...) we just don’t 
talk about it.’ (Ruth, in her 50s, black Caribbean IPF patient) 
SB: And how do you, how does that make you feel? 
‘Frustrated I suppose, annoyed (clears throat).’ (Ruth, in her 50s, black 
Caribbean IPF patient) 
 
Informal caregivers clearly worried about their loved ones and many HPs including the ILD CNS 
felt this worry and the impact of the disease on the informal caregiver were underestimated by 
HPs. Importantly, the effects of the disease on informal caregivers and relationships was not 
always felt to be recognised by HPs: 
‘I think we underestimate the eh impact that it has on the carers, relatives, 
[their] relationship (...) relations who live with the family and I think they 
equally worry and I think that is a cause of concern for patients as well as 
the family and I think that’s underestimated by us.’ (ILD CNS) 
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 Implications for the requirements of a palliative intervention from the qualitative 4.4.3.3
work in identifying/developing theory phase 
The qualitative work from the identifying/developing theory stage has indicated that in adapting 
the H2H model, guidance and education in delivery in symptom control to this group of patients 
is needed. Secondly, an adapted H2H model would need to focus on addressing both the 
physical and psychological symptoms. Finally, an adapted H2H model would need to maximise 




 Presentation of the qualitative findings related to the modelling 4.4.4
theory and processes phase 
In this section I will initially present the results from the qualitative interviews relating to the 
modelling theory/process phase of the MRC guidance. This is the same data set as the results 
presented in section 4.4.4.  I will first present the published paper followed by the more detailed 
results. Finally, I will discuss what the findings from the qualitative results presented indicate 
would be needed from the adapted H2H intervention.  
 
 Bajwah S, Koffman J, Higginson IJ, Ross JR, Wells AU, Birring SS, Riley J. “I 4.4.4.1
wish I knew more….” - the end-of-life planning and information needs for end-stage 
fibrotic interstitial lung disease: views of patients, informal caregivers and health 

























 Further results of qualitative findings related to modelling theory and processes 4.4.4.2
phase 
Six main themes emerged from the qualitative analysis: (i) Making sense of the inexplicable (ii) 
End of life care information needs iii) Sources  and timing of information iv) End of life planning, 
decision making and care v) Co-ordination and satisfaction with current care vi) Views of the 
H2H CC model of care 
 
4.4.4.2.1 Theme 1 Making sense of the inexplicable 
Patient and informal caregiver participants held varying views of what their illness meant to 
them. For example Penny described how her husband who had advanced IPF had become 
fixated on his health since becoming ill. She recognised that the disease was at the forefront of 
his mind and that he needed to keep talking about it but she felt that it had taken over his life:   
‘he talks about his health quite a lot… we can be talking about something 
completely different and it's suddenly back to (...) to the health...’ (Penny, 
wife of James.)  
Patients such as Peter, in his 60s with advanced IPF, were shocked at the profound changes 
the disease had brought to their physical state. Consequently, they had considerable difficulty 
coming to terms with the loss of who they had been, and what they had now become: 
‘looking at myself in a full length mirror and seeing those legs that used to 
score 20 goals a season, look as those they are a pair of (...) match sticks, 
so the weight, not weight loss, muscle loss in my legs came comes as a 
shock to me...’ (Peter, in his 60s with IPF) 
Ruth, a younger Black Caribbean woman in her 50s, could not fully comprehend the rapid 
deterioration in her health. She felt challenged by the lack of control: 
‘you know (2) it’s just (...) really frustrating to tell you the truth (1) these 
things are happening to my body (...) that I can’t do anything about it 
(higher pitch voice).’ (Ruth, in her 50’s, black Caribbean IPF patient) 
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Patients and informal caregiver participants all appeared to understand that the disease was 
affecting the lungs and restricting ability to breathe but had limited understanding of the exact 
mechanism involved or how the disease may manifest in the end/terminal stages. Most 
participants understood the gravity of the diagnosis but this realisation had been gradual.  Joan, 
in her 50s and wife of Paul, who had rapidly advancing IPF, reported her realisation had been 
precipitated by the gradual deterioration in Paul’s health rather than any information provided. 
As Paul found it increasingly hard to cope, this had forced them both to accept that he was 
never going to improve and that death ‘was not going to be pleasant’.  
Interestingly, patients or informal caregivers rarely knew about prognosis. Informal caregivers 
such as Jane, who was in her 40s and daughter of Anne who had advanced IPF, had 
researched the disease and were aware that there was no cure but understandably wanted to 
try and maintain hope. Jane was particularly close to her mother having only moved out of the 
family home two years previously: 
‘I think because I’ve researched it so much we’ve become very real about 
the disease… we=you know we’re not living in fairyland, we’re not looking, 
we’d love there to be something, there’s always that grasping at straws 
and that glimmer of hope that something will (.) materialise that may… so 
she can feel that she’s actually doing something rather than waiting for 
something to happen…..’ (Jane, in her 40s and daughter of Anne who had 
advanced IPF) 
Both patients and informal caregiver participants had little understanding of how the disease 
may manifest in the end/terminal stages and how they may eventually die. Patients such as Jim, 
who was in his 70s and suffered from IPF for 2 years and COPD for a number of years, thought 
that he would get more and more short of breath and then die of ‘oxygen starvation’. Most 





4.4.4.2.2 Theme 2 End of Life Care information needs 
All participants shared a common sentiment about the lack of information to help plan for the 
future.  For example two patients, Jim and Peter, both wished they knew more about their 
disease and its likely outcome.  Central to this was a wish to understand exactly how they would 
deteriorate at the end of life. This is best illustrated by Jim who was aware he knew very little 
about his fate, but at the same time felt ambivalent about wanting to ask HPs for information; he 
explained he was deeply apprehensive about their reply and had at times wanted to remain in 
the dark: 
‘I haven't sort um I haven't really discussed (1) um (2) how it will develop 
with anybody, but you know that may be me me own fault um if I don't talk 
about it, to somebody, and you don't know then I've got nothing to worry 
about (laughs).’ (Jim, in his 70s, with advanced IPF) 
Importantly however, patient participants wanted to have the option of knowing further 
information about their condition and being able to discuss issues if they wished which they did 
not feel was currently the case. 
All informal caregiver participants wanted to know more about their dependants’ situation but 
also wanted to maintain hope. HP participants recognised the importance of delivering 
information: 
‘empowering the patient with information about what their disease is (...) 
eh… what’s likely to happen and the treatment so you’re involving them 
very early on so they have a good understanding of the whole… (...) 
package of what’s wrong with them.  I think that is the single most import 
thing that we can do (...) eh to help them to understand.’ (ILD Consultant) 
However, HP participants recognised the complexities of delivering information to patients and 
that this required an appropriate balance of hope and realism. They also recognised that this 




‘I think sometimes the delivery is wrong (..) which could be a problem.  Um what you 
don’t want to do is completely say ‘you’re going to die’ what you want to do is give them 
some hope (.) I mean for example in IPF, which is a good example of this, you want to 
say that ‘you may be able to try and stabilise (.) um the disease with eh… with 
treatments’ um but you have to also… sort of balance that with you know ‘things may 
not get any better’ ….So there’s a balance to be had and some physicians are better at 
it than others…..’ (ILD CNS) 
 
4.4.4.2.3 Theme 3 Sources and timing of information 
Despite HPs recognising the importance of providing information to patients in preparation for 
the end of life, patients and informal caregivers were often getting information from other 
sources such as the internet. Jane, who had lived with her mother Anne for much of her adult 
life, had been the one to break the news of the poor prognosis to her mother which she had 
clearly found difficult and distressing: 
‘myself and my husband got on the internet and found out ‘well actually life 
spans 5 years,’ she had no idea, no one’s even told her that (...) so we go 
‘how do we tell her this’ (...) so actually the actual breaking the news was 
myself and my husband not the consultant to say, ‘well actually there isn’t 
a cure for this.’’ (Jane, in her 40s and daughter of Anne who had advanced 
IPF) 
HP participants recognised this was occurring and the pitfalls of this: 
‘I think that the healthcare professionals involved tend to… (...) tell patients 
verbally a lot of information, but that’s not the same as having written 
information that they can take away, digest and share with their 
family…they’ll go and look it up on the internet and read lots of horror 
stories perhaps (...) and I think what we should be better at is providing our 




The timing of information was commented on by both patient and HP participants. Patients such 
as Peter felt that HP should be able to judge what information was appropriate and when it 
should be delivered, not the patient. Peter had a great deal of faith in his doctors and felt a great 
deal of trust that they would be able to judge when that time had come as they had done it 
many times before.  However, HPs such as the Palliative Care Consultant did not feel that this 
was done with no allocated responsibility being a contributing factor.  This resulted in patients 
and informal caregivers being left ill informed: 
‘I think the other problem is that in some ways it is nobody's clear 
responsibility to do this, and therefore people often um have (1) um (4) you 
know attend clinics where there's decisions taken about their management 
um but (2) maybe not um enough thought and enough time is given to 
giving them (1) information really about things.’ (Palliative Care 
Consultant-Community)  
 
4.4.4.2.4 Theme 4 End of life care planning, decision making and care.  
No patient participants and no patients cared for by the informal caregiver participants reported 
they had formulated end-of-life care plans or considered end-of-life care preferences such as 
preferred place of care or preferred place of death. A number of informal caregiver participants 
were aware of broad preferences but in-depth conversations had not occurred.  All patient 
participants and all informal caregiver participants realised the importance of such 
conversations but did not know how to initiate conversations with their loved ones.  
Worryingly, some patient participants like Peter held unrealistic perceptions of how they were 
likely to die which had led them to not consider important end of life preferences: 
SB – have you made any decisions about how you want to be looked 
after? 
‘(2) in the time leading up to the big day? No no I haven't in that respect 
except that um no I haven't because I don't expect to be looked after, I just 
expect sooner or later I'm going pop off the edge of the cliff. So I won’t 
need looking after. ’ (Peter, in his 60s with IPF) 
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No patient or informal caregiver participants reported palliative care involvement stating that 
they were not aware of any such services. All HPs felt that there was still an association of 
palliative care with malignant disease and a failure to appreciate that fibrotic lung disease 
towards the end stage behaves much like malignant disease and causes unpleasant symptoms. 
However, all HP participants felt that all patients should be referred earlier for palliative input 
and have more symptom control interventions. Interestingly, HP participants recognised that 
respiratory physicians were not always aware of or had confidence in delivering effective 
symptom control:  
‘the patients get used to the breathlessness, their doctors and nurses get 
used to the breathlessness, and (..) the penny doesn't drop that maybe 
they need to have um (1) to use drugs for the symptomatic relief of 
breathlessness.’ (GP) 
There was a clear feeling that the focus of care at the end of life should be in the community 
rather than the secondary or tertiary care setting but that this wasn’t always possible due to a 
lack of confidence/provision of resources in the community. This was expressed by the patients, 
informal caregivers and HPs alike. The ILD Consultant explained that the patients were kept in 
the secondary/tertiary care setting out of necessity: 
‘I think in most cases it is relatively straight forward to recognise when 
we've reached the limit of (..) what we can achieve medically, er and I think 
the major incentive for keeping patients under hospital care is to try and 
provide some supervision of the end of life (..) to ensure that they are at 
least getting some management of that, whereas in an ideal situation I 
think that would transfer (..) fully to the community with us providing a sort 
of backbone of hospital based setting just providing back up for 
unexpected complications or disease developments…… patients often I 
find like to come and see us (..) over and above their secondary care 
provider or their GP and my perceptions the reason for that are are really 
that when they come here they see a whole team of nurses, physios, OTs, 




Clearly HP participants such as the ILD Consultant and ILD CNS felt that PIF-ILD patients 
needed support in the community at the end of life above and beyond that of seeing the GP. 
There was a universal view across HP participants that there was poor end of life care for these 
patients. None of the patient participants or any of the loved ones cared for by the informal 
caregiver participants had palliative care involvement and all the HP participants felt that this 
was rare. All HP participants felt that there was still an association of palliative care with 
malignant disease and a failure to appreciate that pulmonary fibrosis towards the end stage 
behaves much like a malignant disease and causes unpleasant symptoms towards death. This 
had contributed to a lack of referrals. HP participants felt that all patients should be referred 
earlier for palliative input and have more symptom control interventions.  All HP participants felt 
that their appeared to be an inconsistency across the group on whether patients were referred 
and this affected their overall management and end of life care. Interestingly, HP participants 
recognised that respiratory physicians were not always aware of or had confidence in delivering 
effective symptom control interventions: 
‘My perception is that again with malignant disease I think people are well 
trained now to recognise (..) when it's reached a point when medical 
treatment is futile, I think in interstitial lung disease that's much less well 
recognised even though we know that the sort of physiological parameters 
that indicate (..) the patient has less than 6 months to live, I think there is a 
failure to sort of use that to trigger um palliative (..) end of life treatment for 
these patients.  Er and I think that's particularly so when patients are of an 
age that they can be considered for transplant and that's almost a double 
edged sword. I mean the list of the transplant people almost don't want to 
provide to palliative treatments yet we know that over half the patients on 
the transplant waiting list will die of their disease and won't be 
transplanted, so (..) I don't think we the respiratory community are very 
well switched on to the management of these patients.’ (ILD  Consultant) 
All HP participants recognised the importance of accurate prognostication and timely 
conversations to ensure that patients and informal caregivers had the opportunity to make end 
of life plans. However, these did not appear to be occurring. 
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4.4.4.2.5 Theme 5 Co-ordination and satisfaction with current care 
The vast majority of patient and informal caregiver participants were happy with the care from 
the specialist centres. However, involvement of the GP was limited and 2 patients (Jim and Lea) 
said that they were not happy with care from the GP and did not feel confident in going to them 
for management of their PIF-ILD. This was supported by Joan, wife of Paul, who felt that the GP 
appeared disinterested as Paul was under the care of a specialist hospital and Jane, daughter 
of Anne, who felt that the GP was ill-informed about the disease as she had needed to provide 
him with written information about the disease.  
There was poor multi-disciplinary team involvement with a minority of the patients seeing 
respiratory nurses in the community (2/8) and no patients had been referred to occupational 
therapists or physiotherapists in the community. There were also concerns about continuity of 
care with inconsistencies of provision of support which informal caregivers such as Jane 
worryingly felt reflected a lack of concern:  
‘there’s no continuity and when you see so many different people who (1) 
don’t even know who you are (..) then you really don’t feel that anyone 
cares (slight laugh) at all to be honest..’ (Jane, in her 40s and daughter of 
Anne who had advanced IPF) 
In addition, both patients and informal caregivers felt that PIF-ILD was not a priority compared 
to other diseases such as cancer and COPD and this frustration was expressed by Peter: 
‘my opinion, in answer to your question that pulmonary fibrosis is (..) um 
(..) no let's say let's say nowhere near a priority and I think it's nowhere 
near a priority because so much or so little is known about it and at the 
same time, the bit that is known is the bit that they can't do anything about 
it and so that's why it's not a priority.’ (Peter, in his 60s with IPF) 
Informal caregivers such as Penny, wife of James, expressed that they would like to know more 
information about the services that were available as she felt completely in the dark. Penny also 
mentioned that it would be helpful to have an appropriate point of contact in the community as 
she did not feel that this was available or certainly had not been communicated to her and she 
and her husband would find that comforting. Joan, wife of Paul, reiterated that she would like 
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clarification of what to do or who to contact in an emergency and it had clearly been something 
that had been playing on her mind: 
‘sometimes you think (LAUGHS) who would I phone, who would I speak 
to, would I, if I was panicking, obviously I'd have to phone my own doctor 
he's nearer, but if I wanted information, I don't know that I would get it from 
him, he'd probably say to phone you, it's, it's, that's a grey area there, 
there could be a bit more done there, bit more (..) information from here, to 
say um you can contact this person or that person if you need to, and this 
is here, and possibly from our own doctors to say well this is (..) in place, 
but then perhaps if I went down and made an issue then they would tell me 
all that information, I don't know, you know, it's just sometimes you (..) 
can't be bothered (LAUGHS).’ (Joan in her 50s, wife of Paul) 
HPs such as the physiotherapist and ILD CNS felt that earlier referral to physiotherapy would 
improve care and symptom control and that overall there was under referral for this disease 
group. This was supported by patients such as Peter who had found it extremely helpful to 
attend pulmonary rehabilitation but had been referred 15 months after diagnosis: 
‘I should have been on the pulmonary the rehab when I got the diagnosis.  
Because I found things out in the pulmonary in the rehab that I didn't know 
about and I spent 15 months with the disease, so things were (1) arse 
about face would be the term….I've been I've gone on 15 months with 
things happening to me, that I didn't understand for me until part of the 
education sector of the section of the rehab explained it to me something 
as simple  as breathing exercises, (2) that's had a major impact on me um 
(2) you know when I've been struggling I now know just how to do 
breathing control I've gone 15 months not knowing how, crazy.’ (Peter, in 
his 60s with IPF) 
Worryingly, some patients and informal caregiver participants felt they didn’t know enough 
about the disease, symptom control and services that should be available to comment on 
satisfaction of the current services available to them.  
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Communication between HPs and co-ordination of care was flagged as a problem by all 
participants.  Penny, wife of James stated: 
‘I think they try to liaise between each other but it so often falls apart….. 
there is really a short coming amongst um getting information from one 
aspect of the medical profession to the other. ‘ (Penny, in her 60s, wife of 
James with advanced IPF) 
And also by Jane, daughter of Anne, whom it had clearly affected: 
‘the breakdown of communication over in [local hospital] has been (...) 
dreadful for someone who’s got (...) supposedly um… you know a terminal 
illness, it’s been dreadful. ‘(Jane, in her 40s and daughter of Anne who had 
advanced IPF) 
This sentiment was supported by HP participants who were frustrated at poor communication 
and recognised that vast improvements were needed to ensure adequate co-ordination of end 
of life care: 
‘we need to really (...) review the way we think about people who've got 
(...) um rapidly progressive non-malignant disease or people who've got 
who are literally dying from non-malignant disease, the kind of 
communication we expect around cancer (...) really should happen around 
(...) these other diseases, so take IPF (...) um (...)….I think that the quality 








4.4.4.2.6 Theme 6 Views of the H2H CC model of care 
It was recognised by HP participants such as the Palliative Care Consultant and GP that there 
needed to be changes to the current model of communication in end of life care for PIF-ILD 
patients to bring it into line with the standard of communication that was expected in other end 
of life care diseases such as cancer: 
 ‘I think communication tends to take place mostly by by letter um which is 
a sort of  after you see somebody in clinic or at home or something like 
that, which (2) is helpful to some extent, but also I think [it] has its 
limitations in the sense that um (2) you you tend to deal with single 
particular problems at particular points in time, um, but there is is no kind 
of communication that I've ever been involved in, that sort of stands back 
from things a bit and says ok, what are the issues with these people, or 
even with somebody in particular, and, um tries to get the bigger picture 
and put some planning into place.  So it's always, you are always dealing 
with crisis management to some extent. You know you are always dealing 
with um (1) problems as they happen, but there's never a chance to stand 
back and see the big picture and do things like, say ok have these issues 
of end of life care [have] been addressed properly for example, um whose 
going to do it, um you know clarify what everybody roles are, and that kind 
of thing.’ (Palliative Care Consultant) 
When described to them, the vast majority of patient, informal caregiver and HP participants felt 
that the model of the H2H intervention was an excellent one and were overwhelmingly 
supportive of it.  Informal caregiver participants such as Joan, wife of Paul admitted to panicking 
and not knowing what to do when Paul became short of breath. She could only foresee this 
getting worse in the future but felt that if she clearly knew a plan of action or who to contact, that 
this would help both her and Paul. Patients such as Jim explained that at the moment if he was 
to get breathless and he panicked, he would have no option but to call ‘999’ as both him and his 
wife would not know ‘what else to do’.  In addition, health care professional participants such as 
the ILD CNS felt that clearly allocated roles and responsibilities which were communicated 
across the board would be helpful in ensuring that all HPs took appropriate responsibility when 
necessary. The GP interviewed recognised that the CC model of care would facilitate the GP to 
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take a more prominent role in the end of life care of the patient whilst being supported by other 
HPs in the community.   
Very few concerns were made about the model of care but one included the difficulty of being 
able to get all the HPs to attend a CC at the same time which was raised by the Palliative Care 
Consultant who was overall extremely supportive of the idea.  There was a hesitation from one 
patient (Lea) and this was concerning her confidence in her GP.  She did not feel that her GP 
would be able to manage the care in the community (even with support) and expressed that she 
would not want to transfer the focus of her care from secondary care to primary care.  
Other points made by patients and informal caregiver participants included that flexibility in the 
service would be needed to accommodate people who did not wish to have a great deal of input 
initially but may do at a later stage and also if people had other co-morbidities, then these HPs 





 Implications for the requirements of a palliative intervention from the qualitative 4.4.4.3
work in modelling theory and process phase 
The findings from the qualitative interviews used in the modelling theory and process have 
indicated a number of requirements of an adapted H2H model. An adapted H2H model would 
need to ensure that all the patients’ and informal caregivers’ information needs are met, it would 
need to address any unrealistic perceptions and where appropriate facilitate end of life care 
decisions. Finally, an adapted H2H model would need to facilitate and co-ordinate care, whilst 
improving  communication and allocating clear points of contact for patient and informal 






 Theoretical perspective 4.5.1
This qualitative work is in a group of people with a progressive disease with no cure. Many of 
these patients and informal caregivers are initially under the impression that this is a chronic 
disease. Both patients and informal caregivers have gradual realisation of the seriousness of 
the disease and this journey is often difficult. These are ordinary people trying to manage a 
problem. The problem has a physical basis and patients struggle to come to terms with the 
physical changes and symptoms but this is not always the identity that patients like to present to 
the world and to their loved ones. Social relationships are central to the formation of an 
individual’s identity and self-hood with others.(146) This perspective underlies this qualitative 
work which attempts to show how people with PIF-ILD try to understand and cope with the loss 
of individual identity and threats to social relationships. Bury (147) describes the concept of 
“biographical disruption” in describing the disease and the concept that the disease represents 
an assault not only on the person’s physical self, but also on the person’s sense of identity, 
calling into doubt the person’s self-worth. Bury discusses how the meaning of illness lies in its 
consequences and significance.(148) The consequences of the disease are certainly very 
important in the initial stages. That is, the physical impact with the symptoms and change in 
body image. However, as the disease progresses, the significance of the disease becomes 
more important. The disease had a profound influence on how patients regarded themselves 
and they struggled to come to terms with the loss of who they had been and loss of identity. 
This qualitative work describes a story of an illness concept which Lopowski (149)  described as 
the view that illness is an “irreparable loss”.  Coping in this instance refers to the kind of 
behaviour and meaning which people have constructed around their experience of having PIF-
ILD. Internal control means having the conviction that one can influence the outcome.(150) 
Internal control conviction tends to be more concerned with active coping strategies and a 
greater sense of satisfaction with life, whereas the externalisation of responsibility tends to have 
less favourable effect.(151) However, there was a distinct lack of internal control expressed by 
PIF-ILD patients and this appeared to distress the patients greatly. Patients described a lack of 
control over the disease and the frustrations associated with this. This is referred to not only in 
the physical aspect but also the social aspect. Thoits (152) discusses how a range of 
relationships provides people with a set of positive identities. This set of identities in turn is used 
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as a set of data for a person to use in shaping the self, providing a basis for a sense of control 
and a feeling of well-being. Coping refers to the cognitive processes whereby the individual 
learns how to tolerate or put up with the effects of illness.(148) Coping in the sense of 
maintaining a feeling of personal worth and a “sense of coherence” in the face of disruption has 
been seen as an important buffer against the stress of chronic illness.(153)  Very few patients 
during these qualitative interviews appeared to be coping with their disease. PIF-ILD appeared 
to be disruptive to the patients on both a physical and cognitive level. Living with PIF-ILD 
appeared to weigh heavily on the emotional equilibrium of patients and informal caregivers. 
With patients finding it difficult to cope with the physical changes, sustaining relationships with 
family and friends and coping with the loss of social relationships and identity.  Normalisation 
from this viewpoint, a form of coping, may refer to the psychological “bracketing off” of the 
impact of the illness, so its effects on the person’s identity remain slight.(148) In that sense, very 
few patients and informal caregivers had normalised the disease. In fact, many patients (both 
reported by the patients themselves and by the informal caregivers), worried about their disease 
to the extent that PIF-ILD had taken a dominant role in the identity of the patients. In addition 
there appeared to be a failure to legitimise the disease in the patients’ life. That is a failure to 
maintain a sense of personal integrity, and reduce the threat to social status.(148) The use of 
the term strategy suggests the need for dynamic view of choice and constraint, as people 
attempt to weigh up alternative forms of action.(148)  
 
 Discussion of methods 4.5.2
The Framework method of analysis provided me clear steps to produce highly structured 
outputs of summarised data which can could then be interrogated.(134) This does not suggest 
the currency of the findings are of little worth. Indeed, a number of recent studies that have 
utilised this approach have made important contributions to sociological theory.(154, 155) In 
addition, Framework analysis has been used effectively in clinical research aimed at developing 
interventions.(156, 157) At all stages, steps were taken to maximise rigour and validity. For 
example, where themes/categories were not immediately apparent, I repeatedly followed the 
stages of data analysis with reflection and reviewing the data from different perspectives to 
ensure high quality findings. When considering which method of qualitative analysis to use, 
unquestionably the nature of Framework analysis was intuitively  appealing as it provided clear 
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structure for me as a ‘first time’ qualitative researcher. However, it also allowed me to use both 
a deductive approach to the analysis, with themes and codes preselected (based on the 
literature and discussion with experts on the Project Advisory Group) and an inductive approach 
which allowed themes to be generated from the data independent of the coding framework. I 
believe this has not only provided me with data which is rich and a meaningful reflection of 
patients’ and informal caregivers’ needs and experiences, but also importantly data that are still 
relevant to my research aims.  
 Limitations 4.5.3
There are limitations to this qualitative component of the study. First, the number of participants 
interviewed was relatively small. However, through integration of data from the three groups of 
participants, the elaboration and enhancement of findings has contributed to rigour and the 
credibility of the finding I present. Second, all subjects had a TLCO less than 40% indicating 
severe, if not terminal, disease. There can be marked heterogeneity in progression within the 
disease population.  However, there are clear needs in all these patients and informal 
caregivers. Future work may explore data more widely across the disease trajectory and 
potentially longitudinally. In recruiting informal caregivers, I did not automatically use patient and 
informal caregiver dyads. In hindsight, this may have been an easier way to recruit informal 
caregivers. Finally, all patients and informal caregivers were recruited from specialist ILD 
centres in the UK. Patients and informal caregivers attending non-specialist respiratory clinics 
may have different specialist palliative care needs to the ones recruited in this study. The 
findings are however, in agreement with previous conducted internationally.(37, 38) 
 
 Summary of findings for modelling theory and process phase 4.5.4
In this section, I will model theory and process to be used in the Feasibility and Piloting stage. 
To do this, I will present the findings from the systematic review and qualitative interviews which 
relate to the modelling theory/process stage of the MRC guidance. I will then show how these 
results have been incorporated to adapt the H2H CC model of care for PIF-ILD. Finally, I will 
discuss how the systematic review and qualitative work have informed the outcomes that will be 




 Summary of finding from systematic review 4.5.4.1
In developing and evaluating a palliative intervention developed from the systematic review, I 
would need to use primary outcome measures related to symptom control and Qol and if 
possible use a RCT model of evaluation. 
 
 Summary of findings of specialist palliative care needs from retrospective review 4.5.4.2
and qualitative work 
A summary of the specialist palliative care needs identified in both the retrospective review of 
medical notes and the qualitative work is shown in Table 4-6  Page 180.  
Table 4-6 Summary of specialist palliative care needs identified from retrospective review of medical notes 
and qualitative work during Development phase 
Specialist palliative care needs Development phase  
Physical  Shortness of breath RRM & Qual 
Cough RRM & Qual 
Pain RRM 
Fatigue RRM & Qual 
Psychosocial Anxiety RRM & Qual 
Depression RRM & Qual 
Insomnia RRM & Qual 
Support for informal 
caregiver  
Qual 
End of life planning  Including discussions 
surrounding Preferred 
Place of Care and 
Death 
RRM & Qual 
RRM= Retrospective Review of Medical notes  Qual=Qualitative work 
 
An adapted H2H model of care will therefore need to: 
1. Address the symptom control needs of the patient and psychosocial needs of patient 
and informal caregiver 
2. Address the information needs of the patients and informal caregivers in a sensitive and 
individualised manner 
3. Address end of life decisions and end of life planning where appropriate 
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4. Allocate clear points of contact for patient and informal caregivers for a change in 
clinical state/emergencies 
5. Educate and guide HPs on the symptom control of these patients 
6. Invite other disease groups to the CC 
 
 Integration of the background and qualitative work to adapt the 4.5.5
H2H model  
The current cancer model of H2H is set up to address aims 2-4.  By conducting the H2H CC in 
PIF-ILD, this is likely to increase the profile of PIF-ILD within the community. In addition, 
education about the study and the intervention will also do this. Other disease groups are not 
normally invited to the H2H CC but this can be incorporated into the model. However, education 
and guidance of appropriate palliative care interventions to improve symptom control are 
needed. An appropriate way to do this may be to provide HPs involved with evidence based 
guidelines at the CC for the symptom control of these patients. Guidelines provided from a 
specialist centre may help allay some of the concerns and confidence issues. In addition, it may 
ensure some uniformity to the palliative care delivered. Guidelines for the symptom control of 
patients with PIF-ILD were therefore developed which have incorporated the limited evidence 
base for PIF-ILD with standard palliative care treatments (APPENDIX B).  Graphical depiction of 
the adapted H2H model is shown in Figure 4- Page 182.  
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Contact from H2H CNS 
Multi-disciplinary CC  
Use of evidence based guidelines  
Address psychological/support issues 
Address information needs 
Address end of life planning needs 
Codify responsibility for each HP  
Clear points of contact 
 
Follow up by H2H CNS and then subsequently by 
community services 
Referral to appropriate community HP if needed 
HP invited to CC  
Individualised care plan prepared  
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4.6 Conclusion 
This chapter includes research that adds to the evidence base forming part of the 
identifying/developing theory stage of the Development stage of the MRC framework. The 
palliative care needs of those living with PIF-ILD assessed through qualitative work were 
presented and resultant recommendations for adaption of the H2H model of care.  
I have taken findings from the background work, systematic review and qualitative work to 
develop and adapt the model of H2H to be used in PIF-ILD. I will now present the methods, 
results and discussion from the RCT in the Feasibility and Piloting stage.  
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Chapter 5 Randomised Controlled trial- Feasibility and Piloting 
stage of the MRC guidance 
5.1 Introduction 
This chapter will form the Feasibility and Piloting stage of the MRC guidance. I will initially 
present aims of the RCT and then the submitted paper followed by more detailed methods, 
results and discussion.  
 
Figure 5-1 Figure showing RCT to be presented in overall plan of study 
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5.2 Aims of RCT 
 To define appropriate outcomes and measures for the adapted H2H intervention. 
 To begin to evaluate H2H in a phase II study  
 To evaluate the intervention in terms of feasibility and acceptability in a phase II study.  
 To use the above work to inform a future larger randomised controlled trial (RCT phase 
III/Evaluation trial). 
 
5.3 Bajwah S, Ross JR, Wells AU, Mohammed K, Oyebode C, Birring 
SS, Koffman J, Higginson IJ, Riley J. Palliative Care for Patients 
with Advanced Fibrotic Lung Disease: a randomised controlled 
phase II and feasibility trial of a case conference intervention. 
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I will now discuss the methods, results and discussion in greater detail: 
5.4 Methods  
 Study Design 5.4.1
The study design used is a Phase II fast-track randomised controlled trial forming part of the  
Feasibility and Piloting stage of the MRC’s guidance on development and evaluation of 
complex interventions. The main aim of a phase II trial is to identify therapies that warrant 
further investigation based upon acceptable side effects and promising efficacy. Additional 
purposes include assessing feasibility and acquiring further information about the intervention 
(such as acceptability).(158) A phase II trial highlights if an intervention may be potentially 
efficacious and warrants further study in a larger, appropriately powered phase III or Evaluation 
clinical trial.  
When deciding on the trial design, the benefits and difficulties of experimental and quasi-
experimental designs were considered.(159) It was decided that either a matched control group 
study or a randomised controlled trial (RCT) would be most appropriate. A RCT was chosen as 
it would decrease the effects of patient selection bias and increase ability to ensure that uniform 
evaluation criteria were used. It was felt that if the trial ran without randomisation, it would be 
difficult to conduct a RCT subsequently as staff may feel that there was a reduction in the 
service delivered which would then make recruitment to a phase III or Evaluation trial 
challenging. Also, subsequently it would be problematic to find a suitable non-random 
comparison group. In the Fast-track RCT design all patients have the possibility to receive the 
intervention, some immediately, and other after a wait (equivalent to a normal wait within the 
NHS for PIF-ILD patients). A Fast-track trial has previously been used successfully by 
Higginson et al in delivering a palliative care service to Multiple Sclerosis patients.(159)  A Fast-
track RCT was agreed as it provided the rigour of a RCT whilst allowing all patients to receive 
the intervention. It was felt that if all the patients were to receive the intervention, this would 
maximise recruitment and referral from ILD HPs. The pros and cons of both a matched 
controlled and Fast-track design RCT that were considered are depicted in Figure 5-2 Page 
221.  
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Figure 5-2 Pros and cons of using a matched control design compared to a FT randomised controlled trial 
design as applied to the PIF-ILD H2H intervention 
Matched Control Group FT Randomised Control Trial 
Patients at other hospitals are unlikely to 
be comparable to RBH patients 
Using patients from RBH throughout study 
Not everyone will receive the service Everyone will eventually receive service 
No issues with patients dying before receiving 
intervention 
Patients may die before intervention 
received 
Realistic F/U time period needed Intervention must show result before 
crossover period 
HP in the control group may change their 
practice 
Members of CC might be involved in 
looking after patients in both the WL 
group and FT group which may bias 
results 
Has been used in H2H cancer study Used successfully previously in palliative 
care in Multiple Sclerosis(159) and 
Breathlessness Intervention Service studies 
Pros are shown in italic, Cons in bold 
Mixed methods were used in his study combining a quantitative trial with in-depth qualitative 
interviews. I will now present the methods for the quantitative trial followed by the methods for 
the qualitative interviews. I will then discuss criteria for both feasibility and acceptability that 
were used and what information was collected to inform a future Evaluation trial.  
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 Quantitative component of RCT 5.4.2
 Setting and Participants  5.4.2.1
Patients were approached for recruitment if they had a clinical diagnosis of PIF-ILD (IPF 
(diagnosed using ATS/ERS criteria(160)) or fibrotic Non Specific Interstitial Pneumonia (NSIP)) 
and the following prognostic parameters: extensive disease (>60%) or honeycombing (>35%) 
on HRCT or CPI >50. Previous staging work done has shown that this group of patients have a 
30% survival at one year and a 10% survival at two years. (APPENDIX C-5)  Patients were 
identified by either the ILD or clinical palliative care teams at RBH from either the inpatient or 
outpatient setting. Patients were initially approached about the study by their clinical teams and 
if patients were interested in taking part, their details were passed on to me. At this point I would 
approach and screen patients for suitability. The informal caregivers of these patients were also 
approached. Where possible, dyads of patients and informal caregivers were recruited. 
However, if informal caregivers did not wish to take part or patients did not have an informal 
caregiver, this did not exclude patients from taking part. Patient and informal caregiver 
participants were excluded if they were less than 18 years old, they did not have capacity to 
consent or if they did not have adequate understanding of written English to complete the 
questionnaires.  
 
 Study protocol 5.4.2.2
The full protocol is available in APPENDIX C. A summary will be provided here:  
After providing consent and baseline interview, patients were allocated to Fast Track (FT) or 
Waiting List (WL) by independent off-site computerised randomisation. If patients were 
randomised to FT, their information was passed to the H2H nurse to organise a CC as soon as 
possible. If patients were in the control arm, they continued to receive Standard Best Practice 
(SBP) for 4 weeks. After this time, they received the intervention and were interviewed and 
followed up as for the FT group (see Figure 5-3 Page 223 and APPENDIX C-1b) 
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Baseline 4 Weeks 8 weeks 
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 The intervention 5.4.2.3
Patients affected by PIF-ILD received a range of services (Standard Best Practice SBP). These 
were available to all those who received H2H immediately or after a delay. Services included 
general practitioners, physiotherapy and respiratory services and community palliative care 
teams. All had seen an ILD physician at RBH preceding referral and remained under specialist 
care with access to in-patient care as appropriate. H2H was offered in addition to the SBP 
services outlined. H2H aimed to complement the existing local services and not to duplicate or 
replace them. Preliminary qualitative Development work conducted identified that evidence 
based guidelines for the management of the physical, psychological, spiritual and end of life-
planning needs for these patients was needed. These guidelines were developed and used as 
part of the H2H CC. (APPENDIX B).  The guidelines permitted a structured and evidence based 
practice in delivering palliative care to these patients where there had previously been none. 
The written guidelines acted as a supplement to the actual assessment. With the patients 
consent, a CC was organised in their home (or place of their choice). The patient, informal 
caregiver, H2H Clinical Nurse Specialist (CNS), GP, district nurse, respiratory nurse, community 
palliative care nurse and any other health or social care professional closely involved in the 
patients care were invited to attend. If patients weren’t already under the care of these 
community HPs, referrals were made by the H2H CNS.  
At the CC, current and anticipated care needs were discussed, and an action plan agreed 
allocating a responsible HP for each item. During the CC, individualised care plans were made. 
The care plan aimed to provide a quality comprehensive Palliative Care assessment with clear 
action plan.  This was then communicated with local services, both primary and specialist teams 
aiming to result in streamlining of transfer of data and codifying responsibility for the patient, 
hospital and community care professionals. The aim of the CC was to enable improved 
symptom control, Qol, crisis prevention and decreased hospital admissions. In addition, this 
intervention aimed to manage uncertainty by facilitating early discussion about disease 
progression, improving communication and addressing end of life planning needs. The H2H 
CNS followed up each CC (at 2 weeks, 1 month and 2 months) with the patient or informal 
caregiver. The ongoing palliative care of these patients were delivered by the community 
palliative care team as deemed appropriate by them.  
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The intervention was delivered by a H2H CNS using a standardised proforma for the CC and for 
follow up contacts (APPENDIX C-2a, 2b, 2c). In addition, the H2H CNS used the evidence 
based guidelines (APPENDIX B) to help ensure uniformity of advice given during the CC to 
patients, informal caregivers and HPs. The H2H CNS received training in the delivery of the CC 
from a number of H2H CNSs who were already using the intervention in the cancer setting at 
the Royal Marsden Hospital. This included multiple observations and observed delivery of the 
CC with constructive feedback.  
 
 Quantitative data collection 5.4.2.4
As recommended by the MOREcare guidance (14), where possible, outcome measures that 
have established validity and reliability in the PIF-ILD population, that are responsive to change 
over time, capture clinically important data, are easy to administer and interpret, are applicable 
across care settings and are able to be integrated into clinical care were selected.  
 
5.4.2.4.1 Primary outcome 
The primary outcome was to compare the change in Palliative Care Outcome Scale scores from 
baseline for each group at 4 weeks (4 weeks after the intervention for FT group and just before 
the intervention for the standard best practice group). The POS was developed in advanced 
cancer patients and includes aspects about pain and symptom control, patient and family 
psychosocial needs, and communication and information needs.(161) An adapted version which 
took account of the most common symptoms in this disease group was used in this study to 
provide an assessment of change in palliative care needs (including symptom control) 
(APPENDIX C-11).  The adapted POS used contains eight questions on anxiety, patient and 
informal caregiver concerns, and practical needs, each rated 0-4. It could be completed by the 
patient or informal caregiver. The scoring system ensured that there was some ongoing data 
available if the patient became unwell and was no longer able to complete the study. The POS 
was thought to be an appropriate primary outcome as it assesses overall palliative care need. 
The Development work had shown that patients and informal caregivers affected by PIF-ILD 
are affected holistically and the focus of their need is not just symptom control. There are no 
holistic palliative care measures validated in ILD.  
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5.4.2.4.2 Secondary outcomes 
Outcome measures used in the cancer H2H model were preferred to allow comparison of the 
H2H intervention between the cancer and PIF-ILD population. However to allow comparison to 
other interventions previously used in PIF-ILD, some outcome measures were replaced as 
informed by the systematic review conducted in Chapter 1. The systematic review showed that 
within each symptom, there was a wide range of outcome measures used with no uniformity or 
consensus on the most appropriate measures. Dyspnoea and Qol were the most reported 
outcome with eleven and six different outcome scales used respectively.  Table 5-1 Page 227 
shows the table from the systematic review showing the different outcome measures used in 
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Table 5-1 Table to show different outcome measures used in interventions to improve symptoms and Qol 
in PIF-ILD 
Type of outcome 
measure 
Symptom Outcome measure Papers using outcome measure 
Symptom control Dyspnoea Borg Dyspnoea Index Krowka 2007(162),  Ozalevli  2010(163), Zisman 
2010(164), Hicks 2007(165), Collard 2007(166), 
King Jr 2008(167), Raghu 2010(168), Rammaert 
2009(169), Jackson 2010 (170), Visca 2011(171) 
Medical Research Council Scale Antoniou 2006(172), Holland 2008(173),  Ozalevli  
2010(163), Varney 2008(174), Rammaert 
2009(169), Kozu 2011(175), Strieter 2004(176) 
Baseline Dyspnoea Index Nishiyama 2008(177), King 2011(178), King Jr 
2008(167), Raghu 2010(168), Strieter 2004(176), 
Rammaert 2009(169), Kozu 2011(175) 
Transition Dyspnoea Index King 2011(178), King Jr 2008(167), Raghu 
2010(168), Strieter 2004(176), Kozu 2011(175) 
Visual Analogue Scale  Rammaert 2009(169),  Allen 2005(179) 
4 step improvement in dyspnoea 
scale  
Turner-Warwick 1980(180) 
5 point dyspnoea scale  Agusti 1993(181) 
20 point dyspnoea scale  FioruCCi 2008 (182), Demedts 2005 (183),  
Undurraga 1998(184) 
University of California San Diego 
Scale 
Zisman 2010(164), King 2009(185), Lindell 
2010(113), Strieter 2004(176), Noble 2011(186) 
NYHA Krowka 2007(162) 
Hanania 1993(187) 
Mahler Dyspnoea Scale  Raghu 2008(188) 
Cough Visual Analogue Scale Hope-Gill 2003(189) 
Leicester Cough Questionnaire Lutherer 2010(190)  
 Question 2 on St George’s 
Respiratory Questionnaire 
Horton 2008 (191) 
 Dry, productive or absent Antoniou 2006(172) 
Depression HADS Rammaert 2009(169) 
Beck Depression Lindell 2010(113) 
Patient Health Questionnaire-8 Swigris 2011(192) 
Anxiety Beck Anxiety Lindell 2010(113) 
General Anxiety Disorder-7 Swigris 2011(192)  
Fatigue Fatigue severity scale Swigris 2011(192) 
Sleep Pittsburgh Sleep Quality Index Swigris 2011(192) 
Qol  SF36 
 
Holland 2008(173), King 2011(178), Zisman 
2010(164), King Jr 2008(167), Raghu 2010(168), 
Raghu 2008(188), Rammaert 2009(169), Swigris 
2011(192) 
SF-36 Japanese version Kozu 2011(175),  Tomioka 2005(193) 
 
SF-36 Turkish version 
 
Ozalevli 2010(163) 
St George’s Respiratory 
Questionnaire 
Nishiyama 2008(177), Antoniou 2006(172), 
Varney 2008(174), Zisman 2010(164), King 
2009(185), King Jr 2008(167), Raghu 2010(168),  
Demedts 2005(183), Raghu 2008(188)Rammaert 
2009(169), Mishra 2011(194) 
EQ5D King 2011(178), Zisman 2010(164) 
Chronic Respiratory Disease 
Questionnaire 
Holland 2008(173) 
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The choice of outcome measures for the feasibility/pilot RCT and rationale is explained in Table 
5-2 Page 228.  This is followed by detailed discussion of each measure to be used.   
 
Table 5-2 Outcome measures for Feasibility and Piloting stage and rationale for use 
 
 
VAS: Visual Analogue Scale for breathlessness.(195) The VAS is a vertical line 150mm long 
with anchors at each end to indicate the different levels of breathlessness. The VAS used in this 
study had levels of breathlessness of none, slight, moderate, severe and extreme. The subject 
was asked to mark a point that indicated the amount of breathlessness experienced at the 
time.(204) As breathlessness is a sensation that can change between measurements, the VAS 
is most suited to within-subject repeated measurement as it has the sensitivity required to 
measure minute changes.(205) 
 
D12 Scale: D12 scale is an overall score for breathlessness severity that incorporates seven 
physical items and five affective items.(196) Participants complete the D-12 in reference to their 
experience of breathlessness “these days” at baseline and follow-up. D-12 consists of 12 
BASELINE 
CHARACTERISTIC/OUTCOME 
INSTRUMENT/MEASURE RATIONALE FOR USE OF 
MEASURE 
PATIENT   
Patient Palliative Care Needs Palliative Care Outcome Scale(161) with 
symptom question including most common 
PIF-ILD symptoms- breathlessness, cough, 
fatigue, insomnia (to be completed by 
patient and carer) 
Includes aspects about physical 
needs, patient and family 
psychosocial needs, and 
communication and information 
needs. Validated in cancer.  
Patient breathlessness at best/worst Visual Analogue Scale(195) and D12 
scale(196) 
VAS used in previous PIF-ILD 
studies 
D12 used in H2H cancer trial 
Patient Qol  KBILD(197) and St Georges Respiratory 
Questionnaire SGRQ(198) 
KBILD validated in PIF-ILD 
population 
SGRQ used in previous PIF-ILD 
studies 
Patient functional ability  Palliative Performance Scale(199) 
MRC breathlessness scale(200) 
PPS used in H2H cancer trial 
MRC breathlessness scale used in 
previous PIF-ILD studies 
Patient anxiety Hospital Anxiety and Depression Scale 
(201) 
Used in previous PIF-ILD studies 
and H2H cancer study 
Patient use of other services Service use questions Used in H2H cancer study 
Preferred place of care and death  Used in H2H cancer study 
CARER   
Carer Qol Caregiver Qol Index (202) Used in H2H cancer study 
Carer anxiety Hospital Anxiety and Depression  scale 
(201) 
Used in H2H cancer study 
Carer's assessment of patient's use of 
services 
Service use questions Used in H2H cancer study 
Carer burden Zarit Burden Inventory(203) Used in H2H cancer study 
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descriptor items on a scale of none (0), mild (1), moderate (2), or severe (3). The time reference 
period for “these days” captures the current level of breathlessness experienced by patients as 
opposed to specifically on the day of the test or in response to a specific activity. Total scores 
from the D-12 range from 0 to 36, with higher scores corresponding to greater severity.  
 
K-BILD: The King’s Brief Interstitial lung disease (K-BILD) is a 15 item questionnaire consisting 
of three domains (breathlessness and activities, chest symptoms and psychological).(197) It 
has been validated in all ILD disease groups including IPF. A higher score indicates a higher 
Qol. Scores range from 0-100 with the minimal important difference (MID) having been 
calculated as 8 units of the total score.(206) 
 
SGRQ: St George’s Respiratory questionnaire (198) is a 50 item instrument designed to 
measure impact on overall health, daily life, and perceived wellbeing in patients with obstructive 
airways disease. Part 1 has a symptoms component (frequency and severity) with a 1, 3 or 12 
month recall (several scales); Part 2 has a activities component looking at activities that cause 
or are limited by breathlessness and an impact component looking at social functioning, 
psychological disturbances resulting from airways disease and referring to current state as the 
recall (dichotomous (true/false) except last question (4 point Likert scale).(207) The MID for IPF 
in each of the SGRQ domains is Symptoms 8 units, Activity 5 units, Impact 7 units and Total 7 
units.(198) A lower score indicates a better Qol. The generic SGRQ has been validated in 
IPF.(198) 
 
PPS: The purpose of the Palliative Performance Scale (PPS) is to assess the physical condition 
and functional status of persons receiving palliative care. Scores may range from 0 (dead) to 
100 (normal functioning).(199) The PPS measures three broad areas of function: intake, level of 
consciousness, and mobility. The PPS is scored from 0–100% at 10% increments. The PPS 
level for a given patient is determined by reading across the table at each 10% decrement to 
find the overall best fit. 'Stronger' performance factors are noted to be located on the left of the 
instrument 'softer' ones on the right. Patients who have a lower PPS generally are more 
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functionally impaired than those with higher scores. Prognosis is generally related to functional 
status in most palliative care patients. PPS has not been validated in ILD patients.  
 
MRC Dyspnoea scale: Medical Research Council (MRC) dyspnoea scale (score range, 1-5, 
with higher scores indicating greater impairment) (200) is used to classify participants according 
to activity limitation. The MRC scale comprises five statements that describe almost the entire 
range of respiratory disability from none (Grade 1) to almost incapacity (Grade 5). It is self-
administered by asking subjects to choose a phrase that best describes their condition. The 
MRC breathlessness scale does not quantify breathlessness itself. Rather, it quantifies the 
disability associated with breathlessness by identifying that breathlessness occurs when it 
should not (Grades 1 and 2) or by quantifying the associated exercise limitation (Grades 3–5). It 
has not been validated in ILD patients.  
 
HADS: The 14-item Hospital Anxiety and Depression Scale (HADS) is a widely used tool for 
assessing psychological distress.(201) The HADS comprises seven items that tap anxiety 
(score range, 0-21) and seven items that tap depression (score range, 0-21), with higher scores 
corresponding to greater distress. The HADs may be completed by both patient and informal 
caregiver. The HADs has not been validated in IPF. The MID in COPD is 1.5.(208) 
 
CQOLC: The Carer Quality of Life Cancer (CQOLC) measures four conceptual domains of QoL: 
physical functioning, emotional functioning, family functioning and social functioning.(202) The 
CQOLC consists of 35 items that have a five-point Likert format that range from 0 (not at all), 1 
(a little bit), 2 (somewhat), 3 (quite a bit) and 4 (very much): ten items relate to burden, seven to 
disruptiveness, seven to positive adaptation, three to financial concerns and eight single items 
to additional factors (disruption of sleep, satisfaction with sexual functioning, day-to-day focus, 
mental strain, informed about illness, protection of patient, management of patient’s pain and 
family interest in caregiving). The CQOLC scale is scored by adding up the score on each item 
to yield a total score for the instrument and scores can range from 0-140. For all items and 
domains that measure QoL, a higher score represents a better QoL.(202) There is no current 
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tool to measure informal caregiver Qol in non-malignant respiratory disease. Therefore the 
CQOLC was used which has been validated in cancer patients. Informal caregivers were clearly 
informed that the patient did not have cancer.  
 
ZBI: The Zarit Burden Interview (ZBI) was developed to measure subjective burden among 
informal caregivers of adults with dementia.(203) Items were generated based on clinical 
experience with informal caregivers and prior studies resulting in a 22-item self-report inventory 
that examines burden associated with functional/behavioural impairments and the home care 
situation. The items are worded subjectively, focusing on the affective response of the informal 
caregiver.(209, 210) Each question is scored on a 5 point Likert scale ranging from - never to 
nearly always present. Total scores range from 0 (low burden) to 88 (high burden). There is no 
validated tool to measure caregiver burden in ILD.  
 
Primary and secondary outcome data were collected at baseline, 4 weeks and 8 weeks as 
shown in Figure 5-4 Page 232.  
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(a) Baseline research interview and consent on entry to the study before randomisation 
B H2H CC arranged and conducted 
C 2 week post CC F/U by H2H CNS 
(d) Week 4 repeat of baseline interviews (for WL group, this would be pre H2H CC) 
E 1month post CC F/U by H2H CNS 
(f) Week 8 repeat of baseline interviews 
G 2 months post CC F/U by H2H CNS 
 
Figure 5-4 Graphical depiction of H2H intervention and outcome measurement in FT versus WL group 
 
  
Timeline FT  
(immediate referral to H2H service) 
Standard Best Practice 
(WL group) 




Week 1 B  
Week 2  
Week 3  C  
Week 3  
Week 4  (d) 
Week 4  B 
Week 5 E  
Week 6  C 
Week 7  
Week 8  E 
Week 8 (f) 
Week 9  G  
Week 12   G 
Death Place of death documented 
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 Qualitative component of RCT 5.4.3
 Settings  5.4.3.1
Patients and informal caregivers were recruited from those who had completed the trial. 
Participants who the H2H CNS felt would be amenable to taking part in qualitative study were 
approached. All interviews except for 3 (HP2, HP3 and HP4) were conducted by myself. A 
Specialist Registrar from the Royal Marsden Hospital (Neil Nijhawan) who had attended a 
qualitative interview course and been trained (including practice and observation interviews) by 
myself in qualitative interviewing conducted the other 3 interviews.  
All interviews were conducted in the patients’ and informal caregivers’ homes and HPs’ work 
places. The patients and informal caregivers were already aware of my role within the research 
team. Where possible, participants were interviewed on their own to ensure that there was 
minimal bias. This was possible for all interviews. Informed consent was obtained prior to 
starting the interview.  Whilst obtaining informed consent and prior to starting the interview, 
participants were assured that they could request for the interview to be stopped at any stage 
and for any reason.  
 
 Topic guide 5.4.3.2
The interview broadly followed the topic guide shown in Figure 5-5 Page 233 and APPENDIX C-
4. This was developed based on the literature and discussion with experts on the Project 
Advisory Group. The interviews were semi-structured so even though the topic guide provided 
direction and highlighted areas that needed to be addressed, I was able to be led by the 
participants on discussing areas they felt to be important and relevant.  
 
 What do you feel are the most important aspects of Hospital2Home 
(H2H)? 
Prompts: evidence based guidelines, codifying responsibility, multi-
professional working, crisis management, advance care planning 
 What have you found particularly helpful? 
Prompts: evidence based guidelines, codifying responsibility, multi-
professional working, crisis management, advance care planning 
 Is there anything about the intervention that you found unhelpful? 
 What if any improvements would you like to see in the H2H model of care? 
Figure 5-5 Topic guide for in-depth interviews for RCT 
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 Conduct  5.4.3.3
The interview process began by introducing the research and who I was. It was made clear that 
all data would be anonymised and kept completely confidential from anyone outside the 
research team. It was explained that the interview would be audio recorded and that if there 
were any questions that the participant did not wish to answer, then they could choose to omit 
or terminate the interview. In addition, it was explained that if the participant required a break or 
had any questions which they did not wish to be part of the interview, then the interview could 
be stopped.  
Recordings were made using a small unobtrusive digital recorder which was placed between 
myself and the participant. No one objected to the interview being recorded nor did anyone ask 
for the recording to be stopped during the interview.   
Participants appeared motivated to help take part in the interviews largely because they wanted 
to feed back about the intervention. 
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 Feasibility 5.4.4
There is no detailed description in the MRC guidance on how feasibility of a complex 
intervention should be measured and appropriate reference points at which an intervention is 
deemed feasible. It was also noted by Bugge et al (211) that there is no systematic guidance on 
how to categorise and explore issues that have risen related to feasibility. However, Shanyinde 
et al (212) reported 14 issues that need to be evaluated in feasibility or pilot studies. These are 
shown in  
Figure 5-6 Page 235 and will be used to analyse and present the feasibility data.  
Methodological issues 
1. Did the feasibility/pilot study allow a sample size calculation for the main trial? 
2. What factors influenced eligibility and what proportion of those approached were eligible? 
3. Was recruitment successful? 
4. Did eligible participants consent? 
5. Were participants successfully randomised and did randomisation yield equality in groups? 
6. Were blinding procedures adequate? 
7. Did participants adhere to the intervention? 
8. Was the intervention acceptable to the participants? 
9. Was it possible to calculate intervention costs and duration? 
10. Were outcome assessments completed? 
11. Were outcomes measured those that were the most appropriate outcomes? 
12. Was retention to the study good? 
13. Were the logistics of running a multicentre trial assessed? 
14. Did all components of the protocol work together? 
 
Figure 5-6 Methodological issues for feasibility of research highlighted by Shanyinde et al. 
 
In addition, time taken to arrange H2H CC, length of interview, deviations from H2H CC protocol 
and uncompleted CCs and reasons why amongst other details were recorded. A full list of 
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Pre CC Registered with appropriate GP?   
Involvement of HP prior to randomisation-
district nurse, community matron, community 
respiratory nurse, community palliative care? 
  
Referrals and designation of HP referred to by 
H2H CNS 
  
Refusal of any HP to accept referral  Designation Reason why 
Total time taken to set up CC   
CC Time taken from randomisation to CC   
Reason for delay if any   
Length of CC   
Number of relatives and designation of HP 
present 
  
Symptom control discussed? Number of 
symptoms  
Which symptoms 
Positive feedback about CC? Who from  Comments made 
Negative feedback about CC? Who from  Comments made 
H2H CNS comments re CC   
PPC (Preferred Place of Care) discussed at CC? If No, why 
not? 
PPC at time of CC 
PPD (Preferred Place of Death) discussed at 
CC? 
If No, why 
not? 
PPC at time of CC 
Post CC Did patient have an unplanned admission post 
CC and before trial completion? 
If so, for how 
long? 
Was reason 
anticipated in care 
plan? 
H2H CNS contacts outside of regular follow up 
(total in mins) 
  
Did patient have booked OP/IP/investigations 
which were cancelled post CC? 




Date of death   
Number of days from CC to death   
Number of days in PPC   
Death PPC achieved? If not, why 
not? 
 
PPD achieved? If not, why 
not? 
 
Did PPD change after CC? Details  
Place of death   
Figure 5-7 Information recorded about Case Conference (CC) 
  
There were no reference points in the literature on when a trial involving a complex intervention 
ought to be deemed feasible. Decisions about feasibility appear to be individual. For this trial, 
the trial will have been deemed to have been feasible if all three of the below criteria are met: 
 Consent rate of patients is at least 25% 
 There is recruitment of 52 patients over time period of the trial 
 80% of patients in the FT group were able to receive the H2H intervention within 14 
days of their allotted time.  
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 Acceptability 5.4.5
There is no formal guidance within the MRC guidance on how acceptability ought to be 
measured. However, previous trials (213, 214)  looking at acceptability of complex interventions 
using MRC guidance have looked at using a mixed methods approach with incorporation of 
both quantitative data (such as attrition rates) and qualitative interviews. Interestingly, I could 
find no reference point in the literature about levels at which an intervention would be deemed 
to be acceptable.  
For this trial, in addition to collecting recruitment and retention rates, a qualitative approach was 
used in the post-trial evaluation to assess the acceptability of the intervention for patients, 
informal caregivers and HPs using the topic guide shown in Figure 5-5 Page 233. In addition the 
H2H CNS recorded her experiences of delivering the intervention and observations of patients’ 
and informal caregivers’ responses during and after the CC was delivered.  
 
 Informing a future larger evaluation trial  5.4.6
The following information was recorded to inform a future larger evaluation trial: 
 exclusions, and drop-out rates 
 interpretation of study information  
 views of study design and outcome measures 
 problems with completing measures, including missing data.  
  
 Sample size and recruitment 5.4.7
Phase II studies are exploratory. They are not powered to provide a definitive answer of efficacy 
compared to standard treatment. However, they may be used to be to conduct exploratory 
analyses which may help to inform a future exploratory trial.(158) There is no robust data to 
enable calculation of precise sample size needed to identify a significant change in POS scores 
between each arm. As such interpretation of the analysis was treated with caution but it was 
thought that it may be helpful in hypothesis generating and in providing estimates of effect size 
for a larger evaluation RCT. As stated in the MOREcare guidance (14), it is important to 
estimate in advance levels of attrition and integrate these into sample size estimates. I 
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anticipated recruiting 26 patients per group ie 52 in all. Based on the local patient numbers, I 
estimated to identify 2 patients per week, and recruit and retain at least 1 each week giving 52 
patients in one year. I anticipated that this number was sufficient to estimate the change in POS 
score between baseline and 4 weeks with reasonable precision (assuming a standard deviation 
of 2, a 95% confidence interval for the difference between the intervention and usual care group 
would be 2.2 units wide ie mean difference ± 1.1 units, which I judged to be sufficiently precise). 
It was recognised that the POS data were likely to be skew and the study would allow time to 
identify the most appropriate way to analyse these data for a later larger evaluation study.  




Randomisation was provided by The Institute of Cancer Research - Clinical Trials and Statistics 
Unit (ICR-CTSU).Treatment allocation (FT/WL group) was by computer generated random 
permuted blocks with stratification dependent on severity of patient POS at baseline (patients 
with a POS score of equal or greater than 28 were classed as severe).  
 
 Amendments to protocol   5.4.9
After completing the systematic review (215) in Chapter 1, it came to light that the McGill Quality 
of Life questionnaire was not an appropriate Qol measure. The systematic review showed that 
this was not a measure that had been used previously in interventional studies in PIF-ILD. 
Therefore comparison of the H2H intervention in changes of score with previous interventions 
would not be possible. I therefore decided to use SGRQ instead as it would enable comparison 
with a number of other interventional studies. This amendment was made after recruitment and 
completion in the trial of the first patient.  
During the course of the trial, it became apparent that it was extremely difficult to get the CC for 
those patients who are randomised to the FT group organised within one week and sometimes 
the WL group’s CC at exactly 4 weeks. An amendment was therefore filed after recruitment of 
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the first patient to allow flexibility in the time points of the CCs and the assessments to be able 
to capture the data pre and post CC.  
Patients with PIF-ILD who fulfilled the diagnostic criteria but did not necessarily rate as having 
extensive disease were being referred to the study. These patients had clear specialist palliative 
care needs. As recruitment had been slower than expected, an amendment was filed requesting 
to recruit these patients. All patients recruited continued to be scored on the prognostic scoring 
system (APPENDIX C-5).  Amendments to protocol approval letters can be found in APPENDIX 
A.  
 
 Data Analysis 5.4.10
The primary endpoint for quantitative analysis was the change in total POS score (Baseline to 4 
Week) which was compared between groups. Independent sample t-test were used to compare 
POS total scores between the FT and WL group at 4 weeks (before the WL group received the 
intervention). For all other outcome measures, mean scores with standard deviations at week 4 
and week 8, mean change scores with standard deviations from baseline to week 4 and where 
appropriate, intervention effect size at week 4 are presented. If assumptions of normality were 
not met, non-parametric methods of analysis were used. Only patients with week 4 data were 
included in change analysis. The extent of missing data was explored and reflected on to 
assess whether occurred at random or whether there was a systematic pattern (whether data 
was missing at random or not, influenced how it was handled). The nature of missing data was 
classified and then a decision on how it was handled was made.  Descriptive statistics were 
used to report time taken to organise H2H CC, time and duration of CC and time taken in follow 
up. All quantitative data were analysed using SPSS v 20.  
 
All interviews were digitally recorded and then transferred verbatim onto a secure transcription 
database at the Royal Marsden NHS Foundation Trust. A palliative care secretary, who 
received appropriate training, transcribed the 15 interviews verbatim. All interviews were 
anonymised. During this process I listened to all tapes to identify the initial themes. I analysed 
transcripts line by line and coded relevant themes and categories into a coding framework 
developed a priori and built on during coding. The coding framework is shown in Figure 5-8 
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Page 240. Emergent themes were discussed with supervisor JK. Analysis of the data was 
conducted using a constant comparison approach (132) within Framework analysis as 
described by Ritchie and Spencer.(133) A number of stages were undertaken in this process 
and these were familiarisation, identifying a thematic framework, indexing, charting and finally 
mapping and interpretation (described fully in Chapter 4).  All qualitative data were analysed 
using NVivo 9.  
In keeping with the mixed methods approach, analyses is first presented as quantitative 
baseline clinical and demographic data and then drawing on both quantitative and qualitative 
data, I have compared and contrasted the quantitative findings with the findings from the 
qualitative work. The systematic comparison across data sources enabled me to begin to 
explain the nuances of outcomes and reasons why we may observe them and to begin to 














1. Overall positive comments about H2H 
2. Negative comments about H2H 
3. Possible effects of H2H CC model:  
i. symptom control 
ii. psychosocial wellbeing  
iii. communication between patient and family 
iv. communication between HP 
v. codifying responsibility 
vi. linking in to community services 
vii. change in relationship with specialist ILD service at RBH 
viii. multi-professional working 
ix. co-ordination of care 
x. crisis management 
xi. advance care planning 
xii. efficiency 
 
4. Ways in which H2H could be improved 
5. Feasibility/acceptability  of CC 
6. Feasibility/acceptability  of study design 
 Fast-Track design 
 Appropriate outcome measures 
 Timing of questionnaires 
 
7. Burden of questionnaires 
 Length 
 Number of times needing to be completed 
 Distress caused 
Figure 5-8 Coding framework for qualitative interviews in RCT 
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 Consent and ethical approval  5.4.11
Prior to enrolment, written informed consent was obtained from all patients, informal caregivers 
and HPs. The study was approved by the NRES Ethics Committee London – Chelsea (ref 
number 11/LO/0999).  Submitted and approved ethical approvals and amendments are in 
APPENDIX A.  
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5.5 Results 
 Quantitative results 5.5.1
Figure 2 in the published paper shows the CONSORT diagram of flow of patients through the 
study.  
 
 Baseline measures 5.5.1.1
Table showing baseline demographic and clinical characteristics for patients and informal 
caregivers are presented in the published paper as Table 2.  
At baseline, patients were found to be similar in age, sex and ethnicity. In addition, there was a 
similar distribution of disease group and disease severity (as measured by TLCO, CPI and 
extent of disease on CT). However, the FT group appeared more likely than the WL group to 
have co-morbidities FT 17 (65%) vs WL 13 (48%).  
 
 Implementation of intervention 5.5.1.2
25 patients in the FT and 24 patients in the WL group received the CC. Table 5-3 Page 244 
shows that the vast majority of the patients referred and included for the study came from ILD 
HPs (n=22 (88%) for FT, n=24 (83%) for WL) via either the outpatient clinic where I was 
regularly attending or via email. The vast majority (24 (96%) and 22 (92%) for FT and WL 
respectively were registered with a GP prior to recruitment. However, very few patients had 
either district nurse or community matron involvement prior to recruitment. Interestingly, more of 
the WL group had community respiratory nurse and community palliative care involvement prior 
to recruitment (community resp nurse FT n=2 (8%) vs WL 6 (25%) and CPCT FT n=1 (4%) vs 
WL 4 (17%)). The mean (range) time taken to set up the CC was 204 (60-360) mins in the FT 
group and 219 (60-390) mins in the WL group.   
The mean length (range) of CC in the FT group was 94 (60-120) mins and in the WL group was 
93 (60-150) mins. All patients in the WL group who received the CC had an informal caregiver 
who was also present at the CC. However only 19/25 patients who received the CC in the FT 
group had informal caregivers. 18/25 (72%) of these informal caregivers attended the FT CCs. 
  243 
There was no difference in the HP attendance at either groups’ CC.  The majority of patients 
had at least 3 symptoms which needed to be addressed at the CC. The 2 main symptoms 
addressed were shortness of breath and cough. PPC was discussed in 17 (68%) of FT and 23 
(96%) WL CCs. For 13 (52%) of FT and 23 (96%) of WL group this was home. PPD was 
discussed at 11 (28%) of FT and 10 (42%) of WL CC. Reasons for non-discussion for both PPC 
and PPD were patient choice. Implementation of the intervention in the 2 groups is compared in 
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Table 5-3 Comparison of pre-CC demographics 
 FT n=25 WL n=24 
Referring profession n (%)   
ILD 22 (88%) 20 (83%) 
Palliative Care 3 (12%) 4 (17%) 
   
Referral mode   
via clinic 16 (64%) 15 (62%) 
Via in-patient palliative care list 2 (8%) 3 (12%) 
Via phone from ILD HP 0 2 (8%) 
Via email from ILD HP 7 (28%) 4 (17%) 
   
IP/OP   
IP 2 (8%) 3 (12%) 
OP 23 (92%) 21 (88%) 
   
H2H nurse   
DLL 6 (24%) 8 (33%) 
CO 19 (76%) 16 (67%) 
   
Registered with a GP prior to recruitment?   
Yes 24 (96%) 22 (92%) 
No 1 (4%) 2 (8%) 
   
District nursing team involved prior to recruitment?   
Yes 2 (8%) 3 (12%) 
No 23 (92%) 21 (88%) 
   
Community matron involved prior to recruitment?   
Yes 0 0 
No 25 (100%) 24 (100%) 
   
Community respiratory nurse involved prior to recruitment?   
Yes 2 (8%) 6 (25%) 
No 23 (92%) 18 (75%) 
   
CPCT involved prior to recruitment?   
Yes 1 (4%) 4 (17%) 
No 24 (96%) 20 (83%) 
   
Total time taken to set up CC in min    
Mean (SD) 204 (78) 219 (86) 
Range  60-360 60-390 
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Table 5-4 Comparison of delivery of CC 
 FT WL 
Length of CC (mins)   
Mean (SD) 94 (17) 93 (23) 
Range 60 to 120 60 to 150 
Median 90 90 
   
Carer present at CC   
Yes 18 (72%) 24 (100%) 
No 7 (28%) 0 
Number of family members present at CC   
Mean 1.3 1.6 
Mode 1 1 
Range 0 to 6 1 to 4 
Number of HP (excluding H2H CNS) at CC   
Mean 2.6 2.8 
Mode  2 3 
Range 1 to 6 1 to 4 
GP present at CC   
Yes 8 (32%) 11 (46%) 
No 17 (68%) 13 (54%) 
District Nurse present at CC   
Yes 14 (56%) 19 (79%) 
No 11 (44%) 5 (21%) 
Community matron present at CC   
Yes 6 (24%) 4 (17%) 
No 19 (76%) 20 (83%) 
Community respiratory nurse present at CC   
Yes 5 (20%) 3 (12%) 
No 20 (80%) 21 (88%) 
CPCT present at CC   
Yes 19 (76%) 21 (88%) 
No 6 (24%) 3 (12%) 
Social Worker present at CC   
Yes 3 (12%) 0 
No 22 (88%) 24 (100%) 
Marie Curie present at CC   
Yes 1 (4%) 0 
No 24 (96%) 24 (100%) 
   
PPC discussed  at CC   
Yes 17 (68%) 23 (96%) 
No 8 (32%) 1 (4%) 
   
Reasons for non-discussion   
Patient did not wish to discuss 8 (100%) 1 (100%) 
   
PPC at CC   
Home  13 (52%) 23 (96%) 
Hospital 4 (16%) 1 (4%) 
   
PPD discussed at CC   
Yes 11 (28%) 10 (42%) 
No 18 (72%) 14 (58%) 
   
Reasons for non-discussion   
Patient did not want to discuss 18 (100%) 14 (100%) 
   
PPD at CC   
Home  7 (64%) 5 (50%) 
Hospital 0 0 
Hospice 0 2 (20%) 
Home/hospice 0 2 (20%) 
Undecided at present  4 (36%) 1 (10%) 
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 Missing data 5.5.1.3
Missing data is shown in Table 5-5 Page 246. As percentage of missing data for completed 
outcome measures is minimal and less than 5%, I have not used any imputation methods. 
Outcome data for completed (fully or partial) measures have been presented in section 5.5.1.4.  
Unfortunately the VAS breathlessness scale was not completed appropriately. As a result, 
patients were classing their breathlessness on a 5 point Likert scale of none, slight, moderate, 
severe and extreme. Data for VAS has been presented as such.  
Table 5-5 Amount of missing data for completed measures in the study, by time point for patient interviews 














POS Baseline 53 12 53 0 0 
 Week 4 47 12 52 1 <1% 
 Week 8 34 12 52 1 <1% 
VAS Baseline 53 1 53 (100%) 0 0 
 Week 4 47 1 47 (100%) 0 0 
 Week 8 34 1 34 (100%) 0 0 
D12 Baseline 53 12 51 (96%) 9 1% 
 Week 4 47 12 46 (98%) 5 <1% 
 Week 8 34 12 33 (97%) 1 <1% 
KBILD Baseline 53 15 47 (89%) 6* <1% 
 Week 4 47 15 44 (94%) 7** <1% 
 Week 8 34 15 33 (87%) 1 <1% 
MRC Baseline 53 5 53 (100%) 0 0 
 Week 4 47 5 47 (100%) 0 0 
 Week 8 34 5 34 (100%) 0 0 
SGRQ Baseline 52*** 50 29 (56%) 32^ 1% 
 Week 4 46 50 26 (57%) 31^ 1% 
 Week 8 33 50 22 (67%) 18^ 1% 
HADS Baseline 53 14 53 (100%) 0 0 
 Week 4 47 14 47 (100%) 0 0 
 Week 8 34 14 34 (100%) 0 0 
*5 patients missed the question “in the last 2 weeks, has your lung complaint made you feel fed up or down in the 
dumps?” ** 4 patients missed the question “in the last 2 weeks, has your lung complaint made you feel fed up or 
down in the dumps?” *** the first patient into the study completed the McGill quality of life questionnaire rather than 
SGRQ ^ The most commonly unanswered question was paid employment question with 20, 17 and 11 patients not 
answering in the baseline, week 4 and week 8 groups respectively.  
The paid employment question is: 
If you have ever had paid employment: 
My chest trouble made me stop work altogether  
My chest trouble interferes with my work or made me change my work  
My chest trouble does not affect my work  
 
Therefore if you have never worked or are retired, this question is not applicable to you. However, there isn’t a N/A 
response. Therefore, it is possible that patients completing this part of the questionnaire may have left it blank as they 
couldn’t find a N/A option 
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 Outcomes  5.5.1.4
5.5.1.4.1 Primary endpoint data 
There was a significantly greater reduction in total POS score between baseline and week 4 for 
the fast-track group than those in the waiting list group; mean change (SD) -5.7 (7.5) vs -0.4 
(8.0) respectively. The mean change difference between the two arms was -5.3 (95% CI: -9.8 : -
0.7) independent t test p=0.02; effect size (95%CI) of -0.7 (-1.2 to -0.1).  
5.5.1.4.2 Secondary endpoint data 
5.5.1.4.2.1 Patient data 
The primary and secondary endpoint data is shown in Table 5-6 Page 249. The change in POS 
at week 4 in the FT group was sustained at 8 weeks. In addition, there was a reduction in POS 
scores between week 4 and week 8 (week 4 score (SD) 16.8 (8.9), week 8 score (SD) 12.5 
(6.6)).  
There was an improvement in the VAS breathlessness scores as time progressed in the FT 
group. Of note, there was no improvement in VAS scores between baseline and week 4 in the 
WL group but there was improvement between week 4 and week 8. There was no improvement 
in D12 scores in FT group but there was an improvement in D12 scores between week 4 and 
week 8 with a reduction of mean value (SD) at week 4 from 25.0 (10.7) to 21.3 (10.5) at week 8 
in the WL group. There was no change in the MRC scores across both groups over time.  
There was an improvement in patient Qol data with effect size (95% CI) of the intervention at 4 
weeks of 0.6 (0.0 to 1.2) for KBILD. The KBILD score continued to improve in the FT group 
between weeks 4 and week 8 from 40.0 (16.2) to 43.2 (18.4). In addition, the KBILD score 
improved between week 4 and week 8 data collection in the WL group (30.3 (16.2) to 34.9 
(18.0) respectively). For the SGRQ, there was an effect size of -1.0 (-1.6 to -0.4) at week 4 for 
SGRQ impact and -0.9 (-1.5 to -0.3) for SGRQ total. Of note, there were marked improvements 
in SGRQ symptoms (65.8 (23.0) vs 60.2 (23.8)), impact (74.8 (14.9) vs 62.3 (13.5)) and total 
scores (78.6 (11.8) vs 70.8 (10.8)) in the WL group between week 4 and week 8.  
In addition there were positive effects on patient HADs scores with effect sizes (95% CI) for 
patient anxiety -0.6 (-1.1 to 0.0), patient depression -0.7 (-1.3 to -0.1), patient total HADs score -
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0.7 (-1.2 to -0.1) at week 4. This effect appeared to be sustained in the FT group with continued 
improvement in scores at week 8. Of note, there was improvement from week 4 to week 8 in the 
WL group- Anxiety (10.8 (5.5) vs 7.9 (5.5)), Depression (12.3 (4.8) vs 9.3 (4.5)) and Total Score 
(23.0 (9.7) to 17.2 (9.4)).  
5.5.1.4.2.2 Informal caregiver data 
Effect size of the intervention on POS scores as reported by the informal caregiver at week 4 
was -0.4 (-1.1 to 0.2). However, there was an improvement of POS scores in the WL group 
between week 4 and week 8 (18.0 (8.4) vs 13.7 (6.3)) respectively.  
Effect size of intervention on ZBI at week 4 was -0.6 (-1.2 to 0.1). However, there was an 
improvement in ZBI scores between week 4 and week 8 in the WL group (31.7 (17.3) vs 25.4 
(13.4)).  
Effect sizes of intervention on informal caregiver depression and informal caregiver total HADs 
score were -0.7 (-1.3 to 0.0) and -0.7 (-1.3 to 0.0) respectively. Of note, there was improvement 
between week 4 and week 8 scores for the WL group for Anxiety (11.7 (5.6) vs 9.8 (4.6)), 
Depression (9.6 (4.9) vs 7.2 (3.9)) and Total Score (21.3 (9.9) vs 17.0 (8.2)).  
There did not appear to be an effect of the intervention at week 4 on CQLC scores. However, 
there was improvement in score between week 4 and week 8 in the WL group: Burden (25.2 
(8.5) vs 22.1 (9.2)), Disruptiveness (9.3 (5.5) vs (7.6 (5.9)), Financial (2.7 (2.8) vs 2.3 (2.1)) and 
Total Score (66.3 (18.4) vs 60.2 (23.9)).  
 
5.5.1.4.2.3 Data related to study 
Table 5-7 Page 250 shows quantitative outcomes measured after the CC. As of study close on 
31/12/2013, a greater number of WL patients had died than FT: FT 8 (32%) vs 13 (54%). There 
appeared to be a similar length of time from randomisation to death for both groups. PPC and 
PPD was achieved in lower percentages of patients who died in the WL group; PPC: FT 8 
(100%) vs WL 11 (84%), PPD: FT 7 (88%) vs WL 10 (77%). A larger percentage of patients 
died at home in the FT group; FT 5 (62%) vs WL 5 (38%) and in hospital in the WL group; FT 1 
(12%) vs WL 5 (38%). All 3 patients who died before being able to receive the CC were in the 
WL group and all died in hospital.   
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Effect size  (95% 




4 weeks  
(mean (SD) 









or n (%) 
4 weeks  
(mean (SD) 







Primary endpoint N=26 N=23   N=27 N=24    
POS 16.8 (5.6) 11.2 (7.9) -5.7 (7.5)  17.0 (6.3) 16.8 (8.9) -0.4 (8.0)  -0.7 (-1.2 to -0.1) 
 The mean change difference between the two arms was -5.3 (95% CI: -9.8 : -0.7) Independent t test 
p=0.02 
  
Secondary endpoint   
Patients  
POS    N=19    N=15  
    11.2 (7.3)    12.5 (6.6)  
VAS N=26 N=23  N=19 N=27 N=24  N=15  
None  0 0  0 0 0  0  
Slight 0 2 (9%)  4 (21%) 0 0  2 (13%)  
Moderate 15 (58%) 15 (65%)  11 (58%) 8 (30%) 8 (33%)  10 (67%)  
Severe 11 (42%) 6 (26%)  4 (21%) 19 (70%) 16 (67%)  3 (20%)  
Extreme 0 0   0  0 0  0  
           
D12 N=25* N=22*  N=19 N=27 N=24  N=15  
 22.8 (8.7) 21.6 (10.1) -0.8 (7.2) 20.4 (9.8) 25.9 (8.2) 25.0 (10.7) -0.6 (21.3) 21.3 (10.5) -0.3 (-0.9 to 0.3) 
KBILD† N=26 N=23  N=19 N=27 N=24  N=15  
 35.8 (13.0) 40.0 (16.2) 3.5 (11.0) 43.2 (18.4) 32.3 (12.9) 30.3 (16.2) -2.6 (21.3) 34.9 (18.0) 0.6 (0.0 to 1.2) 
SGRQ  N=25** N=22**  N=18** N=26*** N=24  N=15  
symptoms 62.2 (17.7) 62.0 (20.5) 1.4 (16.5) 52 (20.1) 66.3 (24.5) 65.8 (23.0) -2.0 (23.7) 60.2 (23.8) -0.2 (-0.8 to 0.4) 
activity 88.9 (9.7) 85.3 (17.6) -3.1 (13.6) 87.1 (10.7) 93.7 (5.0) 92.4 (7.8) -1.6 (6.8) 91.4 (5.2) -0.5 (-1.1 to 0.1) 
impact 61.6 (18.0) 56.3 (20.3) -4.0 (19.7) 57.4 (20.8) 71.4 (12.8) 74.8 (14.9) 2.8 (13.3) 62.3 (13.5) -1.0 (-1.6 to -0.4) 
total 70.0 (13.0) 66.0 (16.4) -2.8(14.9) 65.7 (14.7) 76.8 (10.1) 78.6 (11.8) 0.7 (10.5) 70.8 (10.8) -0.9 (-1.5 to -0.3) 
PPS† N=26 N=23  N=19 N=27 N=24  N=15  
Median 60 60  60 60 60  60  
IQR (25-75) 50-60 50-60  60-70 50-60 50-60  60-70  
MRC  N=26 N=23  N=19 N=27 N=24  N=15  
Median 4  4  4 5 5  4  
IQR (25-75) 4-5 4-5  4-5 4-5 4-5  4-5  
HADs N=26 N=23  N=19 N=27 N=24  N=15  
Anxiety 9.6 (4.6) 8.1 (4.1) -1.7 (3.3) 7.1 (4.6) 9.7 (5.7) 10.8 (5.5) 1.2 (4.8) 7.9 (5.5) -0.6 (-1.1 to 0.0) 
Depression 9.0 (3.1) 9.4  (3.0) 0.3 (3.2) 8.3 (3.7) 11.0 (4.7) 12.3 (4.8) 1.5 (4.12) 9.3 (4.5) -0.7 (-1.3 to -0.1) 
Total Score 18.6 (6.4) 17.5 (6.3) -1.4 (5.0) 15.4 (7.7) 20.7 (9.0) 23.0 (9.7) 2.8 (8.1) 17.2 (9.4) -0.7 (-1.2 to -0.1) 
 
Carers  
POS N=19 N=15  N=13 N=26 N=22  N=15  
 17.8 (6.5) 14.7 (6.5) -2.9 (5.8) 16.1 (6.9) 18.5 (6.2) 18.0 (8.4) -0.7 (9.6) 13.7 (6.3) -0.4 (-1.1 to 0.2) 
ZBI N=19 N=16  N=13 N=26 N=23  N=16  
 22.2 (15.2) 22.3 (15.3) 0.1 (0.2) 26.2 (13.4) 32.2 (11.7) 31.7 (17.3) -0.1(0.3) 25.4 (13.4) -0.6 (-1.2 to 0.1) 
HADS N=19 N=16  N=13 N=26 N=23  N=16  
Anxiety  9.3 (4.3) 8.8 (4.8) -0.5 (4.8) 9.2 (3.7) 11.0 (5.9) 11.7 (5.6) 0.6 (5.3) 9.8 (4.6) -0.6 (-1.2 to 0.1) 
Depression  7.0 (4.9) 6.4 (4.1) -0.3 (3.5) 7.0 (4.2) 8.7 (5.0) 9.6 (4.9) 1.0 (4.6) 7.2 (3.9) -0.7 (-1.3 to 0.0) 
Total Score  16.3 (8.7) 15.2 (8.3) -0.8 (8.0) 16.2 (7.4) 19.7 (10.4) 21.3 (9.9) 1.7 (8.7) 17.0 (8.2) -0.7 (-1.3 to 0.0) 
CQLC† N=18 N=15  N=13 N=25 N=21  N=13  
Burden  21.9 (8.3) 21.5 (7.1) -0.6 (6.9) 20.2 (5.7) 25.2 (8.3) 25.2 (8.5) -0.2 (8.0) 22.1 (9.2) -0.5 (-1.1 to 0.2) 
Disruptiveness  7.8 (6.0) 7.1 (6.9) -0.6 (4.3) 7.7 (4.8) 9.6 (5.4) 9.3 (5.5) 0.0 (4.9) 7.6 (5.9) -0.4 (-1.0 to 0.3) 
Adaptation  15.6 (5.1) 15.8 (6.1) 0.5 (4.3) 15.9 (5.4) 14.7 (6.8) 14.4 (5.7) 0.1 (5.3) 16.8 (4.2) 0.2 (-0.4 to 0.9) 
Financial  2.8 (3.0) 2.5 (3.0) -0.4 (2.1) 2.4 (3.6) 2.7 (2.9) 2.7 (2.8) 0.3 (2.5) 2.3 (2.1) -0.1 (-0.7 to 0.6) 
Total Score 60.8 (17.4) 58.5 (15.3) -2.5 (11.0) 58.3 (15.6) 66.7 (16.3) 66.3 (18.4) 0.7 (15.2) 60.2 (23.9) -0.4 (-1.1 to 0.2) 
*1 patient had greater than 3 items missing on the D12 questionnaire and was therefore excluded as per 
author’s instructions. , ** 1 patient completed McGill quality of life not SGRQ, *** 1 patient removed as 




  250 
Table 5-7 Comparison of post CC outcomes 
 FT WL 
Number of deaths of patients who received CC (as of study close 
on 31/12/2013) 
8 (32%) 13 (54%) 
   
Number of days from CC to death n=8  n=13  
Mean (SD) 168 (106) 139 (129) 
Range 18 to 368 21 to 420 
   
Number of days in PPC   
Mean (SD) 166 (103) 133 (134) 
Range 18 to 358 0 to 419 
   
PPC achieved    
Yes 8 (100%) 11 (84%) 
No 0 2 (16%) 
   
PPD achieved (NB PPD changed for some patients after CC) n=8 n=13 
Yes 7 (88%) 12 (92%) 
No 1 (12%) 1 (8%) 
   
Actual place of death  n=8 n=13 
Home 5 (62%) 5 (38%) 
Hospital 1 (12%) 5 (38%) 
Hospice 2 (25%) 3 (23%) 
   
Place of death of those who died before receiving CC n=0 n=3 
Home  0 0 
Hospital 0 3 (100%) 
Hospice 0 0 
   
H2H contacts in addition to scheduled follow up (min)   
Mean (SD) 48.8 (77.5) 35.0 (48.1) 
Range 0-300 0-120 
  
  251 
 Qualitative findings 5.5.2
Qualitative findings are presented in Appendix 2 of the published paper.  
 Feasibility  5.5.3
1. Did the feasibility/pilot study allow a sample size calculation for the main trial? 
The sample size calculation for an Evaluation trial is based on using the population variance of 
the POS.(216) This is estimated by means of the common standard deviation from the phase II 










N=37 per group 
 
2. What factors influenced eligibility and what proportion of those approached were 
eligible? 
The main factor which influenced eligibility was diagnosis. Patients were referred to the study 
who did have an ILD diagnosis but were not IPF or NSIP patients. These patients were 
therefore excluded from the study on diagnosis.  82/120 patients who were approached were 
eligible.  
3. Was recruitment successful? 
Recruitment was successful. There were a number of barriers to recruitment as discussed in 
section 5.6 but these were not related to problems within the trial and would not be applicable if 
the trial were to be repeated.  
4. Did eligible participants consent? 
There were 82 patients eligible to participate in the trial (120 patients were referred for the trial 
and 38 did not meet inclusion criteria). 15/82 of these patients died before they could be 
approached to take part in the trial. Of the remaining 67 patients, 53 consented to be included 
with 14 declining to participate. Therefore 79% of patients eligible to take part in the trial that 
were approached, consented.  
  252 
5. Were participants successfully randomised and did randomisation yield equality in 
groups? 
Randomisation yielded equality in clinical parameters and POS scores for which the patients 
were stratified. However, more patients in the FT group had informal caregivers than in the WL 
group.  
6. Were blinding procedures adequate? 
No blinding. 
7. Did participants adhere to the intervention? 
The patients adhered to the intervention but they did not adhere to the study protocol at all 
times. Principally, this related to patients and informal caregivers no longer returning 
questionnaires once they had received the CC. This is discussed further in section 5.6.  
8. Was the intervention acceptable to the participants? 
The intervention of the CC was acceptable to participants.   
9. Was it possible to calculate intervention costs and duration? 
Cost was not calculated but would need to be done for any future studies. Length of CC and 
input needed from the H2H CNS after delivery of the intervention were recorded. If needed 
approximate costs of delivering the intervention may be calculated to assess feasibility of 
delivering the intervention from a cost perspective.  
10. Were outcome assessments completed? 
Questionnaires were more likely to not be completed once the patient had received the 
intervention. The questionnaires could be simplified or they could be completed by a researcher 
visiting the patient/informal caregiver to try to alleviate some of the burden. This is discussed 
further in section 5.6 
11. Were outcomes measured those that were the most appropriate outcomes? 
There are limited palliative care outcomes which have been validated in this group. In particular, 
there are no validated outcomes in the informal caregiver group. The outcomes measured 
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appear to be appropriate. However, it may be valuable to have a greater number of detailed 
symptom control outcomes which may fully capture any changes to other symptoms such as 
cough. A potential outcome measure which could be used is the Leicester Cough Questionnaire 
which has been validated in ILD.  
 
12. Was retention to the study good? 
Please see section 5.5.4 
13. Were the logistics of running a multicentre trial assessed? 
No- this was not a multi-centred trial.  
14. Did all components of the protocol work together? 
All components of the protocol did work together. However, there were difficulties in ensuring 
that the intervention was delivered when it was supposed to be and outcomes measures 
completed in a timely manner.  
 
The original criteria set for feasibility were: 
 
 Consent rate at least 25% 
 Recruitment of 52 patients 
 80% of patients in the FT group were able to receive the H2H intervention within 14 
days of their allotted time.  
 
The first two points were achieved. However, the final point was not. This will be discussed 
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 Acceptability  5.5.4
 Recruitment, follow up and attrition 5.5.4.1
Patients were recruited for the phase II trial from October 2011 to October 2013 and followed up 
until study close December 2013 when place of death was documented if applicable.  
It was difficult to get participants to return questionnaires at exact time points of 4 weeks and 8 
weeks. In addition, it was also difficult at times to get the CC arranged for within one week (for 
FT) or just after 4 weeks (for WL). It was not possible to get 80% of the FT group to have their 
CC within 14 days from randomisation. Therefore, if needed the week 4 and subsequent week 8 
assessments were delayed. Exact timings of interventions and assessment points for the 2 
groups are shown in Table 5-8 Page 254.  
Table 5-8 Table to show timings of CC and follow up 
 FT WL 
Time from baseline questionnaire to CC (days) n=25 n=24 
Median 23 40 
Range  12 to 51 7 to 100 
Number of patients having CC within 14 
days of randomisation  
6 (24%) N/A 
   
Reasons for delay in CC if any   
Difficulty finding convenient date for HP 19  7  
Difficulty finding convenient date for patient 
or family 
 1  
   
Time from CC to 4 week questionnaire (days) n=23 n=24 
Median 19 -1 
Range -4 to 35 -11 to 38 
   
Time from week 4 to week 8 questionnaire (days) n=19 n=15 
Median 28 29 
Range 20 to 49 7 to 69 
 
Reasons for loss to follow up included attrition due to death (ADD) FT 1, WL 6, attrition due to 
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Table 5-9 Table to show reasons for attrition 
 FT WL 
 Baseline Week 4 Week 8 Baseline Week 4 Week 8 
ADD 0 1 0 0 3 3 
ADI 0 0 0 0 0 1 
AAR 0 1** 1*** 0 0 0 
Other 0 1 3* 0 0 4* 
*Patients were less likely to return their questionnaires that they completed themselves once they had received the 
H2H CC. This was despite follow up reminder phone calls. They were however contactable via phone. ** lost to 
follow up- went abroad on holiday  *** lost to follow up- went abroad for transplant assessment 
 
 Qualitative acceptability findings 5.5.4.2
5.5.4.2.1 Timing 
The timing of the intervention was thought to be appropriate and the earlier in the disease 
process it occurred, the more perceived benefit there was: 
“it is (1) better (3) than (3) later you know if all these things happen once 
you’re bed ridden (2) erm (3) you know you’ve got people coming in (2) 
that you don’t know at least you know this way I mean we kno:::w the 
nurses…you know we know them first name terms erm you know you you 
feel comfortable with them erm (5) you know I do thinks it’s definitely it 
nee- it needs to be done that way erm and that much earlier.” (Leslie, 54 
year old wife of Ted who had advanced IPF).  
The length of questionnaires was deemed to be acceptable. In addition, the interval between 
questionnaires was also deemed to be appropriate; a 4 week interval between questionnaires 
was felt to be adequate to capture any changes in symptom control or quality of life. In addition, 
the questionnaires used were also felt to assess change satisfactorily by patients, informal 
caregivers and HPs with the right outcome measures being used. One patient (Alfred) had felt 
that there was some repetition between questions in outcome measures and had become 
confused at times as some measures had asked about experiences over last 3 days (POS) and 
others over last 2 weeks (SGRQ).   
Patients and informal caregivers alike did not feel that the questionnaires caused distress. 
There was a recognition that questions about death and dying were necessary but patients and 
informal caregivers alike did not feel that these caused suffering.  
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5.5.4.2.2 Evidence based guidelines 
At the CC, patients and informal caregivers as well as the HPs were given the evidence based 
guidelines.  Both patients and informal caregivers were grateful for the guidelines (even though 
they weren’t specifically tailored to the lay person). Patients such as Alfred felt that they 
encouraged him to research areas that were not familiar but found it encouraging that he was 
using the right things in other areas. 
All HPs were extremely grateful for the guidelines. For example, the ILD Consultant found them 
very useful and he felt they allowed systematic evidence based symptom control rather than ad 
hoc delivery of symptom control as he had previously done. Generalists such as the GP found 
them invaluable and specifically appreciated having guidance from specialists which again 
reassured him and instilled confidence that he was doing the right thing and guided him on 
aspects of symptom control he wasn’t sure about.  
 
5.5.4.2.3 Fast Track design 
Patients and informal caregivers interviewed did not feel that there was any problem with the FT 
design. One informal caregiver in particular (Penny, wife of a 67 year old patient with IPF) did 
not feel it was significant to have to wait one month for the intervention as she did not feel that 
her husband’s prognosis was so short that waiting would matter. However, the Community 
palliative care CNS did feel that it mattered especially if a patient was particularly unwell, she 
felt the wait could affect the care:  
“I do think with some of them that it would cause problems. Erm I think that 
it would have been too late particularly if they’re very poorly…. and you 
can’t necessarily predict that with everybody and actually some of them (1) 
4 weeks (2) would be too much without all that help….” Community 
Palliative Care CNS 
However, there was an understanding from those with a research background such as the ILD 
Consultant that 4 weeks was a reasonable time period for the WL group to wait before receiving 
the intervention as it often took longer than that to set up support in the community.  
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5.5.4.2.4 Positive comments 
All patients and informal caregivers interviewed were grateful for having taken part in the study: 
“…just to say I'd like to thank you erm (1) for giving me the opportunity to 
go on this in- like on this survey [study] and to get the help that I've I've 
now got I really do appreciate it……” (Peter, 63 year old with advanced 
IPF). 
“I think the study’s excellent” (Stephen, a 81 year old patient with NSIP) 
In addition, HPs also felt extremely positive about the CC and reported that patients and 
informal caregivers had fed back to them about their experience: 
“we've had good (1) er quite a lot of good feedback from patients as well 
that it's been very useful for them with regards to symptom management 
and having someone coordinate their overall care” ILD Consultant 
“on every level I found it very very (3) er::: (4) useful……I think it’s 
brilliant…” GP 
Overall patient participants were extremely positive about the intervention and in particular the 
CC which they had found excellent, well organised and incredibly useful. Patients and informal 
caregiver participants felt that the CC “laid everything on the table” and importantly improved 
quality of life as it addressed concerns and anxieties that had been playing on patients’ and 
informal caregivers’ minds. Patient and informal caregiver participants felt that the intervention 
had been delivered in a “very compassionate and understanding way” where all the patients’ 
and informal caregivers’ concerns were acknowledged and addressed.  Patient participants 
appreciated that the CC was in their home with all the HPs involved in their care in the same 
place at the same time making patients and informal caregivers feel “important” –what was 
imperative is that this allowed patients’ and informal caregivers’ concerns to be addressed on 
their terms. Patient participants thought it important that HPs had a clear understanding of the 
environment they lived in on a day to day basis and conducting the CC in the patient’s home 
facilitated this.  
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5.5.4.2.5 Harms 
There were very few if any negative comments related to the intervention; even though the 
nature of palliative care involvement had been clearly communicated with the patient and 
informal caregiver involved in the study, in one instance another family member had become 
upset when attending the CC to see that the local hospice team were attending. In addition, one 
informal caregiver had initially felt upset when their loved one had discussed PPC and PPD at 
the CC but on reflection, they realised how important having the conversation at that point had 
been. One patient in the WL group did not feel there was any point to the CC and he did not feel 
that he had gained anything from it.  
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5.6 Discussion 
This mixed methods Fast-track RCT trialed the H2H intervention in PIF-ILD patients and 
informal caregivers. This trial has provided valuable information on possible effects of the 
intervention on the palliative care needs of patients and informal caregivers in this group, whilst 
showing the intervention to be largely feasible and acceptable.  
I will now discuss the main findings from this trial in relation to the main aims followed by 
limitations and implications for clinical practice.  
 
 Aim 1- To begin to evaluate H2H in a phase II study  5.6.1
This Fast-track RCT of a case conference intervention in advanced fibrotic ILD patients and 
carers identified an improvement in both symptom control and quality of life. Of note, there was 
no worsening of any outcome after receiving the intervention. This suggests that no harm and 
potentially a prevention of deterioration may have occurred. The quantitative results showed a 
positive and significant effect on patients’ POS scores at the primary endpoint of 4 weeks with a 
mean change score of 5.7 points in the FT group which was sustained at 8 weeks.  In addition, 
there was improvement in the WL POS score between week 4 and week 8 of 4.3 points. For the 
POS, a variation of one point in individual items is linked to clinical meaningful change.(161) 
This suggests that the H2H intervention may improve the palliative care needs of PIF-ILD 
patients in a clinically meaningful way. The 2 RCTs that have previously trialled CCs in the 
cancer setting (78, 80) have not used the POS or a global palliative care assessment tool so a 
direct comparison cannot be made on effectiveness in the PIF-ILD setting.  
At the CC, the evidence based guidelines were used and a comprehensive palliative care 
assessment (including symptom control, psychological, social needs and crisis management 
plan) was carried out. Ongoing management of the patients’ palliative care needs were carried 
out by the community teams. It is possible that the intervention of the evidence based guidelines 
and the ongoing management of the palliative care needs identified at the CC, resulted in the 
improvements in the patients’ POS seen. It is difficult to know whether the benefit from the 
intervention seen is due to the CC, palliative care involvement or the added time with care 
providers. However, the results are promising and warrant further investigation.  
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Of note, the WL group had a higher percentage of informal caregivers. Informal caregivers play 
a vital role in the management of symptoms in the home setting.(217) In addition, HPs providing 
palliative care in the community setting report that they rely on informal caregivers’ assessments 
of the patients’ condition and use them as cues for action.(217) Therefore it may be expected 
that if a patient does not have an informal caregiver, this interface is more difficult potentially 
leading to more unmet palliative care needs. The WL group also had a higher GP, DN and 
CPCT presence at the CC than the FT group. This may have influenced outcomes. Palliative 
care teams have been shown to positively influence patient and informal caregiver outcomes 
(218) and it would usually be the GP, district nurses and CPCT who would instigate the 
symptom control interventions and manage the patients’ palliative care needs on a day to day 
basis. The higher presence of these HPs at the WL CC may have led to false improvements in 
the WL scores which would only have diluted the effect size, suggesting that the potential effect 
of the intervention may be greater than reflected in the primary outcome.  
Baseline scores showed that patients were living with poor Qol. There was an improvement in 
Qol scores on both the KBILD and SGRQ impact and total scores at week 4 in the FT group. 
The improvement in the WL SGRQ impact and total scores were marked between week 4 and 
week 8 where both domains showed improvement greater than the Minimal Important Clinical 
Difference (MID) for IPF. Mitchell et al (78) investigated the impact of a telephone CC between 
GPs and specialist palliative care teams (without the patient or informal caregiver present) in a 
RCT of 159 cancer patients in Australia. They found that the primary outcome- global Qol was 
not influenced by the intervention but the CC group showed better maintenance of physical and 
mental health measures of Qol in the 35 days before death. The authors suggest this is 
because care plans at referral were not implemented until severe symptoms developed. 
However, the Mitchell et al study was a CC to meet professional needs, whilst the H2H service 
was a patient-centred, face-to-face intervention involving, patients, informal caregivers and HPs. 
This may have been an influencing factor. The Qol measures used in the Mitchell et al study 
were the Assessment of Quality of Life at the end of Life (AQEL) (219), the McGill Quality of Life 
Questionnaire (220) and the Subjective Wellbeing Scale (221) so direct comparisons between 
the two studies are not possible. Interestingly, the complex intervention of a breathlessness 
intervention service delivered by Higginson et al study (222) also showed some improvements 
in Qol domains. The Higginson et al study is a RCT of 105 patients with refractory 
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breathlessness which included ILD patients. It found that the patients who received the 
integrated palliative care and respiratory breathlessness support service had, at 6 weeks, 
significantly improved breathlessness mastery, a domain of the Chronic Respiratory Disease 
Questionnaire. Mastery assessed patients' feeling of control over their breathlessness and its 
effects on Qol and function, and was on average 16% higher for those patients receiving the 
breathlessness support service. However, numbers of ILD patients were small 19 (18%) and 
ILD patients’ diagnoses were not differentiated.  
 
Improvements were also identified in anxiety and depression scores. Of note, baseline mean 
patient anxiety and depression scores and mean carer anxiety scores in both groups were 
borderline abnormal or abnormal. Subsequently, there were improvements in anxiety and 
depression scores of both patients and informal caregivers at week 4 in the FT group.  This 
effect appeared to be sustained with continued improvement in scores at week 8. Importantly, 
the WL group showed deterioration for all anxiety and depression scores in both the patients 
and informal caregivers during the 4 week wait. Scores subsequently improved after the WL 
group received the intervention-improvements in HADs scores seen were greater than the MID 
(1.5) for COPD. Even though the HADs has not been validated in IPF, the MID for COPD has 
been used previously for IPF patients.(223) Lindell et al (113) conducted a mixed methods RCT 
of 21 patients looking at a disease management program delivered using a format of support 
group for both IPF patients and informal caregivers with a control group of best usual care. They 
found on quantitative analysis, that there was an increase in anxiety scores and decrease in Qol 
scores in the intervention group. In contrast, the qualitative work indicated that patients did not 
feel isolated and felt the intervention had enabled them to put the disease into perspective, gave 
comfort and provided an improved mental picture. In the Higginson et al study (222) 
breathlessness intervention service trial, there were also non-significant improvements in 
depression. The quantitative and qualitative results in the H2H trial were in agreement. In 
addition, the effect on anxiety and depression scores seen in patient scores were mirrored in 
the informal caregiver results with improvements in the depression and total HADs scores at 
week 4 in the FT group and improvements (greater than the MID) in the WL group between 
week 4 and week 8 in all 3 domains of the HADs.  
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Improvements were seen in the ZBI and CQLC between week 4 and week 8 in the WL group. In 
the Mitchell et al study(78), there was a positive impact on caregiver burden with significantly 
lower carer burden in two of the five domains (impact on schedule and lack of family support) on 
the Caregiver Reaction Assessment (79) as well as the total score. Knowing what to monitor, 
how to interpret the signs successfully and when to inform a HP were all issues of concern for 
informal caregivers in a previous palliative care study.(217) In the H2H trial, a copy of the 
individualised care plan made at the CC was given to the patient, informal caregiver and HPs 
involved in the care of the patient. This included direct contact numbers for all HPs and step-
wise instructions of what to do in the event of deterioration. Patients, informal caregivers and 
HPs reflected in the qualitative interviews that they were very grateful for this individualised care 
plan with patients and informal caregivers expressing that this greatly reduced their anxiety and 
HPs expressing that it allowed them to provide better care. In addition, the qualitative data 
suggests that the intervention facilitated improvement in both the co-ordination and efficiency of 
care delivered with patients and informal caregivers expressing that they now felt that they were 
“fast-tracked” through the system as HPs had been made aware of the seriousness of their 
condition. Qualitative results suggest that this resulted in patients and informal caregivers being 
able to access help when needed. The actual process of the CC, having a clear individualised 
care plan and being supported in this way by the community HPs may have helped to reduce 
both patients’ and informal caregivers’ anxieties seen in the quantitative results.  
The H2H intervention aimed to manage uncertainty by facilitating early discussion about 
disease progression, improving communication and addressing end of life planning needs. At 
the CC, not all patients wanted to talk about advance care planning decisions such as PPC and 
PPD. This was also found in the cluster randomised study conducted by Abernethy et al (80) 
where prognosis, end of life issues and previous experiences of death and dying were rarely 
discussed at the CC for cancer patients.  For those patients who did discuss advance care 
planning at the H2H CC, even though it could initially be distressing for relatives present, it was 
seen as incredibly useful. For some patients, the CC gave permission to conduct these 
important conversations. Interestingly, many patients who had not wanted to discuss these 
issues at the CC, then went on to have subsequent discussions with their community HPs in the 
weeks after the CC. This may have been precipitated by the initial discussions by the H2H 
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nurse and the development of relationships with the community palliative care team after the 
case conference. This is in itself an important influence that the intervention may have had.  
A diagrammatic representation of the possible effects of the H2H intervention is shown in Figure 
5-9 Page 264 .  
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indirect effects. 
Figure 5-9 Figure to show possible mechanism by which H2H may be effective 
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3 of the WL patients died before receiving the CC. All 3 of these patients died in hospital. During 
the CC, for patients who wished to discuss PPD, no patient expressed hospital as their PPD. 
The actual place of death for patients having received the CC was hospital in only 28% of 
patients. This is much less than found in the retrospective case note review in Chapter 1 which 
found that 76% of PIF-ILD patients attending RBH and KCH died in the acute hospital setting.  It 
has been noted in the literature that patients with IPF experience increased healthcare resource 
utilisation, and direct medical costs.(224) This is especially important at the end of life. It is 
possible that the CC, through establishing links in the community setting and preventing crisis 
admissions, enabled patients to not die in hospital. The extent of the economic benefit of this 
needs to be further investigated. Interestingly in the Abernethy et al trial (80), patients who lived 
the longest derived the most benefit in terms of better maintained performance status and fewer 
hospitalisations, supporting early referral to palliative care.  The qualitative work in this trial 
showed that during the trial, patients became less likely to return to the specialist centre for 
investigations and out-patient appointments. This may be because as community HPs gained 
confidence in delivering care to these patients and patients’ confidence in HPs ability to deliver 
this care grew, patients felt less reliant on the specialist centre and became less likely to return 
to the specialist centre. The qualitative findings indicated that there was recognition from 
patients and informal caregivers that the palliative care needs of these patients were best 
delivered in the community setting but patients and informal caregivers hadn’t previously been 
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 Aim 2- To evaluate H2H in terms of feasibility and acceptability in a 5.6.2
phase II study 
 
 Attrition and missing data 5.6.2.1
Attrition is defined as the loss of patients from the study. A suggested taxonomy is attrition due 
to death (ADD), attrition due to illness (ADI) and attrition at random (AAR).(121)  In this trial 
there was attrition of 3 patients between baseline and week 4 in the FT group and baseline and 
week 4 in the WL group. For all the patients in the WL group, this was ADD. In addition, there 
was attrition of patients who having received the intervention, did not complete and return their 
questionnaires. There were 3 patients in the FT group and 4 in the WL group this applied to. 
The patients were still contactable via phone and were not unwell. The qualitative interviews 
suggest that the questionnaires were not too burdensome. It is possible that after receiving the 
CC, participants did not feel motivated to return the questionnaires.  
Missing data can more generally be defined as the absence of parts of patient’s data.(121) 
Rubin’s classification defines three types(225): missing at random (MAR) when missingness 
may depend on single variables, completely missing at random (CMAR) when missingness is 
not related to the specified variables and missing not at random (MNAR). For data in this study, 
the data is likely to be MNAR.  The questions in the KBILD which were most likely not to be 
answered related to low mood and were consistent between questions. The most commonly 
unanswered question on the SGRQ was related to paid employment which was not applicable if 
you were retired. As there was no “not applicable” option, participants would have been likely to 
leave this blank if it did not apply to them. The average age for both the FT and WL groups was 
greater than 65 years, even though employment status was not collected in the demographic 
information, it is likely that a significant proportion of the patients would have been retired.  
 
 Feasibility of trial 5.6.2.2
Patients and informal caregivers when interviewed did not have any concerns with the FT 
design. However, there were some concerns expressed by a community HP who felt that 4 
weeks was an unreasonable time period to wait if a patient was unwell and in need of 
community support. Only 10% of patients receiving CCs had CPCT involvement prior to referral 
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to the trial. Through the trial, the remainder of these patients were referred. The lack of referral 
appears to be due to a lack of recognition by HPs of the palliative care needs of these patients. 
These patients would therefore have been unlikely to have received any community support if 
they had not been recruited to the trial. In addition, the waiting period of 4 weeks used in this 
trial would equate to a normal wait within the NHS for referral to community services. Even 
though patients in the WL group did not receive the CC until after 4 weeks, referrals to 
community services were made at randomisation. A number of these community services were 
then making contact (and sometimes visiting) with the patients and informal caregivers before 
the CC- it is unclear for how many WL patients this was the case. This is likely to have affected 
and potentially diluted the effect size of the intervention at the primary end point of 4 weeks. 
Over three quarter (79%) of patients eligible to take part in the trial that I approached consented 
to participate. In a very few instances, patients who were suitable for the trial refused to take 
part. On feedback, they expressed that they were not quite ready to “accept they were 
palliative”. In these instances I encouraged patients to keep the information sheet and contact 
me if they changed their mind. However, I did not feel it ethical to approach them again. The 
qualitative work observed that patients, informal caregivers and HPs had misconceptions of 
what palliative care and its role represented.  This finding has been observed elsewhere  (226) 
among cancer patients. As palliative care becomes more prominent in managing the symptoms 
of ILD patients and becomes involved in the disease journey at an earlier stage, perhaps these 
misconceptions will change. 
Randomisation yielded equality in clinical parameters and POS scores. However, more patients 
in the FT group had informal caregivers than in the WL group and this may have been an 
influencing factor (as discussed previously).  
The timing of the intervention was thought to be appropriate with patients and informal 
caregivers appreciating the benefit of conducting the CC before the patient entered the terminal 
stages of the disease.  
Importantly all information, including time points, about who received the H2H intervention is 
clearly presented. This has been highlighted as important when assessing the feasibility and 
fidelity of complex intervention trials in healthcare. (227) 
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 Feasibility of assessments 5.6.2.3
Patients and informal caregivers alike did not feel that the questionnaires caused distress. 
There was a recognition that questions about death and dying were necessary but patients and 
informal caregivers alike did not feel that these caused suffering. There were 3 patients in the 
FT group and 4 in the WL group who received their CC and did not return subsequent 
questionnaires. The patient representative on the Project Advisory Group and the qualitative 
interviews suggest that the questionnaires were not too burdensome. It is possible that after 
receiving the CC, participants did not feel motivated to return the questionnaires. The 
questionnaires were postal and were reliant on the patient completing and posting them back.  
An amendment to the wording on the patient and informal caregiver information sheet was 
submitted and approved. This removed suggestion that “care is being transferred from the 
hospital setting to the community”. Feedback from patients and informal caregivers had 
indicated that this was perceived negatively by patients and informal caregivers and as a result 
may have affected recruitment. This is likely to be due to the reliance that patients and informal 
caregivers placed on the specialist centre before involvement in the trial and was reflected in 
the qualitative findings.  
Both the length and interval between questionnaires was deemed acceptable. The outcomes 
used were felt to capture and assess change satisfactorily for both symptom control and Qol. 
There are limited palliative care outcomes which have been validated in this group. The 
outcomes measured appear to be appropriate. One patient did find the varied time periods 
measured in each outcome confusing. In addition, it may have been valuable to have a greater 
number of detailed symptom control outcomes for other significant symptoms such as cough.  
 
 Feasibility of the intervention 5.6.2.4
Patients, informal caregivers and HPs alike praised the CC model of care. In previous 
qualitative work following the Mitchell et al RCT, GPs reported that the CC allowed them to be 
better informed, made discharge planning easier and allowed clear delineation of role between 
the GP and the palliative care service.(76) All of these findings were supported in this trial and 
the qualitative results supported feasibility of the intervention. In addition, there was adherence 
to the intervention (completion of the CC and follow up phone contacts).  However, there was 
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some “gatekeeping” within the ILD department when patients were identified as possibly 
suitable for the trial. There had been very little communication within the ILD department at RBH 
with patients about end of life issues before commencement of the trial.  Therefore some 
patients were not referred to the trial by the ILD HPs to “protect the patients” from end of life 
discussions which would occur as part of the intervention. A recent qualitative study exploring 
how transitions to a palliative care approach are perceived to be managed in acute hospital 
settings in England observed that health professionals believed achieving consensus among 
the clinical team about transition to palliative care was  fundamental to the transition being 
effected.(228) I gently encouraged HPs to refer and questioned them in clinic. However, I 
believe the most effective tool in negotiating this barrier was the positive feedback from patients 
and informal caregivers who had already participated in the study who returned to the ILD out-
patient clinic. ‘Gate-keeping’ became less of a problem as the trial progressed and I believe this 
was a direct result of the positive feedback that patients and informal caregivers provided. 
Importantly, the H2H CNS felt that not all attendees at the CC were grateful for the intervention. 
In particular, there were instances that members of the community palliative care team did not 
engage at the CC. It is possible that this is because they felt that the H2H CNS was trying to 
give them advice about an area that they already felt capable of managing. It is not clear 
whether this may have been related to the evidence based guidelines component of the 
intervention. This was not reflected in the qualitative interview with the community palliative care 
nurse. However, this would need to be further investigated in qualitative work for a phase III 
study.  
Most recent models for provision of palliative care encourage a gradual shift, with palliative care 
provided alongside active treatment from diagnosis of a life limiting illness.(229) Interestingly, 
very few patients (10%) involved in the study were known to palliative care services prior to 
referral. As a result, the shift to palliative care (facilitated by the study) was a sudden rather than 
gradual process. This is likely to have affected the feasibility of the intervention.  There were 
very few negative comments related to the intervention and these related to other relatives (not 
the informal caregiver) not realising that palliative care would be involved in the intervention and 
that an end of life discussion would occur as part of the intervention.   
Very few GPs attended CCs (less than a third in the FT and less than 50% in the WL group) 
and in some instances community palliative care refused referrals. It is only after follow up 
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phone calls and discussions that I would have with the Consultants in the community palliative 
care team, that the referral would be accepted. This is very different to the cancer H2H model of 
care being delivered at the Royal Marsden. In the cancer H2H model, there is often 4-5 HPs 
present at each CC (including GPs) and community palliative care referrals are always 
accepted. This is likely to reflect the lack of understanding amongst community HPs of the 
terminal nature of PIF-ILD and their substantial palliative care needs. In the Abernethy CCs, all 
CCs included the GP, patients and/or family member.(80) In addition, a palliative care 
representative  were present at every CC. The number of participants at the CCs ranged from 5-
8. Again these were conducted in the cancer setting where HPs are more likely to have an 
understanding of the palliative care needs and poor prognosis that patients have. The length of 
CCs in the Abernethy trial ranged from 20-58mins with a median time of 36mins.(80) In the H2H 
trial, the median for both the WL and FT CCs collectively was 90 mins with a range of 60-150 
mins. Reasons for the longer CCs in the H2H trial are unclear but may reflect trying to manage 
patients and informal caregivers with very little information about the terminal nature of their 
disease or HPs’ uncertainties and lack of confidence around management.  
At the CC, patients and informal caregivers as well as the HPs were given the evidence based 
guidelines.  Patients, informal caregivers and HPs indicated that they were grateful for the 
guidelines as they allowed systematic delivery of symptom control and provided reassurance 
that they were already “doing the right thing”.  
 
 Aim 3-To inform methods for a future randomised controlled trial 5.6.3
Despite many of the points raised by Shanyinde et al (212) that were successfully achieved in 
this trial, not all the criteria set pre-study were met. Even though both the consent rate and 
recruitment numbers were realised, only 24% of the FT group received the CC within the 14 day 
allotted timeframe that is well below the 80% feasibility criteria. This was largely due to the 
difficulty in getting HPs to schedule a CC within one week’s notice. Interestingly, Abernethy et al 
(80) also observed it was difficult to ensure that CCs were held within 28 days with only 38/167 
CCs being held within this time period. They noted that CCs often became more of a priority to 
organise when there were changes in clinical status. Certainly in qualitative work done by 
Mitchell et al (76) following their RCT, both GPs and palliative care teams felt that routine CCs 
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were less useful than those held at critical points in the patients’ illness (before discharge home 
or when there were complex issues). Abernethy et al (80) suggest that it may be necessary to 
align timing of CCs with clinically determined need.  In any future trial, if the Fast-track design 
was used, the time between randomisation and CC for the FT group and subsequently the time 
before the WL group receive the intervention would need to be increased to ensure that there 
was enough time for the H2H CNS to organise the CC for the FT group.  
Interestingly, there appeared to be a greater change in outcomes in the WL group between 
week 4 and week 8 than the FT group between baseline and week 4. This may be related to the 
fact that the majority of the CCs for the FT group could not be organised within the 2 week time 
period but the majority of the WL CCs were organised within their 2 week allocated period. This 
may have resulted in a more marked difference between the week 4 and week 8 WL data 
compared to the baseline and week 4 data of the FT group and the full effect of the intervention 
may have been under estimated at the primary end point of 4 weeks.   However, Mitchell et al 
(78) CC group showed better maintenance of physical and mental health measures of Qol in the 
35 days before death. It was suggested that CCs may improve clinical relationships and care 
plans at referral, which were not implemented until severe symptoms develop or the patient 
becomes less well. The authors hypothesise that this is because of improved links between GP 
and specialist teams, and the development of more effective care plans that are enacted when 
the rapid deterioration experienced in the terminal phase takes place. It is not clear from this 
trial if this is the case and compliance of participants with the intervention, more information 
surrounding quality assurance post CC and further formal outcome measures post CC would be 
needed before this could be ascertained.  
The trial opened to recruitment 10/2011 and research CNS cover was in place to allow 
recruitment during my maternity leave 11/2011-6/2012. However, only 1 patient was recruited 
during this time. On reflection this is because a medical presence was required in the ILD clinics 
to identify potential patients and to discuss and challenge ILD doctors about their management 
and potential benefit for patients. This is especially important in a speciality in which there has 
historically been poor palliative care involvement.  
The H2H intervention is a complex intervention with multiple different active components. As a 
result, there will inevitably have been some variation in the manner in which the service 
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received by individual patients and informal caregivers. Implementation fidelity is “the degree to 
which…programs are implemented….as intended by the program developers”. (230) Only by 
understanding and accurately recording how a complex intervention has been delivered, can a 
more detailed understanding of how and why the intervention works be achieved.(231) For 
instance, a study of a parent training programme found that when the programme was 
implemented with high fidelity, the parenting practices improved significantly, but the effect was 
much less when implementation fidelity was low.(232) As discussed, attempts were made to 
standardise delivery of the intervention as much as possible with training, observation of 
delivery of the CC, proformas and evidence based guidelines.  This level of standardisation 
does seem reasonable considering the time and cost restraints. However, if the H2H service 
were to be further evaluated in an Evaluation trial, it would be important to ensure further 
standardisation of the service delivered by including a measure to determine the consistency 
with which the intervention was delivered.  The CCs could be audio or video taped to give 
feedback of performance to the H2H CNS with subsequent training to promote consistency. In 
addition, this would allow detailed information to be gathered on the content of the CC which 
may provide insight on the mechanisms of effect of the complex intervention and allowed 
deeper consideration and understanding of which part of the complex intervention is effective. In 
hindsight, it would have been useful if compliance of patients and informal caregivers had also 
been recorded. This may have provided valuable information on how outcomes for users may 
differ between compliant/non-compliant patients and informal caregivers. Recording this 
information is unlikely to have been too burdensome in terms of cost or time and would have 
been helpful in considering the real life implications of delivering this service within the NHS.   
Future work needs to consider which specific aspects or components of the H2H intervention 
are effective.  For example, it is difficult to know whether the benefit from the intervention is due 
to the CC or palliative care involvement. Certainly patients who receive timely palliative care will 
have better co-ordination of services, symptom care, emotional support, education and family 
support and this is something that the H2H intervention facilitates. In developing understanding 
into the active ingredients in the H2H intervention, the CC needs to be examined more closely 
during delivery. Aspects which need to be considered include content of each CC, themes 
considered and the interaction with patients, carers and HPs. This may be done through 
quantitative or qualitative measures. This may provide valuable information on how the H2H 
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intervention is working in the PIF-ILD setting and how and why this differs to the cancer setting 
or to normal specialist palliative care input.  In the Abernethy et al RCT, there were positive 
effects of both the CCs and patient/caregiver educational visits (80) therefore future studies 
should include an attention control to determine whether the intervention per se, ie the added 
face-to face time with care providers, or a combination of both accounted for the change in 
outcomes. In addition, future work should consider how implementation of the H2H intervention 
fits within conceptual theoretical models such as Normalization Process Model (233) prior to 
embarking on a phase III study. This may allow a better understanding of how to normalise the 
H2H intervention within ILD clinical practice.(234) 
In the Mitchell et al study (78), the CC was conducted between specialist palliative care teams 
and GPs via telephone. The study was conducted in the cancer group and patients and informal 
caregivers were not involved in the CCs. Telephone participation for GPs (rather than face-to-
face participation) was felt to be a less successful form of communication when used in a RCT 
looking at case conferencing in Australia.(235) It is difficult to know whether this form of mode of 
delivery could be used in this group effectively but warrants further investigation.  
The RCT was carried out at a specialist centre in London therefore generalisability nationally 
and internationally may be limited; this warrants further investigation. In addition, the majority of 
the patients were White British. It may be argued that the palliative care needs for these 
patients may vary across different cultures. However, the qualitative work in the Development 
stage was conducted across KCH and RBH. KCH has a very different socio-demographic 
patient group to RBH. Importantly, this showed no difference in the palliative care needs of the 
patients and informal caregivers interviewed across the 2 hospitals.  Within the constraints of 
cost, it was not possible to make the RCT multi-centre. However, any future Evaluation trial 
would ideally need to be multi-centred, national and if possible, international to assess 
outcomes across different cultures and to ensure generalisability of findings.   
The RCT was a phase II trial and was therefore not powered to show efficacy. Any positive 
results should be interpreted with caution and need to be evaluated in an adequately powered 
trial.  
Delay in delivering the FT CCs affected comparison of the efficacy of the intervention at the 
primary endpoint of 4 weeks. However, this is likely to have under-estimated rather than over-
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estimated any effect. In addition, referrals to community services for WL group were made at 
randomisation and a few community services contacted (and sometimes visited) with the 
patients and informal caregivers (exact numbers unknown and not recorded) before the CC. 
This may also have potentially diluted the effect size of the intervention. In hindsight, it would 
have been preferable to not make any referrals to community services for the WL group until 
after 4 weeks. However, it is only when these referrals were made, that a date for the CC could 
be set. Consideration needs to be given between achieving a balance of allowing enough notice 
to community HPs to set a convenient date for the CC and not contaminating the WL group with 
contact from community HPs prior to the CC. On reflection, it would also be useful to have 
noted how many community HPs had made contact and the nature of the contact.  
At follow up, the H2H nurse contacted the patient/informal caregiver 2 weeks, 4 weeks and 2 
months after the CC. This involved the H2H CNS discussing with the patient or informal 
caregiver whether outcomes from the care plan had been achieved. It would have also been 
beneficial to have assessed with more uniformity (e.g. a needs assessment tool) at the CC, the 
2 week, 4 week and 2 month follow up, what baseline and subsequent needs there were for the 
patients and informal caregivers. This would have provided helpful information on whether the 
intervention was meeting unmet need identified at the CC.  This is unlikely to have added to 
time or cost.  
 
A potential outcome measure which could be used is the Leicester Cough Questionnaire which 
has been validated in ILD. As discussed previously, informal caregivers may be an influencing 
factor on symptom control measures.  Therefore, in any future RCT, patients ought to be 
stratified on whether they have informal caregivers or not. In addition, there would need to be 
strict control of referrals to community HPs to ensure that the WL group are not referred and 
subsequently receiving community support prior to the CC. This may be facilitated by not 
passing the details of the patients to the H2H CNS before the WL period has expired.  
To improve return of questionnaires after receiving the CC- It is possible that if a research nurse 
were to arrange to complete the questionnaires in person with the patient and informal 
caregiver, this may improve attrition post the CC.  
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 Limitations 5.6.4
The trial took place in a specialist ILD unit in central London and therefore its generalisability is 
likely to be restricted. This was a phase II trial and was therefore not powered to show efficacy. 
Any positive results should be interpreted with caution and need to be evaluated in an 
adequately powered Evaluation trial. In addition the difficulty in being able to conduct the FT 
CCs within one week of randomisation resulted in some difficulty in being able to compare the 
efficacy of the intervention at the primary endpoint of 4 weeks. However, this is likely to have 
under-estimated rather than over-estimated any effect.  
The H2H intervention is a complex intervention with multiple different components. Attempts 
were made to standardise delivery of the intervention as much as possible with proformas and 
evidence based guidelines. However, there will have been some inevitable variation in the 
intervention delivered between each CC. In addition, there was a changeover of H2H CNS 
during the study which will have introduced some variability to the delivery of the intervention. 
To limit this, both H2H CNSs underwent the same training in delivering the intervention which 
included quality assurance observation which helped to keep this bias to a minimum.  
The participants for the qualitative interviews were chosen by the H2H CNS. It is possible that 
she may have chosen only those patients, informal caregivers and HPs who had had a positive 
experience influencing the outcome at interview and this may have introduced some bias. I 
conducted the majority of the qualitative interviews. The patients and informal caregivers were 
already aware of my role within the research team. This may have influenced the qualitative 
interviews and made patients and informal caregivers less likely to make negative comments 
about the intervention.  
 
 Implications for clinical practice  5.6.5
Resistance to accepting referrals to CPCT is likely to reflect the bias in England’s CPCT to 
malignant work and a lack of understanding of the palliative care needs of PIF-ILD patients 
(supported by preliminary qualitative work). This is clearly an area for education and 
development going forward.  
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The qualitative work from this trial also found that some patients had not been referred earlier in 
their disease journey to palliative care by community HPs. This was despite requests from 
patients and informal caregivers. There was also some gatekeeping by hospital HPs who felt 
that some patients were not “ready to hear they were palliative”. This was also mirrored in the 
refusal of some patients to take part in a “palliative care trial”. It is clear that there is still a mis-
conception that palliative care is a last resort and referral should only be made at the end of life. 
This is despite the World Health Organisation’s advice (20) that palliative care should be 
delivered in parallel to active care once a life-limiting illness has been recognised. Supporting 
this, recommendations of both the British Thoracic Society (12) and NICE (236) state that 
palliative care teams should be involved in patient management to ensure adequate symptom 
control and psychological support. If palliative care is only delivered at the end of life, patients 
and informal caregivers may be denied valuable symptom control and psychosocial support in 
earlier stages of the disease and important decisions around end of life preferences may not be 
explored. Strategies on improving the knowledge of patients, informal caregivers and HPs on 
the benefits of early palliative care need to be explored. 
The background qualitative work identified that HPs did not feel confident in managing the 
symptoms of patients with PIF-ILD. During the H2H CC, the evidence based symptom control 
guidelines were discussed and distributed with targeted education of HPs as needed. This 
highlighted that HPs required support regarding symptom control in this non-malignant group.  
Strategies to improve HPs’ knowledge in managing the symptoms of patients with PIF-ILD are 
needed to improve the future care of these patients. In addition, patients and informal 
caregivers at the beginning of the study expressed a lack of confidence in community HPs’ 
ability to manage PIF-ILD- strategies to improve this relationship are needed.  Abernethy et al 
(80) suggested that the CC may be used to identify gaps in knowledge and provide targeted 
teaching to community HPs. This was done in an informal way through the H2H CC through the 
use of the evidence based guidelines. However, in the future, identification of educational needs 
could be recorded in a more uniform way with formal evaluation in changes in knowledge.    
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5.7 Conclusion 
The aims of this mixed methods trial looking at the H2H intervention in PIF-ILD patients were to 
begin to evaluate H2H in a phase II study, to evaluate the H2H intervention in terms of feasibility 
and acceptability in a phase II study and to inform a future larger RCT (RCT phase 
III/Evaluation trial). Preliminary evidence from this trial suggests that there may be a positive 
effect on both patients and informal caregivers of the H2H intervention on palliative care needs, 
Qol and anxiety and depression. In addition, the intervention may manage uncertainty by 
facilitating early discussion about disease progression, improving communication and 
addressing end of life planning needs. There may also be effects on death rates and survival 
related to early use of a palliative care intervention which warrant further investigation. The H2H 
intervention appears to be both largely feasible and acceptable.  
As this is a phase II study, any positive effects may be promising but would need to be further 
examined in a full-scale phase III study forming part of the Evaluation phase of the MRC 
guidance before conclusions about effectiveness may be drawn. Despite this, the information 
obtained from this trial will allow sample size calculation in future studies, has provided valuable 
information on the spectrum of needs of patients and informal caregivers affected by PIF-ILD, 
the potential effects of the H2H intervention and the feasibility and acceptability of delivering the 
H2H intervention in this group. As this study is underpowered, negative or borderline results of 
outcomes should not prevent further development and investigation of the effects.  
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Chapter 6 Summary and Discussion 
6.1 Summary  
The aim of this thesis was to develop and evaluate a complex intervention, which comprised a 
new service, in PIF-ILD by adopting the MRC complex intervention guidance supported by the 
MOREcare guidance as the methodological approach. The adapted service was developed 
after qualitative interviews. This formed the Development stage of the MRC guidance. The 
adapted service was then tested in a RCT in the Feasibility/Piloting stage of the MRC 
guidance. The RCT found that there were improvements in patient Qol, anxiety and depression 
scores and informal caregiver anxiety and depression scores. The adapted service and study 
design were largely both feasible and acceptable.   
 
6.2 Discussion 
 Summary of objectives 6.2.1
To develop the service and then evaluate it, I needed to complete 8 sequential objectives. Each 
of these objectives and the findings from this study will be briefly summarised here and the 
findings from this research compared and contrasted to previous research in PIF-ILD or other 
relevant areas.  
 
The findings from objectives 1-3 formed the identifying theory/developing theory and modelling 
theory/processes stage of the Development stage of the MRC guidance: 
 
The first objective was to identify and describe the specialist palliative care needs within the 
PIF-ILD population. Qualitative research interviewed patients and for the first time, informal 
caregivers and HPs. Many patient participants reported that the main physical symptoms 
associated with PIF-ILD were dyspnoea and cough. This supports what has been found 
previously in two qualitative studies conducted in the Netherlands and USA (37, 38) and that 
found by Schoenheit et al (36) in their in-depth interviews with 45 IPF patients from five 
European countries. The findings from the qualitative work in the Development stage agreed 
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with the Swigris et al (38) and Schoenheit et al (36) studies which found that dyspnoea and 
cough were found to be distressing, sleep quality was affected and low energy or exhaustion 
affected daily activities. The findings from this qualitative work also found similarities to other 
disease groups’ experiences. Dyspnoea as a reminder of one’s mortality has been seen in 
COPD patients, disability with social isolation and depression has been seen in heart failure 
patients and anxiety/panic associated with bad episodes is similar to that previously seen in 
MND patients.(237) Furthermore, similar to that found by Swigris et al (38), patients were 
worried about being a physical burden and PIF-ILD led to decreased ability to undertake sexual 
activity. Interestingly, participants in this study did not appear to have financial concerns nor did 
they worry about paying for medical care which were found by both Swigris et al (38) and 
Schoenheit et al (36). This is likely to reflect that the majority of patients were of retirement age 
and that patients in the UK do not pay for NHS medical care.  
The qualitative research conducted as part of this study adds to the previous data by revealing 
that the burden of these palliative care needs is more considerable than previously noted with 
impact on every aspect of patients’ and informal caregivers’ lives with the psychological impact 
greater than previously noted. This research showed a more pronounced strain than previously 
noted in spousal relationships. This may be because through interviewing informal caregivers, 
the full impact of the disease on relationships and the family unit as a whole is revealed. 
Informal caregivers provide valuable support to patients and often enable them to stay in their 
preferred place of care. Whilst support for informal caregivers has been addressed in part in the 
cancer population towards the end-of-life (238, 239), there is no current literature for the ILD 
population and this should be a priority for further research. Interestingly, some of the HPs had 
limited appreciation of the palliative care needs of patients and the psychosocial effects on both 
patients and informal caregivers. In addition, there seemed to be resignation amongst some 
HPs that patients would inevitably suffer poor symptom control. This appeared to be partly due 
to some HPs’ lack of knowledge and misconceptions of effective symptom control interventions. 
This is the first time that HPs’ views on the palliative care needs of those affected by PIF-ILD 
have been researched and therefore there are no previous studies to compare to. However, it is 
important that HPs understand informal caregiver experiences of PIF-ILD and what support they 
require in caring for someone with PIF-ILD.   In addition, the disparity in the knowledge of how 
to manage symptoms is important. Education of symptom control interventions may empower 
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HPs to deliver effective specialist palliative care to these patients where they have not 
previously felt confident to do so.  
The second objective was to identify patients’, informal caregivers’ and HPs’ perceptions on co-
ordination of care, communication and information needs.  The qualitative research conducted 
in this study for the Development phase (same study sample as Objective 1) showed a good 
general understanding from both patients and informal caregivers that PIF-ILD is a serious 
illness which is terminal. This finding supports what has previously been noted: Quantitative 
analysis of the perceptions of illness in IPF patients and their family members in one previous 
study is limited as numbers were small (N=32). However it observed that most patients 
understood their disease to be a ‘serious condition’ and that family members understood the 
patient might not survive (N=16).(39) Interestingly, in the qualitative interviews for the 
Development phase, this realisation appeared to be a gradual process and often precipitated 
by deterioration in health rather than any formal information provided. There is no previous 
literature on end of life planning and decision making in PIF-ILD. Importantly, no patients had 
made end of life plans.  In addition, informal caregivers had not had conversations concerning 
end of life decisions such as preferred place of care and preferred place of death with their 
loved ones. This supports similar findings in other non-malignant diseases such as heart 
failure.(44)  Challenges were apparent. First, some informal caregivers did not know how to 
broach the subject. Second, patients had unrealistic perceptions of how their disease would 
progress and how the terminal stages would manifest. This led to unrealistic perceptions that 
they would not need care or help at the end of life. However, the willingness of participants to 
discuss their preferences was clear. Clinicians caring for patients with PIF-ILD face a 
challenging task regarding information needs for both patients and informal caregivers.  They 
are a group of conditions that the general public is on the whole unfamiliar with and so natural 
introductions to questions regarding prognosis and end of life care are usually not initiated by 
patients themselves.  In contrast to malignant disease, this places the onus for developing such 
conversations almost completely with the HP, in the main a respiratory physician. In the context 
of busy clinic appointments during which information regarding diagnosis, treatment options and 
medical care also has to be communicated it is not surprising that the uncomfortable topic of 
end of life care is neglected. However, the qualitative work in this study shows the importance 
that patients and their informal caregivers place on these issues.  
  281 
Previous studies have identified that patients are often prescribed sub-therapeutic doses of 
information; a recent quantitative survey of 52 defined choice and open-ended questions of 
1448 IPF patients and informal caregivers conducted in the United States reported that two-
thirds of respondents felt there was a clear lack of information.(40) Also, Schoenheit et al (36) 
found in their qualitative study of 45 European IPF patients that there was a lack of information 
provided to them about their disease. In the cancer setting, clinicians tend to underestimate the 
amount of information that patients require.(240, 241) In fact, a large multi-centre UK cancer 
study (2331 patients) showed that 87% of participants wanted to know all information, both 
good and bad news.(242) This is the first qualitative research which has been done in PIF-ILD 
which has also examined informal caregivers’ information needs. This research has shown that 
patients and informal caregivers felt that information provided about the future was lacking and 
could be improved. All HPs recognised the importance of providing information about prognosis 
and end of life with accurate prognostication and timely conversations to ensure that patients 
and informal caregivers had the opportunity to make end of life plans. Despite this, many 
informal caregivers reported receiving information from other sources for example the internet; 
the delivery of difficult news that the disease was terminal was not from the doctor. Patients and 
informal caregivers felt it was the HPs’ responsibility to provide them with information and to be 
able to judge what information should be provided when. Both patients and informal caregivers 
expressed a wish to receive more information from clinicians and implicitly trusted ILD HPs to 
deliver this information at the most appropriate time. HPs recognised the difficulty of balancing 
information needs with maintaining hope and often struggled with conducting discussions 
around end of life issues. However, HPs did not feel that this was done well. In addition, many 
patients in the cancer setting assume that the doctor would have told them everything 
relevant.(243) This was similar in this study where patients were trusting in the skills of doctors. 
Literature repeatedly states that patients have high information needs and wish to be kept well 
informed about their illness regardless of diagnosis.(244, 245) However, whilst the physical care 
skills of respiratory clinicians may well be excellent, this is not necessarily the case as far as 
effective communication of end of life issues are concerned.(246) It may be the case that there 
is a purposeful non-disclosure of information which may result from poor training or a lack of 
awareness of the impact that a failure to disclose has on patients and informal caregivers.(246) 
This qualitative research showed that patients and informal caregivers wanted to know but 
might be too afraid to ask. This is similar to what has been seen in other non-malignant disease 
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groups. (45) Clinicians need to anticipate this and continuously assess patients and informal 
caregivers’ information needs throughout the disease trajectory and although discussions about 
prognosis in time pressured clinics are difficult, HPs can learn effective communication skills to 
assist them in delivering this information sensitively.(247-249) This is especially important as 
research conducted in other non-malignant disease groups has identified that limited discussion 
between patients, informal caregivers and HPs directly addressing patients’ and informal 
caregivers’ concerns has been shown to affect psychological morbidity.(44)  
It has been noted that there is inadequate communication between HPs.(250)  This study also 
found that there was poor communication between the acute and primary care setting leading to 
frustration for patients, informal caregivers and HPs alike. There was also a feeling that 
malignant diseases had much better communication surrounding end of life issues than was 
currently being seen for PIF-ILD patients. It is not clear whether this is due to non-recognition of 
the terminal phase or inadequate provision for communication. In addition, this qualitative work 
found that there was poor co-ordination of care with reliance on the specialist ILD centre and a 
lack of confidence in community services. Schoenheit et al (36) found in their study of 45 
European IPF patients interviewed, that the majority of participants had experienced delayed 
diagnoses and criticised the care they received, while a minority of participants who were 
diagnosed promptly reported their care more positively. The results from the qualitative work in 
this study supported the need for the development of a palliative intervention for this group of 
patients which aimed to improve communication and co-ordination of care whilst facilitating 
discussions surrounding information needs and important end of life preferences.  
The third objective was to identify patients’, informal caregivers’ and HPs’ views on the H2H 
model of care and ways in which it may be improved/adapted for the PIF-ILD population. The 
qualitative work showed that the vast majority of patient, informal caregiver and HP participants 
felt that the model of the H2H intervention was an excellent one and were overwhelmingly 
supportive of it.  Patients and informal caregivers valued knowing a plan of action of who to 
contact in a crisis as they felt that this was lacking.  In addition, HP participants felt that clearly 
allocated roles and responsibilities which were communicated across the board would be 
helpful in ensuring that all HPs took appropriate responsibility when necessary. Community HPs 
felt that the CC model of care would facilitate them to take a more prominent role in the end of 
life care of patients whilst being supported by the specialist ILD centre.  Very few concerns were 
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made about the model of care but one included the difficulty of being able to get all HPs to 
attend a CC at the same time. 
 
The findings from objective 1-3 were integrated with the background work to present the 
adapted H2H model of care as objective 4.  
 
Objective 5 focussed on defining appropriate outcomes and measures for the adapted H2H 
intervention. Appropriate outcomes and measures for the adapted H2H intervention were 
chosen through information provided by the background systematic review and qualitative work 
forming the modelling theory/processes phase of the Development stage. The systematic 
review identified that there were a wide range of symptom control and Qol outcome measures 
that had previously been used in interventional studies (23 and 6 different outcome measures 
for symptom control and Qol respectively). In addition, there were no validated outcome 
measures used in interventional studies. In choosing outcome measures for the H2H trial, to aid 
comparison, some outcome measures that had previously been used in the H2H cancer study 
at the Royal Marsden Hospital were used. The primary outcome measure chosen for the 
Feasibility/piloting stage was the POS. This appeared to be an appropriate outcome measure 
as the qualitative work forming part of the Development phase identified that patients had 
holistic palliative care needs which did not just focus on symptom control or Qol but 
encompassed every part of the patient’s life.  
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Objectives 6-8 formed the Feasibility/Piloting stage of the MRC guidance:  
Objective 6 focussed on beginning to evaluate the adapted H2H service in a phase II study. The 
FT RCT conducted provided preliminary information related to the outcomes chosen in objective 
5. The quantitative results showed a positive and significant effect on patients’ POS scores at 
the primary endpoint of 4 weeks with a mean change score of 5.7 points in the FT group which 
was sustained at 8 weeks.  In addition, there was improvement in the WL POS score between 
week 4 and week 8 of 4.3 points. For the POS, a variation of one point in individual items is 
linked to clinical meaningful change.(161) This suggests that the H2H intervention may improve 
the palliative care needs of PIF-ILD patients in a clinically meaningful way. The 2 RCTs that 
have previously trialled CCs in the cancer setting (78, 80) have not used the POS or a global 
palliative care assessment tool so a direct comparison cannot be made on effectiveness in the 
PIF-ILD setting.  
At the CC the evidence based guidelines were used and a comprehensive palliative care 
assessment (including symptom control, psychological, social needs and crisis management 
plan) was carried out. Ongoing management of the patients’ palliative care needs were carried 
out by the community teams. It is possible that the intervention of the evidence based guidelines 
and the ongoing management of the palliative care needs identified at the CC, resulted in the 
improvements in the patients’ POS seen. It is difficult to know whether the benefit from the 
intervention seen is due to the CC, palliative care involvement or the added time with care 
providers. However, the results are promising and warrant further investigation.  
Of note, the WL group had a higher percentage of informal caregivers. Informal caregivers play 
a vital role in the management of symptoms in the home setting.(217) In addition, HPs providing 
palliative care in the community setting report that they rely on informal caregivers’ assessments 
of the patients’ condition and use them as cues for action.(217) Therefore it may be expected 
that if a patient does not have an informal caregiver, this interface is more difficult potentially 
leading to more unmet palliative care needs. The WL group also had a higher GP, DN and 
CPCT presence at the CC than the FT group. This may have influenced outcomes as it would 
be the GP, district nurses and CPCT who would instigate the symptom control interventions and 
manage the patients’ palliative care needs on a day to day basis. However, this may have led to 
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false improvements in the WL scores which would only have diluted the effect size, suggesting 
that the potential effect of the intervention may be greater than reflected in the scores.  
There was also an improvement in Qol scores on both the KBILD and SGRQ impact and total 
scores at week 4 in the FT group. The improvement in the WL SGRQ impact and total scores 
were marked between week 4 and week 8 where both domains showed improvement greater 
than the Minimal Important Clinical Difference (MID) for IPF. Mitchell et al (78) investigated the 
impact of a telephone CC between GPs and specialist palliative care teams (without the patient 
or informal caregiver present) in a RCT of 159 cancer patients in Australia. They found that the 
primary outcome- global Qol was not influenced by the intervention but the CC group showed 
better maintenance of physical and mental health measures of Qol in the 35 days before death. 
The authors suggest this is because care plans at referral were not implemented until severe 
symptoms developed. Though the Mitchell et al study was a CC to meet professional needs, 
whilst the H2H service was a patient-centred, face-to-face intervention involving, patients, 
informal caregivers and HPs. This may have been an influencing factor. The Qol measures 
used in the Mitchell et al study were the Assessment of Quality of Life at the end of Life (AQEL) 
(219), the McGill Quality of Life Questionnaire (220) and the Subjective Wellbeing Scale (221) 
so direct comparisons between the two studies are not possible. Interestingly, the complex 
intervention of a breathlessness intervention service delivered by Higginson et al study (222) 
also showed some improvements in Qol domains. The Higginson et al study is a RCT of 105 
patients with refractory breathlessness which included ILD patients. It found that the patients 
who received the integrated palliative care and respiratory breathlessness support service had, 
at 6 weeks, significantly improved breathlessness mastery, a domain of the Chronic Respiratory 
Disease Questionnaire. Mastery assessed patients' feeling of control over their breathlessness 
and its effects on Qol and function, and was on average 16% higher for those patients receiving 
the breathlessness support service. However, numbers of ILD patients were small 19 (18%) and 
ILD patients’ diagnoses were not differentiated.  
 
There were improvements in anxiety and depression of both patients and informal caregivers at 
week 4 in the FT group.  This effect appeared to be sustained in the FT group with continued 
improvement in scores at week 8. In addition, there was marked improvement from week 4 to 
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week 8 in the WL group which was greater than the MID for COPD on the HADs. Even though 
the HADs has not been validated in IPF, the MID for COPD has been used previously for IPF 
patients.(223) Lindell et al (113) conducted a mixed methods RCT of 21 patients looking at a 
disease management program delivered using a format of support group for both IPF patients 
and informal caregivers with a control group of best usual care. In contrast to this trial, they 
found that on quantitative analysis, there was increased anxiety and decreased Qol in the 
intervention group. However, the qualitative work showed that patients did not feel isolated and 
felt the intervention had enabled them to put the disease into perspective, gave comfort and 
provided an improved mental picture. The quantitative and qualitative work in this trial is in 
agreement. The qualitative work in the H2H trial showed that the community palliative care 
teams were providing similar support to patients and informal caregivers.  In the Higginson et al 
study(222) of their breathlessness intervention service, there were also non-significant 
improvements in depression. In the H2H trial, the effect on anxiety and depression scores was 
also mirrored in the informal caregiver results with improvements in the depression and total 
HADs scores at week 4 in the FT group and much larger improvements (greater than the MID) 
in the WL group between week 4 and week 8 in all 3 domains of the HADs. These 
improvements in anxiety and depression scores in both the patient and informal caregiver were 
supported by the qualitative results.   
There were also large improvements in the ZBI and CQLC between week 4 and week 8 in the 
WL group. In the Mitchell et al study(78), there was a positive impact on caregiver burden with 
significantly lower carer burden in two of the five domains (impact on schedule and lack of 
family support) on the Caregiver Reaction Assessment (79) as well as the total score. Knowing 
what to monitor, how to interpret the signs successfully and when to inform a HP were all issues 
of concern for informal caregivers in a previous palliative care study.(217) In the H2H trial, a 
copy of the individualised care plan made at the CC was given to the patient, informal caregiver 
and HPs involved in the care of the patient. This included direct contact numbers for all HPs and 
step-wise instructions of what to do in the event of deterioration. Patients, informal caregivers 
and HPs expressed in the qualitative interviews that they were very grateful for this 
individualised care plan with patients and informal caregivers expressing that this greatly 
reduced their anxiety and HPs expressing that it allowed them to provide better care. In 
addition, the qualitative data suggests that the intervention facilitated improvement in both the 
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co-ordination and efficiency of care delivered with patients and informal caregivers expressing 
that they now felt that they were “Fast-tracked” through the system as HPs had been made 
aware of the seriousness of their condition. Qualitative results suggest that this resulted in 
patients and informal caregivers being able to access help when needed. The actual process of 
the CC, having a clear individualised care plan and being supported in this way by the 
community HPs may have helped to reduce both patients’ and informal caregivers’ anxieties 
seen in the quantitative results.  
The H2H intervention aimed to manage uncertainty by facilitating early discussion about 
disease progression, improving communication and addressing end of life planning needs. At 
the CC, not all patients wanted to talk about advance care planning decisions such as PPC and 
PPD. This was also found in the cluster randomised study conducted by Abernethy et al (80) 
where prognosis, end of life issues and previous experiences of death and dying were rarely 
discussed at the CC for cancer patients.  For those patients who did discuss advance care 
planning at the H2H CC, even though it could initially be distressing for relatives present, it was 
seen as incredibly useful. For some patients, the CC gave permission to conduct these 
important conversations. However, many patients who had not wanted to discuss these issues 
at the CC, then went on to have subsequent discussions with their community HPs in the weeks 
after the CC. It is possible that planting the seed of thought about these important issues at the 
CC precipitated these conversations and decisions. This is in itself an important influence that 
the intervention may have had.  
 
Objective 7 was to evaluate the H2H intervention in terms of feasibility and acceptability. There 
were no set criteria for feasibility or acceptability which had previously been used for complex 
interventions within the MRC guidance. Therefore after reviewing previous studies, feasibility 
criteria of:  consent rate of >25%, recruitment of 52 patients and 80% of patients in the FT group 
were able to receive the H2H intervention within 14 days of their allotted time were set. Even 
though both the consent rate and recruitment numbers were met, only 24% of the FT group 
received the CC within the 14 day allotted timeframe. This was largely due to the difficulty in 
getting HPs to be able to schedule a CC within one week’s notice. This in turn led to some 
difficulty when conducting analyses at the 4 week point and may have led to under-estimation of 
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the effect of the H2H intervention.  Abernethy et al (80) also find it difficult to ensure that CCs 
were held within 28 days with only 38/167 of their CCs being held within this time period. The 
study design of a FT randomised controlled trial however worked well and is likely to be an 
influencing factor as to why recruitment rates were met.  
Qualitative work conducted during the RCT showed views of the H2H intervention as expressed 
by patients, informal caregivers and HPs to be extremely positive and the intervention was 
acceptable. Support in the community for patients and informal caregivers before the start of the 
study was minimal. All patients and informal caregivers interviewed were very grateful to have 
received the H2H intervention. Patients, informal caregivers and HPs alike praised the CC 
model of care. In previous qualitative work following the Mitchell et al RCT, GPs reported that 
the CC allowed them to be better informed, made discharge planning easier and allowed clear 
delineation of role between the GP and the palliative care service.(76) All of these findings were 
supported in this trial. Very few GPs attended CCs (less than a third in the FT and less than 
50% in the WL group) and in some instances community palliative care initially refused referral 
for these patients. In the Abernethy et al study (80), all CCs included the GP, patients and/or 
family member and a palliative care representative. The poor attendance of community HPs in 
the H2H trial is likely to reflect the lack of understanding amongst community HPs of the 
terminal nature of these diseases and their substantial palliative care needs.  
 
Objective 8 was to use the Phase II study to inform a future larger randomised controlled trial 
(RCT phase III/Evaluation study). The Phase II study has provided valuable information on 
appropriate time periods between randomisation and CC. There is clearly a need for a greater 
time period between randomisation and the CC in the FT group if this trial design were to be 
used again. In addition the Phase II study has highlighted that mechanisms need to be put in 
place to minimise attrition after the CC has been delivered. The information provided from the 
phase II study has enabled calculation of a sample size for any potential phase III study.  
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 Limitations of thesis  6.2.2
The retrospective review of medical notes used in the identifying/developing theory phase of the 
Development stage is limited. As such, palliative care needs identified through this piece of 
work have been taken treated with caution and this piece of work has been used as background 
in this study.  
For both the qualitative work in the Development and Feasibility/Piloting stages, numbers 
were small so information is limited. However, this is the first time a complex intervention 
looking at improving symptom control or Qol has been developed in this group of patients using 
the MRC guidance. Therefore information provided as a result of this study is especially 
important. For the qualitative work conducted as part of the Development work, on analysis of 
the later interviews, no new themes were emerging. Therefore, it is unlikely that further 
interviews would have made any difference to the conclusions drawn. However, for the 
qualitative interviews conducted as part of the Feasibility/Piloting stage, participants for 
interviews were identified by the H2H CNS from patients, informal caregivers and HPs who had 
completed the H2H trial. This is likely to have introduced bias into the sample as she may have 
identified participants who were more likely to be positive about the H2H intervention. In 
addition, due to time and cost limitation, a pre-determined set number of interviews (5 patients, 
5 informal caregivers and 5 HPs) were conducted. However, there was ongoing emergence of 
themes in later interviews. It is possible that there were further themes that may have emerged 
if further interviews had been conducted. This may have affected the qualitative outcomes in the 
Feasibility/Piloting stage. However, as I was also running the RCT, I do not think it would have 
been realistic for me to have conducted any more interviews. In conducting qualitative work in 
future trials for H2H, I would approach all participants who received the H2H intervention 
sequentially to limit bias and interview patients, informal caregivers and HPs until there was 
saturation of themes.   
The H2H intervention is a complex intervention with multiple different active components. As a 
result, there will have been some variation in the service received by each patient and informal 
caregiver. As discussed in Chapter 5, attempts were made to standardise delivery of the 
intervention as much as possible with training, observation of delivery of the CC, proformas and 
evidence based guidelines.  This level of standardisation does seem reasonable considering the 
time and cost restraints. However, if the H2H service were to be further evaluated in an 
  290 
Evaluation trial, it would be important to ensure further standardisation of the service delivered 
by including a measure to determine the consistency with which the intervention was delivered.  
The CCs could be audio or video taped to give feedback of performance to the H2H CNS with 
subsequent training to promote consistency. In addition, this would allow detailed information to 
be gathered on the content of the CC which may provide insight on the mechanisms of effect of 
the complex intervention and allowed deeper consideration and understanding of which part of 
the complex intervention is effective. In hindsight, it would have been useful if compliance of 
patients and informal caregivers had also been recorded. This may have provided valuable 
information on how outcomes for users may differ between compliant/non-compliant patients 
and informal caregivers. Recording this information is unlikely to have been too burdensome in 
terms of cost or time and would have been helpful in considering the real life implications of 
delivering this service within the NHS.   
The RCT was carried out at a specialist centre in London therefore generalisability nationally 
and internationally may be limited and warrants further investigation. In addition, the majority of 
the patients were White British. It may be argued that the palliative care needs for these 
patients may vary across different cultures. However, the qualitative work in the Development 
stage was conducted across KCH and RBH. KCH has a very different socio-demographic 
patient group to RBH. Importantly, this showed no difference in the palliative care needs of the 
patients and informal caregivers interviewed across the 2 hospitals.  Within the constraints of 
cost, it was not possible to make the RCT multi-centre. However, any future Evaluation trial 
would ideally need to be multi-centred, national and if possible, international to assess 
outcomes across different cultures and to ensure generalisability of findings.   
The RCT was a phase II trial and was therefore not powered to show efficacy. Any positive 
results should be interpreted with caution and need to be evaluated in an adequately powered 
trial.  
Delay in delivering the FT CCs affected comparison of the efficacy of the intervention at the 
primary endpoint of 4 weeks. However, this is likely to have under-estimated rather than over-
estimated any effect. In addition, referrals to community services for WL group were made at 
randomisation and a few community services contacted (and sometimes visited) with the 
patients and informal caregivers (exact numbers unknown and not recorded) before the CC. 
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This may also have potentially diluted the effect size of the intervention. In hindsight, it would 
have been preferable to not make any referrals to community services for the WL group until 
after 4 weeks. However, it is only when these referrals were made, that a date for the CC could 
be set. Consideration needs to be given between achieving a balance of allowing enough notice 
to community HPs to set a convenient date for the CC and not contaminating the WL group with 
contact from community HPs prior to the CC. On reflection, it would also be useful to have 
noted how many community HPs had made contact and the nature of the contact.  
At follow up, the H2H nurse contacted the patient/informal caregiver 2 weeks, 4 weeks and 2 
months after the CC. This involved the H2H CNS discussing with the patient or informal 
caregiver whether outcomes from the care plan had been achieved. It would have also been 
beneficial to have assessed with more uniformity (e.g. a needs assessment tool) at the CC, the 
2 week, 4 week and 2 month follow up, what baseline and subsequent needs there were for the 
patients and informal caregivers. This would have provided helpful information on whether the 
intervention was meeting unmet need identified at the CC.  This is unlikely to have added to 
time or cost.  
The exact nature of the classification of the RCT has been discussed in detail: A Feasibility 
study can be a small RCT, it need not have a primary outcome and the usual sort of power 
calculation is not normally undertaken. The sample size should be adequate to estimate the 
critical parameters (e.g. recruitment rate) to the necessary degree of precision.(251) Arain et 
al(251) discuss how feasibility studies do not evaluate the outcome of interest as that is left to 
the main study.  Pilot studies are a version of the main study that is run in miniature to test 
whether the components of the main study can all work together. It is focused on the processes 
of the main study, for example to ensure recruitment, randomisation, treatment, and follow-up 
assessments all run smoothly. It will therefore resemble the main study in many respects, 
including an assessment of the primary outcome and calculation of a sample size.(252) It has 
been stated that feasibility and pilot studies are usually distinguished from phase II trials in 
which some sort of evidence for efficacy is sought prior to embarking on a full phase III 
trial.(252) When this PhD was originally commenced and a protocol drawn up for the RCT, the 
original MRC framework was used.(28) In this framework, the Phase II trial is described as 
“exploratory” with aims which may include those shown in Table 6-1 Page 292. 
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Table 6-1 Table to show aims of a phase II trial as defined by the MRC framework 2000. 
Aim  
Testing acceptability and feasibility Testing the feasibility of delivering the 
intervention and acceptability to providers and 
patients 
Designing the main trial The exploratory trial should ideally be 
randomised to allow assessment of the size of 
the effect. This will provide information about 
the sample size for the main trial 
Outcomes Outcomes for the main trial will be piloted 
during the exploratory phase.  
 
Therefore for the definition, aims and outcomes of the Phase II trial used to test the H2H 
intervention, the original MRC framework (28) were used. These aims do not fit neatly into the 
previous definitions of a feasibility or pilot studies and actually span both definitions. The new 
MRC guidance (13), states that aims for the Feasibility/Piloting stage may include testing 
procedures for their acceptability, estimating likely rates of recruitment and retention of subjects 
and the calculation of appropriate sample sizes. The aims of the H2H RCT were to define 
appropriate outcomes and measures for the adapted H2H intervention, to begin to evaluate 
H2H, to evaluate the intervention in terms of feasibility and acceptability and to inform a future 
larger randomised controlled trial. These aims span both the old and new MRC guidance.  
Because the new MRC guidance has clear advantages over the old MRC framework (as 
discussed in Chapter one), the new guidance was used as the PhD progressed.   
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 Implications for clinical practice 6.2.3
This study has shown that these patients have a high symptom burden with unmet palliative 
care needs. In addition, these patients are rarely receiving the support of palliative care 
services. There is an increasing case for properly resourced ILD services to be developed, 
similar to those provided for patients with lung cancer, in which specialist nurse and early 
palliative care involvement is easily accessible.  This study supports such a model.  
The qualitative work from this study found that some patients had been refused referral to 
palliative care earlier in their disease journey.  This was despite requests from patients and 
informal caregivers. There was also some gatekeeping by hospital HPs who felt that some 
patients were not “ready to hear they were palliative”. This was mirrored in the refusal of some 
patients to take part in a “palliative care trial”. It is clear that there is still a mis-conception that 
palliative care is a last resort and referral should only be made at the end of life. This is despite 
the World Health Organisation’s advice (20) that palliative care should be delivered in parallel to 
active care once a life-limiting illness has been recognised. Supporting this, recommendations 
of both the British Thoracic Society (12) and NICE (236) state that palliative care teams should 
be involved in patient management to ensure adequate symptom control and psychological 
support. Strategies on improving the knowledge of patients, informal caregivers and HPs on the 
benefits of early palliative care and how to break down these barriers need to be explored.  
The research in this study found that these patients and informal caregivers not only have 
considerable unmet palliative care needs, but that there are inconsistencies in the provision of 
HP service delivery in the community. This study has further highlighted the needs of the non-
malignant respiratory group. It is clear that clinically we need to spend more time ensuring that 
the needs of non-malignant disease groups are met so that the level of palliative care received 
is equitable with the high standard that has become the norm in cancer.  There is no guidance 
on who ought to be involved in the delivery of care for PIF-ILD patients in the community and 
what the role of these individuals ought to be. As a result, these patients and informal 
caregivers are “falling through the net”. Recently NHS England has recommended the 
establishment of ILD specialist centres where ILD care is centred around tertiary hospitals to 
ensure uniformity of the care delivered in the secondary and tertiary setting.(253) However, 
there also needs to be uniformity of the care delivered in the community with allocated 
responsibility and accountability so that these patients receive the same standard of care 
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experienced by other disease groups such as COPD and cancer throughout their disease 
journey, but very importantly, in the last year of life. The qualitative work in the Development 
phase showed that there was resignation amongst some HPs that patients would inevitably 
suffer poor symptom control. This was partly due to some HPs’ lack of knowledge and 
misconceptions of effective symptom control interventions. Use of the evidence based 
guidelines in this study helped with this, but targeted education is needed. Gradually, the profile 
of the palliative care needs of these patients is being increased. I have recently been appointed 
to the NICE IPF quality standards committee. Through this I have helped to ensure that the 
palliative care needs of these patients and informal caregivers remains on the quality standard 
and a priority at a national level. However, further national and local work is needed.  
Interestingly on referral, 8 community palliative care services refused to take on PIF-ILD 
patients. This was despite clear explanations of the nature of the study and the patients’ 
palliative care needs. This is likely to reflect the bias in England’s community palliative care 
teams to malignant work and a lack of understanding of the palliative care needs of PIF-ILD 
patients. In addition, very few GPs attended CCs (less than a third in the FT and less than 50% 
in the WL group). The poor attendance of community HPs is also likely to reflect the lack of 
understanding amongst community HPs of the terminal nature of these diseases and their 
substantial palliative care needs. Publications from this study may help in disseminating 
information. However, there needs to be targeted education of community HPs to improve this.  
 
 Suggestions for future directions of research in this area 6.2.4
Further research into the best way to support patients and informal caregivers is needed. 
Clinicians caring for patients with PIF-ILD face a challenging task regarding information needs 
for both patients and informal caregivers.  PIF-ILD are a group of conditions that the general 
public is on the whole unfamiliar with and so natural introductions to questions regarding 
prognosis and end of life care are usually not initiated by patients themselves.  In contrast to 
malignant disease, this places the onus for developing such conversations almost completely 
with the HP, in the main a respiratory physician. In the context of busy clinic appointments 
during which information regarding diagnosis, treatment options and medical care also has to 
be communicated, it is not surprising that the uncomfortable topic of end of life care is 
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neglected. However, this study shows the importance that patients and their informal caregivers 
place on these issues. Further research is needed into the most appropriate model to discuss 
end of life issues with these patients and informal caregivers. For example, different ways for 
expressing life expectancy, facilitating hope and discussing the dying process. Both quantitative 
and qualitative methods would be helpful and studies of bereaved informal caregivers’ 
experiences in discussing this topic may obtain useful data both from the point of view of the 
informal caregiver and their perception of the patients’ needs.  
There is a need to develop interventions to facilitate improved end of life care for this group. The 
systematic review I conducted highlighted the paucity of interventions in the ILD population 
which focus on symptom control and Qol outcomes. It also brings to the forefront issues which 
limit comparison across studies; there was a paucity of RCTs (all were published in the last 10 
years), very few studies were powered for Qol or symptoms as primary outcome, there was 
poor reporting of data and mixed group studies did not report outcome measures separately. 
Despite some work at developing outcome scales specifically related to this disease group 
(254) (255, 256) I found poor use of validated outcome measures and a heterogeneity of 
measures used. Future areas of work which are needed include international consensus 
regarding patient reported outcome measures and study methodology to ensure that future 
trials capture accurate symptom control and Qol data.  
Patients with IPF experience increased healthcare resource utilisation, and direct medical 
costs.(224) As the population gets older, we can expect that the burden on healthcare will 
increase.(224) Timely and adequate symptom control may prevent unnecessary hospital 
admissions and therefore contain some expenditure. Interestingly, the systematic review 
conducted showed that government funding provided only 6% of support for trials and over a 
quarter of studies had some source of industry funding. Studies which are funded by industry 
are unlikely to have symptoms and Qol as primary outcome measures. There also needs to be 
detailed health economic analysis accompanying interventional studies to assess the true 
impact of transferring the end of life management of these patients from the specialist to the 
community setting.  
During the CC, for patients who wished to discuss PPD, no patient expressed hospital as their 
PPD. The actual place of death for patients having received the CC was hospital in only 28% of 
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patients. This is much less than found in a retrospective case note review (257) which found 
that 76% of PIF-ILD patients attending RBH and KCH in a one year period died in hospital.  
Patients with IPF experience increased healthcare resource utilisation, and direct medical 
costs.(224) This is especially important at the end of life. It is possible that the CC, through 
establishing links in the community setting and preventing crisis admissions, enabled patients to 
not die in hospital. The economic impact of this needs to be further investigated.  
There is a need for these patients to have clear care planning and co-ordination of their care. As 
discussed in Chapter 5, it is not clear from this research how exactly the CC, as a complex 
intervention, delivered improvements in outcomes seen. Further research is needed to ascertain 
the active component. It is difficult to know whether the benefit from the intervention is due to 
the CC or palliative care involvement. Certainly patients who receive timely palliative care will 
have better co-ordination of services, symptom care, emotional support, education and family 
support and this is something that the H2H intervention facilitates. In developing understanding 
into the active ingredients in the H2H intervention, the CC needs to be examined more closely 
during delivery. Aspects which need to be considered include content of each CC, themes 
considered and the interaction with patients, informal caregivers and HPs. This may be done 
through quantitative or qualitative measures. This may provide valuable information on how the 
H2H intervention is working in the PIF-ILD setting and how and why this differs to the cancer 
setting or to normal specialist palliative care input.  
In the Mitchell et al study (78), the CC was conducted between specialist palliative care teams 
and GPs via telephone. This study was conducted in the cancer group and patients and 
informal caregivers were not involved in the CCs. Telephone participation for GPs (rather than 
face-to-face participation) was felt to be a less successful form of communication when used in 
a RCT looking at case conferencing in Australia.(235) It is difficult to know whether this form of 
mode of delivery could be used in the PIF-ILD group effectively but warrants further 
investigation.
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Further studies with larger samples of patients, informal caregivers and HPs across different 
sites are needed to assess the generalisability of the findings presented in this study. In 
addition, further studies would need to assess the longer term effects of the CC. It may be that a 
short term intervention early on the in the disease process may be as beneficial as and more 
cost-effective than an intervention with follow up until death.  
 
 Personal reflection 6.2.5
This PhD has made me acutely aware of the far reaching impact of having unmet palliative care 
needs and how this impacts every part of patients’ and informal caregivers’ lives. Throughout 
this PhD I have been touched by how PIF-ILD patients and informal caregivers struggled in 
silence. They were unaware of services that were available to them and suffered without 
complaint.  During data collection and the qualitative interviews conducted as part of the RCT, it 
became clear that these patients and informal caregivers were incredibly grateful for the 
support/services that they received from, and as a result of, the H2H intervention. This has 
made me aware that clinical services need to be directed at both the patient and the informal 
caregivers as this is a disease that effects every part of patients’ and informal caregivers’ lives. I 
believe that we have a duty to ensure that disease groups such as PIF-ILD receive an equitable 
share of resources and end of life provision including services that other disease groups, such 
as cancer and COPD, had been receiving for many years. I would hope that this PhD helps to 
highlight some of these issues and may facilitate development of services going forward.  
Even though at times this PhD has been hard work and emotionally draining, I have 
experienced a great deal of personal enjoyment from the sustained contact over time with PIF-
ILD patients and informal caregivers.  I felt a genuine pleasure in learning of their disease 
experiences as well as feeling very privileged that participants felt able to ‘open up to me’ about 
intensely personal issues. I believe that my PhD has positively influenced my clinical practice 
through not only making me a better listener, as a result of skills acquired during qualitative 
interviewing, but also more considerate of informal caregivers and the far reaching and 
devastating impact that having an advanced disease with unmet need can have.  
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6.3 Conclusion 
This mixed methods study to develop a complex intervention provides a major contribution 
towards the understanding of the palliative care needs of patients with PIF-ILD. It illustrates the 
high burden of the unmet symptom control and psychological needs experienced by these 
patients and how these patients and their informal caregivers are suffering in silence. PIF-ILD 
patients rarely receive adequate support in the community and they are not accessing 
community palliative care services. The adapted H2H intervention is innovative in this group in 
its attempt to improve symptom control, co-ordination of care and crisis management through a 
case conference model of care.  The intervention involved patients, informal caregivers and 
HPs in a case conference focussing on addressing the patients’ and informal caregivers’ needs. 
Findings from this study suggest that that a case conference model of care for this group of 
patients and informal caregivers may improve palliative care needs, Qol and anxiety and 
depression. Further research is needed to evaluate these potential effects in a larger Evaluation 
trial.  
As well as providing some of the very first evidence of the palliative care needs of these patients 
and informal caregivers, this study has also presented methodological contributions to research 
at the end of life in PIF-ILD. These include the successful use of mixed methods and the use of 
the Medical Research Council’s guidance supported by the MOREcare guidance to develop a 
complex intervention at the end of life. The use of these methods is novel in this disease group.  
This study has shown that high quality research can be conducted at the end of life in PIF-ILD. 
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Definitions and Glossary 
Acceptability- adequate to satisfy a need, requirement or standard 
Attrition- decreasing sample size at subsequent assessment points due to drop-out or 
withdrawal.  
Authenticity- the portrayal of research that reflects the meanings and experiences that are 
lived and perceived by the participants. (258)  
Axiology- The philosophical study of value 
Complementarity- the elaboration or enhancement of the results from one method with the 
results from another. 
Complex Intervention- usually described as an intervention that contains several interacting 
components but other elements of complexity include difficulty of behaviours required by those 
delivering or receiving intervention, number of groups or organisational levels targeted by 
intervention, number and variability of outcomes and degree of flexibility or tailoring of the 
intervention permitted.(13) 
Constant comparative method- ongoing reflection and analysis formalised in coding 
procedures with generation of categories. Ideas generated during reflection and analysis are 
subject to further comparisons.  
Convergence- the tendency to become more alike over time. 
Criticality-  researchers’ critical appraisal of every research decision. 
Discrepancy- an instance of difference or inconsistency.  
Divergence- difference or deviation. 
Development- results from one method to help develop or inform the other method. 
Epistemology- A justification of knowledge. (83) 
Expansion- extending the breadth and range of enquiry by using different methods. 
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Feasibility study- aims to objectively and rationally uncover the strengths and weaknesses of 
an intervention, the resources required to carry through, and ultimately the prospects for 
success. 
Framework analysis- an approach to analysis developed by the National Centre for Social 
Research, and explicitly geared towards findings orientated towards policy and practice.(101) 
To describe the content of text or communication objectively, systematically and quantitatively. 
Stages include familiarisation, thematic analysis, indexing and charting. 
Hypothesis- a testable proposition.(259) 
IPF- Idiopathic pulmonary fibrosis (IPF) (previously known as cryptogenic fibrosing alveolitis or 
idiopathic fibrosing interstitial pneumonia) is a chronic, progressive form of lung disease 
characterised by fibrosis of lung parenchyma.  Microscopically, lung tissue from patients shows 
a characteristic set of histologic/pathologic features known as usual interstitial pneumonia (UIP). 
The cause of IPF is unknown.(48) 
ILD- Interstitial lung disease (ILD) describes a large group of acute and chronic lung disorders, 
with variable degrees of pulmonary inflammation most of which cause progressive scarring or 
fibrosis of lung parenchyma.(160) 
Initiation- the recasting of questions or results from one method with questions or results from 
the other method.  
Integrity- honesty and probity within the conduct of the research. 
Intervention- any measure whose purpose is to improve health or alter the course of disease. 
Member checking- method of enhancing credibility in qualitative data analysis through 
debriefings and discussions with interviewees.  
Ontology- The science or study of being. 
Paradigm- a set of ideas (hypotheses) about the phenomena under inquiry 
PIF-ILD- a clinical diagnosis of Non-Specific Interstitial Pneumonia, Idiopathic Pulmonary 
Fibrosis or Idiopathic Interstitial Pneumonia or a histological diagnosis of UIP as classified by 
ATS/ERS criteria.(160) 
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Advanced PIF-ILD- Progressive Idiopathic Fibrotic Interstitial Lung Disease with TLCO 
(percentage transfer factor) <40% and deteriorating clinical condition.  
Pilot studies- version of the main study that is run in miniature to test whether the components 
of the main study can all work together. It is focused on the processes of the main study, for 
example to ensure recruitment, randomisation, treatment, and follow-up assessments all run 
smoothly. It will therefore resemble the main study in many respects, including an assessment 
of the primary outcome.  
Recruitment- process of screening and enrolling patients into clinical trials 
Method- a specific research technique.(259) 
Mixed methods research- mixed methods research has been defined as the use of two or 
more methods that draw on different meta-theoretical assumptions to address a research 
question.(260) As a method, it focuses on collecting, analysing, and mixing both quantitative 
and qualitative data in a single study or series of studies.  
Model- an overall framework for looking at reality. (259) 
Palliative Care- is an approach that improves the Qol of patients and their families facing the 
problems associated with life-threatening illness, through the prevention and relief of suffering 
by means of early identification and impeccable assessment and treatment of pain and other 
problems, physical, psychosocial and spiritual. It includes: 
 a primary focus on Qol 
 pro-active and detailed symptom management 
 a patient and family-centred approach 
 consideration of psycho-social and spiritual, as well as physical issues. (20) 
Palliative ILD treatments- non-disease modifying treatments whose only goal is to improve 
symptoms and Qol e.g diamorphine.  
Preferred Place of Care- where a patient would wish to be cared for in the last few days and 
weeks of life.  
Preferred Place of Death- where a patient would wish to die.  
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Radical ILD treatments- disease modify treatments whose primary goal is to slow disease 
progression.  
Respondent validation- cross-checking findings with respondents. Can help to refine 
explanations.  
Triangulation- the use of three or more different research methods (i.e. multiple methods) to 
investigate the phenomenon of interest.  
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